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Abstract: 
 Allogeneic hematopoietic stem cell transplantation is considered to be the main means of 
treatment for hematological malignancies. However, disease relapse and graft versus host 
disease remain the major cause of death post transplantation. To reduce the risk of graft 
versus host disease and in order to improve the graft versus leukemia effect, genetically 
engineered T-cells are used to express tumor specific antigens. This is either through the 
transfer of a recombinant antigen-specific T cell receptor (TCR) or through the introduction 
of antibody-like recognition in chimeric antigen receptors (CARs) toward tumor-associated 
antigens. These methods have made substantial advances. Nevertheless, the complexity in 
modifying and producing autologous specific T-cell products for each patient is a major 
barrier to the broader application of this approach. In this context, the ability to generate an 
“off-the-shelf” mismatched donor-derived therapeutic T cell product was investigated.  To 
overcome HLA barriers and to eliminate the risk of graft versus host disease, tailored 
transcription activator-like effector nucleases (TALENs) knocking out the expression of 
endogenous T cell receptor was utilised. Also, the potential of engineered meganucleases and 
clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) to disrupt the 
genomic sequence of the T cell receptor was evaluated.  
Large numbers of recent clinical trials have suggested that in vivo persistence and expansion 
having a potent anti-tumor activity of the genetically engineered T cells is crucial to have a 
robust clinical response. In order to generate a T cell product possessing these previous 
features, we have investigated the ability to engineer naïve cord blood T cells toward specific 
tumor antigens.  Due to their naivety, the higher telomeres activity, low graft-versus-host-
disease, amongst several other features, have the potential of making cord blood an optimal 
source for the production of a universal allogeneic engineered T cell therapy. Moreover, 
preclinical models have demonstrated that culturing naïve T cells in the presence of 
interleukin-7 and interleukin-15 might retain the modified cells in their naïve like phenotype. 
In conclusion, delivery of CD19CAR genes using lentiviral vectors into naïve cord blood T 
cells could form the basis of generating a universal cell bank of therapeutic T cells against B 
cell lymphoma. With further optimisation to improve efficiency, this could be combined with 
TALENs for site-specific disruption of the endogenous T cell receptor to eradicate the risk of 
graft-versus-host disease. 
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Over the past two decades, the transplant of allogeneic hematopoietic stem cells has become 
a successful therapeutic option for relapsed hematological malignancies in high-risk leukemic 
patients (Weber et al., 2009). However, the difficulty in finding matched HLA-donors, 
coupled with the high risk of graft-versus-host disease (GVHD), remains a significant 
therapeutic limitation (Khouri et al., 2001). Thus, novel, more efficient and less toxic 
remedies are required to eliminate cancerous cells without any relapse or side effects. 
Evidence suggests that the anti-tumour immune surveillance system in the human body 
recognises tumour-associated antigens (TAA) - proteins expressed by malignant cells - and 
discriminates them from normal and healthy cells. This provides a solid foundation to 
develop new, robust and active therapies for cancer such as Adoptive-T cell therapy (Morris 
et al., 2006). Adoptive cellular therapy uses autologous or allogeneic T cells, with highly 
specific tumour recognition, and expands them in vitro then they are administrated back to 
the patients, with the aim of targeting cancerous cells and killing them specifically (Grupp 
and June, 2011). It has been successful in achieving tumour regression in transplant-related 
malignancies, leukaemia, and melanoma. For example, Rosenberg successfully performed 
Adoptive-T cell immunotherapy in patients with advanced metastatic melanomas. Tumour 
reactive infiltrating T lymphocytes (TIL) were isolated from surgically removed tumours, 
expanded in vitro and re-infused back into the patients conditioned by treatment with 
immunosuppressant drugs (Figure 1). The results of this trial demonstrated the clinical 
benefit of adoptively transferring T cells in approximately 50% of the patients (Rosenberg 
and Dudley, 2004). Although Adoptive-T cell immunotherapy has led to remarkably 
successful outcomes in treating certain categories of malignancies, the inability to isolate and 
expand a sufficient number of high-avidity specific T lymphocytes for therapeutic purposes is 
the major obstacle to the success of the therapy (Aqui and June, 2008). 
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An alternative approach to generate large numbers of potent and specific-redirected T cells is 
to genetically engineer T lymphocytes to express an antigen-specific T cell receptor (TCR), 
which is called TCR therapies, or protein-infused chimeric antigen receptors (CARs) (Figure 
2). Consequently, the immune reactivity will be redirected towards a defined TAA. 
Genetically engineered T lymphocyte not only has the potential to redirect T cells’ specificity 
toward tumors, it also has the potential to improve natural immune response and correct 
impaired immunity. These approaches could overcome the fundamental limitations 
associated with central and peripheral tolerance, and produce more efficient redirected-T 
cells that will specifically target tumours without the requirement for de novo T-cell 
activation in the patient (Sharpe and Mount, 2015). 
 
 
 
Figure 1: Clinical application of gene modified T-cells. Diagram illustrates the usage of natural T cells for treatment of cancer.TIL=tumour infiltrating lymphocytes. 
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Figure 2: Different ways to genetically engineer T cells to confer specificity on tumour-associated antigens. Current trials have shown several ways in which T cells can be genetically engineered to recognise tumour-associated antigens: i) allogeneic T cells can be transduced with viral vector-encoding, tumour-specific TCR, resulting in the production of T cell populations expressing tumour-specific TCR; ii) sequences encoding the variable regions of antibodies are engineered to encode a single chain, which is then genetically grafted onto the TCR intracellular domains that are capable of activating T cells. These CARs have antibody-like specificities, which enable them to recognise MHC-unrestricted structures in the surfaces of target cells. 
In 1986, Dembic and colleagues were the first group to demonstrate the feasibility of 
redirected T cell antigen specificity in favour of tumour-specific antigens (Dembic et al., 
1986). Based on this concept, several scientific groups conducted trials attempting to prove 
the feasibility and safety of antigen-specific T cell therapy.  
In addition to discussing the structure and gene rearrangement of TCRs and CARs, the next 
section will review several successful clinical trials that have utilised antigen-specific T cell 
therapy. 
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1.1 T-lymphocytes: 
1.1.1 Structure of T cell receptors (TCRs): 
T lymphocytes recognise a major histocompatible (MHC) epitope complex via a multi-chain 
glycoprotein expressed on their surface. This glycoprotein is known as T cell receptor. TCR 
plays a crucial role in T cell activation, antigen specificity and T cell survival. In 1996, 
monoclonal antibodies targeting a cloned T cell line were used in order to identify the 
structural basis of TCR. This study of clonotypic antibodies concluded that TCR is a member 
of the immunoglobulin gene super family, and it is a heterodimer molecule composed of two 
covalently linked, transmembrane polypeptide chains, denoted α and β (Abbas et al., 2000). 
An analysis of the amino acid sequences of different αβ TCRs demonstrated that each chain 
was composed of: i) an amino-terminal, variable domain (V); ii) a constant region (C), and; 
iii) a short hinge region of cysteine residue, which forms a disulphide bond. Moreover, this 
sequence analysis  revealed that TCR is anchored to the cell membrane by hydrophobic, short 
trans-membrane domain ends in a cytoplasmic tail that contributes to the signal transduction 
process (Abbas et al., 2000). TCR’s combining-antigen binding site, the buried surface of the 
variable region, encompasses hyper-variable loops known as complementarity-determining 
regions (CDRs) 1, 2, and 3 within both the Vα and Vβ regions, and an additional loop termed 
HV4 on the β chain. CDRs are responsible for direct recognition of different antigens and 
binding to the MHC peptide complex. Sequence examination of CDRs revealed that CDR1 
and CDR2 regions are less variable than CDR3. This result suggested that CDR1 and 2 
preferentially bind to the MHC helices and provide a constant interaction point between 
MHC and TCR, while CDR3 binds to the peptide presented in the MHC groove (Garcia et 
al., 1999). TCR is a multi-component assembly of α and β chains and four other membrane 
proteins: CD3ɛ, CD3δ, CD3γ and an invariant ζ chain. The CD3ɛδγ-ζ complex promotes the 
stability and cell surface expression of TCR, and also contributes to carrying out the signaling 
transduction mechanism on antigen recognition by TCR.  
TCR crystallization studies revealed another intra-cellular component of CD3 complex 
attached to TCR, known as immunoreceptor tyrosine-based activation motifs (ITAMs). 
ITAMs play a significant role in the intra-cellular activation of the T lymphocyte and involve 
the phospholyrating of two tyrosine residues on the binding of TCR with peptide MHC 
complex, leading to the generation of docking sites for transduction molecules. These initiate 
downstream signaling and eventually the activation of T lymphocytes (Cantrell, 1996) 
(Figure 3). 
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1.1.2 TCR Gene Rearrangement:  Given the importance of highly diverse repertoires of lymphocyte receptors in the protection 
against infection, a complex genetic mechanism has evolved for producing highly variable 
proteins. The TCR antigen recognition variable region is encoded by a combination of 
discontinuous, multiple gene segments known as variable (V), diversity (D) and joining (J) 
for the TCR β chain, or V and J segments only for TCRα. These genetic segments are 
assembled together via a somatic DNA rearrangement mechanism during T lymphocyte 
maturation to form a complete V region sequence. 
Figure 3: Schematic representation of TCR-CD3/ ξ complex on the T cell's surface.TCR is a disulphide-linked heterodimer β chain. The  chain contains a constant domain (light blue) and a variable region (pink and yellow), and the β chain is composed of a constant region (dark blue) and a variable domain (green, yellow and red). The aβ TCR is not covalently linked to CD3 proteins (CD3δ (yellow), CD3ε (green), CD3 γ (pink), and the ξ chain (grey)). The ITAM regions (black horizontal blocks) are phospholyrated at specific residues creating a docking site for downstream effectors leading to T cell activation. The CDRs consist of complementarity-determining regions 1, 2, and 3 within both the Va and Vβ regions, and are responsible for the direct recognition of different antigens and binding to the MHC peptide complex. ITAM= immunoreceptor tyrosine-based activation motifs  
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Gene segments encoding a TCR α locus are located on chromosome 14. The variable domain 
is encoded by 70–80 gene segments named as variable or V gene segment Vα and a cluster of 
61 joining or J gene segments (Jα) followed by a single, constant gene (Cα) expressing the 
constant region. In contrast, the TCR β locus, located on chromosome 7, has a different 
organization, with a cluster of 52 Vβ segments positioned far away from another two 
separated gene clusters, each composed of a single diversity (Dβ) gene segment and 6–7 J 
gene segments (Jβ), followed by single constant genes (Cβ1 and Cβ2) (Jung and Alt, 2004, 
Yoshikai et al., 1985). 
TCR gene rearrangements take place in the thymus during T cell development, and the beta 
chain locus undergoes genetic recombination before the alpha locus. At some point during T 
cell differentiation, Dβ juxtaposes with one of the 6–7 Jβ segments forming DβJβ 
recombination, and this is followed by rearrangement of one of the 52 Vβ segments with the 
DβJβ to assemble a complete, variable gene exon abbreviated as VβDβJβ. Subsequently, the 
DNA sequence will undergo a transcription process leading to the formation of a primary 
nuclear transcript that contains a non-coding sequence between VβDβJβ and Cβ1. In the 
mature form of mRNA, the non-coding sequence will be spliced out to give rise to  
VβDβJβCβ mRNA, which is then ready for translation. Once a functional β chain has been 
rearranged, genetic recombination of the  chain begins. Alpha locus genes will rearrange via 
a homologous mechanism to the gene recombination of the beta locus. This is initiated by the 
recombination of one segment of 70–80 V and one of the 61 J genes forming VJ, 
which is then transcribed into RNA including C. After splicing the introns, C will become 
proximal to VJ and will form a complete mRNA which is ready for translation (Blom et 
al., 1999) (Figure 4). The V(D)J recombination process is regulated by two important 
components: a specific DNA sequence that flanks gene segments ready to recombine, known 
as the recombination signal sequence (RSS), and V(D)J recombination enzymes, encoded by 
two genes, recombination-activating gene 1 and recombination-activating gene 2 (RAG1 and 
RAG2) (Leiden et al., 1988).  
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1.2 T-cell immunotherapy: 
The elimination of non-self molecules that are expressed not only by the virally infected 
cells, but also by transformed (tumor) cells is one of the immune system’s functions.  
Through an immune surveillance system, immune cells have the ability to recognise the non-
self and neoantigens and to destroy them. However, cancerous cells have developed 
strategies to escape and suppress the immune system, such as downregulating the expression 
of neoantigen; hence, they can evade immune cell detection (Pinzon-Charry et al., 2005, 
Blankenstein et al., 2012). As the field of immunology continues to developed, a large 
number of innovative therapies are being discovered that utilise the immune cells and 
optimise their specificity toward specific diseases through genetic modifications (Katsnelson, 
2013). Over the past two decades, proof-of-concept studies have demonstrated the potential 
of immune-cell therapies against malignancies, based on editing the specificity of immune 
Figure 4: T cell receptor chain rearrangement and expression. The TCR α and β genes are the result of somatic recombination of various gene segments: variable segment (V: red and pink blocks), diversity segment (D: green block), joining segment (J: yellow blocks). For the β chain (upper part of the figure) a Dβ gene segment rearranges to form a Jβ segment, creating a DβJβ segment that will combine with one of the Vβ to create a functional V region exon. Transcription and splicing of the VβDβJβ exon to Cβ generates mRNA that is translated to yield a TCR β chain protein. For the α chain (lower part of figure), a Vα gene segment rearranges to form a Jα gene segment to create a functional V region exon. Transcription and splicing of the VαJα to Cα generates mRNA that is translated to yield the TCR α-chain receptor. The α and β chains pair soon after this synthesis to yield an αβ TCR heterodimer.  
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cells toward specific tumor associated antigens (TAAs). Immune cells that have been widely 
used as therapeutic tools are included in  natural killer cell therapies (Cheng et al., 2013), 
dendritic cell therapies (Vacchelli et al., 2013) and T cell immunotherapies (Maus et al., 
2013). Due to the remarkable clinical success of genetically modified T cell immunotherapies 
in treating certain forms of cancer, the main focus of this project is to improve their treatment 
potential and to evaluate the ability to generate large numbers of T cell therapeutic products 
to be used in the human clinical field.  
1.2.1 Immune Surveillance Hypothesis: 
“It is no means inconceivable that a small accumulation of tumour cells may develop and 
because of their possession of new antigenic potentialities provoke an effective 
immunological reaction with regression of the tumour and no clinical hint of its existence “ 
By sir Frank Mac Farlane Burnet 
Several decades ago, the idea that the immune system could potentially identify and eradicate 
cancerous self-cells from the host, was first proposed by Paul Ehrlich. In 1957, the formal 
hypothesis of cancer immune surveillance was proposed by Sir Macfarlane and Lewis 
Thomas. Their concept demonstrates that adaptive immunity is a primary line of defense 
against cancer and it is responsible for preventing cancer development in the host (Schreiber 
et al., 2011). In mice, immune surveillance was directly demonstrated especially with the 
advent of the knock out technologies; however, this is not the case in humans. Although 
natural immune surveillance is difficult to examine in human cancers, there are  now 
significant studies to strongly support this hypothesis in humans (Reiman et al., 2007).  One 
group argued that the direct correlation between non-viral tumour incidence and immune-
competence status of transplanted patients might be a proof supporting the immune 
surveillance notion (Birkeland et al., 1995). Others postulate that the correlation between 
patient survival and the quantity, quality and spatial distribution of tumour-infiltrating T 
lymphocytes (TILs) might be the strongest evidence of cancer immunoediting in humans. 
The presence of cytokines that promote cancer control such as interferon gamma (INF-γ) and 
tumour necrosis factor alpha (TNF-α) has been linked with having a better outcome for 
patients with different types of malignancies.  The presence of elevated levels of antibodies 
and T cell reactions against tumour associated antigens in cancer patients might be 
considered another indication of immunoediting in humans (Schreiber et al., 2011).   Dunn 
and his colleagues have suggested that transplant recipients maintained on 
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immunosuppressants, and individuals with primary immunodeficiency disease are at higher 
risk of developing malignancy (Dunn et al., 2002).  
In 2001, the concept that the immune system not only protects the human body against 
tumour formation, but also shapes tumour immunogenicity has been evaluated.  Cancer 
immunoediting proceeds sequentially through three phases; elimination, equilibrium and 
escape: “the three Es of cancer immunoediting”.   The elimination phase is the process in 
which both innate and adaptive immunity are working together to detect and destroy the 
presence of a developing tumour before it becomes clinically apparent. However, if rare 
cancer cell variants survive the elimination phase, they enter the equilibrium phase. In the 
equilibrium phase, the outgrowth of tumour cells is prevented by adaptive immunity and 
maintained in a functional state of dormancy.  Finally, tumour cells that have the ability to 
circumvent immune recognition and elimination and still emerge as a growing and visible 
tumour,  proceed to  the escape phase (Dunn et al., 2004). Now with the understanding of the 
cancer immunoediting concept, and the clarification of the molecular and cellular mechanism 
of the three Es, it should be feasible to explore new cancer immunotherapies with high 
efficiency and safety standards (Hanahan and Weinberg, 2011). 
1.2.2 Tumor associated antigens (TAA): 
The identification of a variety of tumour antigens in human and animal cancers has provided 
a solid foundation for cancer immunotherapy. Tumour antigens are peptides derived from 
proteins that are processed in the cytosol and expressed by neoplastic cells due to some 
genetic alternating events such as, mutations or chromosomal rearrangements (Morris et al., 
2006).   
Based on their patterns of expression, tumour antigens can be divided into two categories:   
One category is called tumour specific antigens (TSAs); which are novel non-self-antigens 
that are expressed only by malignant cells, but not by normal cells. On the other hand, the 
tumour antigens that are expressed by both self and malignant cells are called tumour 
associated antigens (TAAs); these antigens are normal cellular components whose expression 
is abnormal or deregulated in tumours (Van den Eynde and van der Bruggen, 1997). 
The modern classification of tumour antigens is based on the molecular structure and source 
of antigens. Some tumour antigens originate due to mutation in oncogenes or tumour 
suppressor genes such as mutation in Ras gene or p53 tumor suppressor gene.  Other 
malignant peptide-derived proteins may be the product of alteration in cellular genes not 
involved in tumourgenesis such as, different mutant proteins in melanomas.  Some tumour 
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antigens may be normal cellular constitutes that are overexpressed or aberrantly expressed in 
neoplastic cells; for instance, Wilm’s Tumour antigen-1 (WT-1) that is overexpressed in a 
number of malignancies such as leukaemia (Abbas et al., 2014).  
For tumour associated antigens to be ideal candidates for immunotherapeutic approaches, 
they should be selectively expressed in tumor tissue and detectable in most patients. For 
example, NY-ESO-1 cancer-testis antigens, are neoantigens that are only expressed in 
neoplastic cells and testis; hence, they are among the most ideal candidates for 
immunotherapeutic applications (Chen et al., 1998). Some studies suggest that most TAAs 
have broader expression in healthy tissue; as a result, using these antigens as targets of an 
immune response might lead to the induction of autoimmune phenomena. Although this risk 
must be taken very seriously, several animal studies have shown that there might be a 
difference in the susceptibility of normal and tumour tissue to the effector arms of immune 
response (Krackhardt et al., 2002). 
1.2.3 Adoptive T-cell Therapy: 
Traditionally, there have been three means to treat malignancies: surgery, chemotherapy and 
radiotherapy. Although to date these are the most beneficial treatments, in the medical field 
as  remedies for cancer, they suffer from limitations; such as killing the dividing, functional 
normal cells; blocking the  cell cycle and having severe implications in the proliferation of 
normal cells (Perica et al., 2015). In hematological settings, allogeneic hematopoietic stem 
cell transplant (HSCT) is considered the standard treatment to mediate the graft-versus-
leukaemia effect (GVL) and hence improve a patient’s conditions (Kennedy-Nasser and 
Brenner, 2007). However, the difficulty in finding a HLA-matched donor, the lethal 
consequences of graft versus host disease (GVHD), and the risk of relapse after disease 
treatment are some critical unresolved limitations of HSCT. As a result of these serious 
limitations, new novel and robust therapies are required (Forman et al., 2016). 
The concept of targeting cancer by harnessing the immune system to recognize and destroy 
neoplastic cells (cancer immunotherapy) has been established over many years and could 
overcome the obstacles of the current therapies. Adoptive T cell immunotherapies have 
proven their success in the clinical field and therefore, are considered the most powerful kind 
of treatment in the field of immunotherapy (June, Yee, 2005).  
Approaches to mitigating the effect of GVHD involve expansion of T cell lines following 
anti-genetic stimulation in order to produce antigen-specific populations, while eliminating  
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alloreactive clones. Although this treatment has been used successfully to treat viral 
reactivation (Bollard and Heslop, 2016) after transplant, and more recently to treat leukemic 
relapse (McLaughlin et al., 2015), the only problem with this approach is the long amount of 
time needed to prepare antigen specific T cells; which can take several weeks of culture 
(Jorritsma et al., 2011). 
Redirecting T cell specificity toward TAAs through the transfer of antigen-specific receptor 
genes is considered as an alternative approach to circumvent the need to culture, grow and 
enrich antigen-specific T cell clones. These strategies may involve the transfer of 
recombinant variants of conventional heterodimeric  T cell receptor chains (TCR gene 
transfer  therapy) (Stauss et al., 2015), or hybrid composites of anti-body-like receptor chains 
linked to trans-membrane and activation domains (CARs) (Maus and June, 2016). One of the 
major differences between TCRs therapy and CARs is that  TCRs have lower affinities 
and recognise processed peptide antigens expressed in the context of the major 
histocompatibility complex (MHC); whereas CARs are high affinity, MHC-unrestricted and 
capable of engaging target cell surface proteins independently of presentation pathways 
(Sadelain et al., 2013).  
1.2.4 TCR Gene Transfer: 
Genetically modified TCR therapies are based on conferring T-cells’ specificity toward 
TAAs through introducing  exogenous genes expressing antigen-specific TCR  and  chains 
(Gross et al., 1989). The tumor specific  and  TCR chains are designed, isolated and 
cloned into a viral vector backbone; replication defective gamma retrovirus or lentivirus 
vectors, to transduce T cells and generate a tumour specific-antigen T cell clone. To produce 
effective, engineered T cells with tumor-specific TCR, an appropriate and specific target 
sequence should be selected and identified. This target sequence might be found integrated 
within rare tumor-reactive T cells; which would be a difficult approach to isolate the 
sequence from (Thomas et al., 2010).  
Alternative technologies have been developed to generate highly active anti-tumor T cell 
clones. For instance, one tactic is to immunise transgenic mice that express human leukocyte 
antigen (HLA) with human tumor peptides to produce  antigen-specific T cell clones that 
could be harvested and later isolating the TCR  chains’ specific sequence (Tey, 2014). 
Retroviral gene transfer of exogenous  and  TCR encoding sequences targeting a tumor 
associated antigen named MART1 in melanoma was the first trial to prove TCR gene transfer 
efficacy in humans. Tumor regression was detected in 2/15 subjects treated with engineered 
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autologous T cells targeting melanoma (Morgan et al., 2006). A higher affinity modified 
TCR targeting MART1 mediated the anti-tumor effect in clinical trials with melanoma and 
with tumor regression of 6/20 patients; however, on target anti-melanin effect on hair, skin 
and eyes was detected (Johnson et al., 2009a). Another side effect was also reported after 
infusing carcinoembryonic antigen-specific TCR T cells targeting colorectal carcinoma, 
where bowel inflammation was noticed after therapy (Parkhurst et al., 2011). Another study 
spotted a minor toxicity following treatment of cancer-testis patients with genetically 
modified T cells targeting Ny-ESO-1 TAA (Robbins et al., 2011). Similar approaches have 
been used by other scientific groups to treat viral complications such as Epstein-Barr virus 
(EBV) (Hart et al., 2008). Engineered autologous T cells with introducing exogenous  
TCR to target Hepatitis B antigen in patients with hepatocellular carcinoma has also proved 
the success of TCR gene transfer therapy (Qasim et al., 2015b).  
In hematological settings, low numbers of protein antigens have proven suitable as candidates 
for T cell immunotherapies. One of the most common TAAs used as a target in treating 
leukemia is Wilm’s Tumor-1 antigen (WT-1); a normal protein that is overexpressed on 
tumor leukemic cells (Casalegno-Garduno et al., 2010). Due to its importance as a potential 
treatment for leukemia; especially acute myeloid leukemia (AML) and myelodysplastic 
syndromes (MDS), and its emerging clinical success, WT-1 TCR therapy is a focus of this 
project and will be discussed in detail in the next section.  
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1.2.4.1 Clinical studies using  TCR gene-modified T cells: 
The following table summaries some of the recent clinical trials that have utilised TCR gene-
modified T cells:  
Data from: Clinicaltrial.gov 10/05/2016 
 
Malignancy  Target antigen  Vector  Comments  References/ClinicalTtrial.govidentifier  
Melanoma  MART-1  TCR- RTV  
17 subjects: two partial. 30% response rate without toxicity   
(Morgan et al., 2006)/NCT00509288  
Melanoma, oesophageal and synovial sarcoma MAGEA3 
TCR-RTV 
9 patients. One complete response. Our partial response )Morgan et al., 2013( 
Metastatic Melanoma GP100 TCR-RTV 
16 subjects: one complete response and two partial responses.  (Johnson et al., 2009b)/ NCT00509496 
Colorectal cancer  CEA  TCR- RTV  
Significant response associated with no off-tumor toxicity  (Parkhurst et al., 2011)/NCT00923806  
Synovial sarcoma and melanoma  NY-ESO-1  TCR- RTV  
17 subjects: two complete response and 7 partial responses. 50% response without toxicity  
(Robbins et al., 2011)/NCT00670748  
Table 1: Examples of published clinical studies of positive responses to TCR gene transfer therapy. 
1.2.4.2 WT1-TCR: 
In 2005, the elimination of human leukemic cells using autologous T cells, which were  
genetically modified to express a novel αβ TCR encoding sequence targeting a Wilms tumour 
antigen-1 (WT-1), was reported in a humanised mouse model. WT-1 is a zinc finger 
transcription factor that plays a crucial role in urogenital development. It has an oncogenetic 
function and it is abundantly expressed in different types of solid tumours such as lung, 
breast cancers, and in the vast majority of leukaemia cells, with restricted expression in 
normal, hematopoietic progenitor and stem cells. Thus, WT1 antigen is considered an 
attractive target antigen for immunotherapy against these malignancies. Clinical trials of 
TCRs gene transfer therapy to treat relapse of AML/MDS by targeting HLA-A2/WT1 
peptides are being planned in centers in Japan (Ochi et al., 2011), the USA (Schmitt et al., 
2013) and the UK (Xue et al., 2005).The notable anti-leukemic effects that were detected 
without toxicity following the infusion of non-manipulated donor-derived WT1-specific CD8 
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T cells in post-transplant patients provides a solid foundation for this approach (Tawara et al., 
2015). 
In 2004, the first phase I clinical trial of cancer immunotherapy using peptide vaccination 
targeting the WT1 protein in patients with leukaemia, myelodysplastic syndrome (MDS), 
lung or breast cancer was reported. Peptides in combination with an appropriate adjuvant 
were injected to stimulate CD8+ CTLs specific to the MHC-class-I-restricted peptides. 
Amongst eight patients with evaluable disease, five achieved reduction in acute myeloid 
leukaemia (AML). Notably, in two MDS patients, the numbers of leukocytes in their 
peripheral blood, the majority of which was likely derived from MDS clones, significantly 
decreased after the first administration of the WT1 peptide. A significant correlation between 
immunological and clinical responses was observed in a cohort of all the patients examined 
(n=26). The correlation between the increase in WT1-specific cytotoxic T lymphocytes 
(CTL) frequencies and clinical responses provided evidence indicating that WT1-specific 
CTLs induced by WT1 vaccination played an important role in the clinical responses. In 
conclusion, this study demonstrated that WT1 vaccination can induce WT1-specific CTLs 
and result in cancer regression without damage to normal tissues in the clinical setting (Oka 
et al., 2004).  
Two groups reported mouse models of adoptive transfer of T cells with WT1-specific TCR 
genes: one group developed a novel strategy to induce both tumour-specific T helper 1 (Th1) 
and type 1 cytotoxic T (Tc1) cells by lentiviral transduction of HLA-A24–restricted TCR α 
and β chain genes isolated from a WT1-specific Tc1 clone. WT1-TCR gene-transduced Th1 
and Tc1 cells, exhibited both cytotoxicity and cytokine production in response to WT1 
tumour peptide–pulsed HLA-A24+ cells and freshly isolated HLA-A24+ WT1+ leukemic 
cells (Morris et al., 2006). Another group confirmed the feasibility of producing WT1-
specific cytotoxic T lymphocytes (CTL) by transferring the WT1-TCR into T cells isolated 
from CML and AML patients. WT1-transduced T cells displayed HLA-A2–restricted 
cytotoxicity against leukaemia cell lines and against CD34+ cells isolated from leukaemia 
patients. This strongly suggests that patient’s T cells are functionally active and that WT1-
TCR gene transfer is likely to enable them to recognize autologous leukaemia cells. The 
survival and efficacy of TCR-transduced human T cells is likely to be greater in patients than 
in the murine model experiments used in this study (Xue et al., 2005). Recently, a 
translational study using mouse xenograft models; which transfused with WT1-TCR  
transduced T cells, for AML therapy was reported. This group developed a safe and effective 
WT1-TCR retroviral vector for adoptive immunotherapy trials with tailored T cells. They 
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generated various types of retroviral constructs encompassing unmodified or codon optimised 
WT1-TCR α/β genes that had been functionally analysed in vitro. The best active construct 
then tested in an autologous primary leukaemia model in vivo. This study provides a solid 
foundation for the planned WT1-TCR gene therapy trial in leukaemia patients (Xue et al., 
2010). 
One of the most significant recent studies using WT1 in adoptive T cell therapy was to study 
the correlation between self-antigen expression in normal tissues and phenotype and function 
of WT1-specific T cells in thymus and peripheral blood. A recent study designed a murine 
model experiment to analyse the thymus development of WT1-specific TCR and to define the 
fate of these cells in periphery. Murine hematopoietic stem cells (HSCs) were purified and 
transduced with WT1-TCR genes; these modified cells were then injected into HLA- A0201 
transgenic mice. The outcome of this experiment showed that WT1-TCR specific T cell 
differentiate into memory T cells and are able to exhibit antigen-specific effector activity; 
moreover, they were not diminished by central or peripheral tolerance. In brief, this study 
demonstrated that WT1 specific T cells did not show any signs of self-antigen tolerance and 
differentiated into fully functional memory phenotype T cells (Pospori et al., 2011). 
1.2.5 Chimeric Antigen Receptors (CARs):  TCR-based anticancer therapies are constrained by HLA restriction, which limits the 
applicability of TCR therapy to patients who express a particular HLA type. Additionally, 
antigen expression of tumours can be lost by HLA down-regulation (Garrido et al., 1997). 
Alternatively, chimeric antigen receptors (CARs) can overcome these considerable barriers 
because they can redirect T cell specificity towards non-HLA-restricted antigens. Moreover, 
the affinity of antigen binding mediated via antibody-derived recognition is much stronger 
than that afforded by conventional  TCR (Kalos et al., 2011).  
Eshhar and colleagues were the first scientific group to explore CARs, conducting their 
research in 1989. CARs design merges both antibody-like detection with a T cell activation 
role (Maher, 2012). CARs are hybrid molecules composed of a tumour-antigen binding 
domain of a single chain variable fragment (scFv) antibody, originating out of a murine 
monoclonal antibody (ectodomain), and fused to one or more T cell intracellular-signaling 
domains. They are responsible for activation, persistence, trafficking and effector functions 
(Finney et al., 1998), (Krause et al., 1998) in transduced T cells (endodomain) after 
stimulation through a transmembrane domain, which  anchors CARs to T cells, and which is 
linked to a spacer protein (Figure 5) (Eshhar et al., 1993, Bridgeman et al., 2010).  
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Figure 5: Schematic diagram exhibits the different components of chimeric antigen receptors (CARs): Left: the sequence of the antigen target motif typically is derived monoclonal antibody which determines CAR specificity. Right: variable regions (H+L) from antibody used to provide specificity to an antigen and are joined by peptide linkers. Spacer protrudes construct from cell surface and intracellular domains allow activation of signaling pathways. 
1.2.5.1 Three Generations of CARs: 
CAR specificity is determined by the antigen-targeting domain (scFv), which consists of 
cloned variable regions of heavy and light chain antigen-specific monoclonal antibodies. The 
scFv is linked to the transmembrane and intracellular signaling domain via linker/spacer 
hinge proteins. The transmembrane domain is derived from the CD4 or CD8 and CD3- 
activation region, in addition to the co-stimulatory molecules which involve CD27, CD28, 4-
1-BB and/or OX40, depending on the CAR generation configuration (Sadelain et al., 2013, 
Qasim and Thrasher, 2014).  
CAR’s design has evolved over many decades.  It was first described as a murine-derived 
receptor, and is now known as a complicated third generation configuration with humanised 
sequence. The main aim of developing more complex configurations of CAR design is to 
enhance the T cell signaling mechanism which leads to sustained in vivo persistence of 
engineered T cells and robust anti-tumour activity. In first-generation CARs, signals 
occurring when activated are transmitted through ITAM domains on CD3-ζ only. Early 
clinical trial data relating to the function of CARs demonstrated that first-generation CARs 
produce a number of signals insufficient to sustain the in vivo persistence of T cells. 
Therefore, another intracellular T cell co-stimulatory molecule, such as CD28 or CD137, has 
been incorporated into CARs to produce second-generation CARs. Animal studies have 
suggested that T cells bearing second-generation, antigen-specific CARs exhibited improved 
anti-tumour activity compared with T cell-expressing, first-generation CARs, as well as, 
longer in-vivo persistence of CAR engineered T cells. Third generation CARs incorporate 
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 additional signaling domains 
family members like 4-1BB or OX40 
survival. Pre-clinical data has 
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elimination of gp120 are powerfully able to kill HIV-1 in vitro and inhibit viral replication in 
HIV infected cells. The CD4-CD3ζ approach has since been transferred to the clinic (Walker 
et al., 2000). In 2002, a randomised phase II study of CD4-ζ T cells in 40 patients confirmed 
that CD4-ζ T cell infusions resulted in elevated CD4+ T cell counts. In addition, this trial 
observed a prolonged and stable persistence of CD4ζ T cells in the blood and in the 
movement of matter towards the gut mucosa (Deeks et al., 2002). Together with other CD4+ 
T cell adoptive-transfer studies (not discussed here), these trials provided substantial data 
illustrating the safety and feasibility of adoptive therapy with CD4ζ gene-modified cells for 
HIV-infected subjects. 
1.2.5.2.b GD2 CARs: 
In 2008, Pule laboratory (Cancer Institute, UCL, London, UK) conducted a clinical trial in 
which a chimeric antigen receptor was designed against disialoganglioside GD2 (a non-viral, 
tumour-associated antigen) for the treatment of neuroblastoma. In this trial, cytotoxic T cells 
(CTLs) against Epstin Barr virus (EBV) (EBV-CTLs) were engineered to express GD2CAR. 
Two sets of engineered cytotoxic T lymphocytes (CTLs) were applied to eleven patients with 
neuroblastoma: human virus-specific CTLs expressing CAR directed GD2 and non-viral-
activated T cells expressing the same GD2-CAR. The outcome data of this study showed that 
four subjects had evidence of tumour necrosis or regression, and none of them developed any 
detectable antibodies to CAR-CTLs; additionally, the study showed that EBV-CTLs  
expressing GD2CAR are able to survive longer than the non-viral activated GD2CAR T cells 
(Pule et al., 2008). Another ongoing study using CAR T cells targeting GD2 antigen in 
neuroblastoma patients has proved the efficiency of CAR T cell therapy; among the 19 
subjects enrolled; three of them with active disease achieved complete remission, and 
persistence of GD2CAR beyond six weeks was associated with superior clinical outcomes 
(Louis et al., 2011). This study is registered at http://www.clinialtrials.gov/as NCT00085930. 
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Cancer  Target Antigen  Gene construct/generation  Gene transfer  Comments  References  
RCC  CAIX  scFv-CD3 1st generation CAR  Gamma RTV  No objective responses, limited persistence.  (Lamers et al., 2013) 
Indolent B- NHL and mantle cell lymphoma  CD20  scFv-CD3ξ 1st generation  EP  
7 patients: 2 maintained CR, 1 PR, 4 SD. Successful demonstration of non- viral gene transfer. Car T cell persisted for 1–3 weeks alone/5–9 weeks with IL-2.  
(Till et al., 2008) 
Indolent B- NHL and mantle cell lymphoma  CD20  
scFv-CD28- 41BB-CD3ξ 3rd generation  EP  4 patients: 2 SD, 2PR. Car T cell persisted for 1 year.  (Till et al., 2012) 
Ovarian cancer  FR  scFv-CD3ξ 1st generation  Gama RTV  
14 patients were assigned to 1 of 2 cohorts in the study. 8 patients in cohort 1 received a dose escalation of T cells in combination with high-dose interleukin-2. 6 patients in cohort 2 received dual-specific T cells (reactive with both FR and allogeneic cells). Toxicity mostly due to IL-2 injections. Limited persistence of CAR T cells.  
(Kershaw et al., 2006) 
Colorectal cancer  ErbB2  scFv-CD28- 41BB-cd3ξ 3rd generation  Gamma RTV  Fatal , early respiratory distress and lung inflammation  (Morgan et al., 2010) Table 2: Summary of some selected clinical trials that have utilised CARs gene-modified T cells. Abbreviations: RCC: renal cell carcinoma; CLL: chronic lymphoblastic leukaemia; ALL: acute lymphoblastic leukaemia; EP: electroporation 
1.2.5.c This CD19CAR:  At the present time, human CD19 antigen is considered the most investigated TAA in T-cell 
CAR therapy and this is due to several factors: CD19 antigen expression is restricted to B-
cells and B-cell progenitors and it is not expressed by other hematopoietic stem cells, which 
allows scientists to target only B-cell lineage without affecting other hematopoietic lineage 
(Stamenkovic and Seed, 1988, Muschen et al., 2002). Also, CD19 is abundantly expressed by 
neoplastic cells that originate from B-cell lineage, such as lymphoma and lymphocytic 
leukaemia (Campo et al., 2011).  B cell malignancies were one of the first types of cancers 
eradicated by CAR T cell therapy in murine models. Nowadays, impressive reports have 
emerged highlighting the remarkable response rate in 60-90% of B-cell malignancies in 
patients with relapsed or refectory lymphoblastic leukaemia. Another CD19CAR trial is 
explained in the following table. 
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Cancer CAR construct Gene transfer  Comments  References  
CLL or ALL  scFv-CD28- CD3ξ 2nd generation  Gamma-RV 
Ten patients: 1 death, 
3 SD. CAR T cells 
persist for 40 days.  
(Brentjens et al., 2011) 
NHL  
scFv-CD3ξ 1st 
generation vs. scFv-
CD28- CD3ξ 2nd 
generation  
Gamma-RV 
6 patients enrolled. 
CD28 co- stimulation 
improved in vivo 
expansion and 
persistence of CAR+T 
cells for more than 6 
months.  
(Savoldo et al., 2011) 
NHL  scFv – CD3ξ 1st generation Electroporation 
4 patients: 2 
maintained CR. 1–7 
days cellular immune 
response against CAR 
T cells  
(Till et al., 2008) 
CLL  scFv-41BB- CD3ξ 2nd generation  LV  
3 patients: 2 CR, 1 
PR. CAR T cells 
persisted for more 
than 6 months.  
(Kalos et al., 2011) 
ALL scFv-41BB- CD3ξ 2nd 
generation 
LV 4 patients: 2 CR, 1 durable >18 months. 1 relapse, with blast cells that no longer expressed CD19  
(Grupp et al., 2013) 
FL,CLL, B-cell 
lymphoma 
scFv-CD28- CD3ξ 2nd 
generation 
Gamma-RV 1 patient shows 
complete regression 
of FL. 
8 patients: 6 obtained 
remission, ` patient 
developed long-term 
depletion of normal 
polyclonal CD19+ B 
cells and 1 has SD. 
CAR T cells persisted 
for 14 weeks. 
(Kochenderfer et al., 2010).clinicaltrials.gov as #NCT00924326. (Kochenderfer et al., 
2011) 
ClinicalTrials.gov as NCT00924326.  
Table 3: Summary of some selected clinical trials that have utilised CD19CARs gene-modified T-cells. Abbreviations: CR: complete response; PR: partial response; CLL: chronic lymphoblastic leukaemia; ALL: acute lymphoblastic leukaemia; FR FL: follicular lymphoma. 
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1.3 Limitations of antigen-specific gene transfer therapy:  Despite the growing number and length of remissions using antigen-specific T cell therapy to 
treat lymphomas and leukemia, considerable barriers might affect the efficacy of the 
genetically modified T cells.  One factor that might have an impact on treatment is the tumor 
microenvironment itself. Tumor microenvironment is an immune suppressive media which is 
composed of neoplastic cells, vasculature and immune cells and also contains some 
molecules that affect the antigen presenting process to T-cells. As a result, T cells will not be 
able to recognise sick cells; leading to the propagation of the cancerous cells (Zou, 2005). 
Additionally, tumor microenvironment is characterised by the presence of large numbers of T 
regulatory cells (Tregs); which have a huge impact in reducing anti-tumor activity of 
genetically modified T cells (Curiel, 2007). Before applying the treatment, lymphodepletion 
regimes might decrease the number of Tregs and improve the efficacy of anti-tumor activity 
of the genetically modified T cells (Schmitt et al., 2009). Moreover, clinical studies have 
demonstrated that reducing the numbers of circulating T cells (lymphodepletion) as part of 
preparative regimes prior to the treatment could promote in vivo persistence, survival and 
expansion of the transferred genetically modified T cells by decreasing the competition for 
IL-7 and IL-15 cytokines that are responsible for T cell proliferation and existence 
(Klebanoff et al., 2005b, Gattinoni et al., 2005a, Paulos et al., 2007).   
Another factor that can influence the long-term outcome of efficacy following genetically 
modified T cell therapy is that cancerous cells might down regulate the expression of the 
targeted TAA (Grupp et al., 2013). In one case study following anti-CD19 CAR T cell 
therapy, scientists noticed that after a complete remission of the lymphoplastic cells, blast 
cells emerged again without the expression of CD19 (Maude et al., 2014).  
The risk of losing TAA expression remains to be elucidated. Also, cell dose of the therapeutic 
product might have an impact on the efficacy of T cell based immunotherapies. Pre-clinical 
experiments have shown that transferring more numbers of genetically engineered T cells 
results in a progressive improvement in tumour regression (Klebanoff et al., 2011). 
Although this technique holds promise as a strategy to eradicate malignancies, there are 
potential safety risks associated with using these genetically engineered T-cells as a therapy. 
Safety hazards include the following: on-target off-tumor reactivity, off-target reactivity and 
cytokines release syndrome (Bendle et al., 2010). Antigen-specific gene transfer therapy 
involves a genetic alteration of donor-derived T cells to express an antigen-specific receptor 
that is directed against a particular TAA. As a result, immunoreactivity of the therapeutic, 
pg. 40  
genetically modified T cells would be induced to eliminate cancerous cells only without 
affecting other normal cells. Choosing an optimal antigen target that is only expressed by 
tumor cells is a demanding and challenging task. Most of the TAAs are expressed by both 
cancer and normal cells; as a result, genetically modified T cells recognise TAAs on normal 
body tissue; even if they express at a very low level, resulting and triggering an immune 
response against normal healthy body tissue (Johnson et al., 2009b); this phenomenon is 
called “on-target off tumor toxicity” (Casucci et al., 2015).  Engineering T cells with higher 
selectivity towards certain tumours might be one solution to improve the treatment and avoid 
on-target off-tumor toxicity. One study has suggested a dual-CAR targeting strategy (Lanitis 
et al., 2013, Pegram et al., 2012); where T cells are engineered to express two CARs targeting 
two different target-antigens on tumour cells to ensure that modified T cells will only activate 
once engaged to both antigens on tumour cells. The proof-of-concept of this strategy has 
shown a promise that modified T-cell therapies might be safer using this approach (Kloss et 
al., 2013). 
The risk of off-target reactivity is mainly related with TCR gene transfer T cell therapies 
where the newly introduced TCR might react against a peptide in proteins other than the 
targeted ones. Some authors have demonstrated that the other cause of off-target reactivity is 
the formation of mixed dimers between the introduced and the endogenous TCR alpha and 
beta chains. The assembly and surface expression of an exogenous TCR is a complex and 
intricate process, requiring the pairing of the introduced alpha and beta chains to form a 
heterodimer that is then joined with the four invariant CD3 chains. In transduced T cells, the 
introduced alpha or beta chains have the potential to form heterodimers with the 
complementary alpha or beta chain. This results in the production of novel TCR with 
unknown specificity, which might provoke off-target autoimmunity (van Loenen et al., 2010, 
Bendle et al., 2010). Additionally, levels of CD3 are finite within T cells, and consequently, 
wrongly mis-paired TCRs might compete with the exogenous TCR for CD3 leading to the 
usage of CD3 stock by endogenous TCR; as a result, the expression level of introduced TCR 
will be reduced (Morris et al., 2003). Several strategies have been explored with the aim of 
overcoming these hurdles: one aims to reduce the mis-pairing phenomenon between α and β 
chains of therapeutic-exogenous TCR and endogenous TCR; others aim to eliminate 
endogenous TCR expression and improve the graft-versus-leukaemia/-lymphoma effect. 
Furthermore, the endogenous αβ TCR may recognise major and minor histocompatibility 
antigens in the recipient, leading to GVHD in the allogeneic setting. As a consequence, most 
clinical trials conducted at present are infusing autologous, re-engineered, antigen-specific T 
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lymphocytes to diminish the possibility that endogenous αβ TCR will recognise normal 
tissues after adoptive transfer (Torikai et al., 2012). Brentjens and his group suggested that 
using autologous, genetically modified; antigen-specific T cells have achieved initial success 
in clinical trials targeting hematological malignancies (Brentjens et al., 2011). However, it 
could be argued that this approach is limited by the time and expense required to manufacture 
an antigen-specific T cell product for each patient.  
Finally, cytokines release syndrome is considered the main drawback of genetically modified 
CAR T cell therapy (Maus et al., 2014). Clinical studies have shown that T-cell therapies can 
induce a fast and potent eradication of tumor cells resulting in the production of high levels 
of cytokines release and macrophage activation syndrome. Following CAR T cell therapy, 
clinical trials have demonstrated that patients might suffer from high fever, nausea, diarrhea 
and rigors which might be due to high levels of INF- and IL-6 production (Maude et al., 
2014). Some recent studies have exhibited that administration of anti-IL6 receptor (Teachey 
et al., 2013) might prevent these reactions, but the timing of applying this reagent is not yet 
known, neither is it known whether  it has any impact on the efficacy of the tumor regression 
and elimination by the genetically engineered T cells. 
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T cell therapy Disease Antigen-target Adverse event Reason Reference 
Genetically 
modified T cells 
Melanoma MAGE-A3 3 patients 
developed 
neurological 
toxicity: 2 died, 
1 had full 
neurological 
recovery 
On-target off-
tumor 
reactivity. 
MAGE-A3 
antigen is 
expressed by 
neurological 
cells.  
(Morgan et al., 
2013) 
Genetically 
modified T cells 
Myeloma and 
melanoma 
Affinity 
enhanced TCR 
against MAG-
A3 
2 subjects died 
of cardiac 
toxicity after 5 
days of infusion 
Off-target 
reactivity; 
peptide from 
heart muscle 
protein was 
identified as an 
alternative 
target of 
MAGE-A3 
TCR T cells 
(Linette et al., 
2013, Cameron 
et al., 2013) 
Genetically 
modified T cells 
Metastatic 
colorectal 
cancer 
CEA Diarrhea, fever On-target off 
tumor 
reactivity; 
(Parkhurst et al., 
2011) 
CAR-T cell ALL CD19 Continuous 
depletion of 
normal B cells 
On-target of 
target toxicity. 
CD19 is 
expressed by 
normal B cells 
(Grupp et al., 
2013) 
CAR- T cell CLL CD19 Persistence 
fever associated 
with 
hypotension and 
respiratory 
distress and 
subsequently 
died  
Cytokines 
release storm 
(Brentjens et al., 
2010) 
CAR-T cell Metastatic renal 
cell carcinoma 
CAIX Liver enzyme 
disruption  
Cytokines 
release storm 
(Lamers et al., 
2013) 
Table 4: Summary of some adverse events from T-cell therapy clinical trials. CLL: chronic lymphoblastic leukaemia; ALL: acute lymphoblastic leukaemia; CAIX: carboxy-anhydrase-IX 
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In addition to the previously mentioned challenges facing antigen-specific T cell therapy, 
efficient gene transfer methodologies to T cells and their acceptable safety profile is still a 
matter of concern. Several means of gene transfer in human T lymphocyte will be discussed 
later in the text. 
1.4 Improving the efficacy of T-cell therapies: 
Multiple research groups have attempted, by different means, to promote the preferred 
assembly and surface expression of the exogenous alpha and beta chains in TCR (Govers et 
al., 2010). The first strategy to lessen mixed dimer formation was to use hybrid TCRs with 
human variable domains and a murine constant region. Compared with human TCR, a 
murine-human TCR hybrid enhanced the homologous pairing of introduced TCR and it 
expressed more efficiently in human T-cells: however, proven immunogenicity against the 
murine compartment might be a major concern (Cohen et al., 2006, Sommermeyer and 
Uckert, 2010, Thomas et al., 2007). Another approach is to replace the threonine-48 on the 
alpha chain and serine-57 on the beta chain with cysteines, forming an additional 
intramolecular disulphide bond within the constant compartment of the exogenous TCR alpha 
beta chains. The modified peptides pair more efficiently, resulting in boosted TCR expression 
and improving its functional activity (Kuball et al., 2009). An alternative approach focused 
on improving the translation of the transgenic TCR mRNA. Codon optimisation of the 
exogenous TCR genes favours the pairing of the introduced chains and increased TCR 
reactivity by introducing a point mutation into constant domain of  and  chain (Gustafsson 
et al., 2004). Recently, an alternative platform has been explored; and has proven its 
efficiency in reducing TCR mis-pairing by knocking down the expression of the endogenous 
TCR by targeted gene therapy using specific DNA nucleases (Provasi et al., 2012, Bunse et 
al., 2014). Several means of disrupting endogenous  and  TCR expression on T 
lymphocyte will be discussed later in the text. Although these strategies led to a significant 
increase in the expression of the introduced TCR, they fall short of ensuring the high 
expression levels that are essential for high-avidity tumour-specific T cell effectors. Most 
crucially, the mis-pairing phenomenon with the endogenously expressed TCR is not fully 
eradicated in these strategies. 
Another important factor in order to improve T-cell therapy is to manipulate or retain T-cell 
differentiation in favor of antigen-specific T cell. Generally, it has been shown that 
adoptively transferred genetically modified T cells are highly differentiated into effector 
memory T cells which display abbreviated survival, impotent anti-tumor activity and immune 
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exhaustion post-infusion. Culturing engineered T cells in an environment containing   
cytokines just as IL-7 and IL-15 (Kaneko et al., 2009); or IL-15 and IL-21 (Pouw et al., 2010) 
pre-infusion to drive T-cell differentiation might retain the central memory T-lymphocytes 
phenotype, prolonged peripheral persistence and potent anti-tumor activity (Zoon et al., 2015, 
Montes et al., 2005). Another different strategy is focused on engineering naïve cord blood T 
cells to express CAR or antigen-specific TCR instead of adult antigen-experienced T cells 
(Thompson et al., 2015, Tammana et al., 2010). CB-T cells have a naïve phenotype and they 
might retain their less differentiated phenotype following in vitro stimulation and genetic 
manipulation prior to the adoptive T-cell transfer; which results in generating potent anti-
tumor engineered T cells with naïve or stem cell memory phenotype and great capacity of in 
vivo survival and proliferation following infusion (Frumento et al., 2013). Moreover, CB-T 
cells mediate potent antiviral and anti-leukemia effects following allogeneic transplantation, 
and further reduce the possibility of graft-versus-host disease occurring, as compared to the 
risk posed by peripheral blood grafts (de Haar et al., 2015). Since single-cord blood graft has 
a limited hematopoietic stem cell dose, it is not unusual to pool matched or partially HLA-
matched donations, and this may provide an opportunity to supplement grafts using 
engineered T cells with additional HLA- matched donations. To mitigate the GVHD effect in 
the allo-setting and to generate “off-the-shelf” universal T cells expressing antigen-specific 
receptors, we proposed a strategy based on using genetically engineered cord blood T cells 
(CB-T cells)(Eapen et al., 2007, Hiwarkar et al., 2015).  
1.5 Eliminating endogenous TCR expression: 
As it has been mentioned before in the text; one of the strategies to reduce the mis-pairing 
adverse event that is related to TCR gene transfer therapy is to knock down the expression of 
endogenous  TCR. Gene editing technology has emerged recently; where specific 
molecular reagents are capable of driving a highly specific DNA cleavage using targeted 
nucleases. 
Gene-specific targeting is a precise gene spotting strategy in which the mutant version of the 
gene might be replaced with the normal, functional copy at the exact site of the endogenous 
gene, the consequence being that the gene restores its normal function. Moreover, by 
targeting the specific locus of the desired gene, unpredictable genetic effects, such as the 
random integration of the transgene, and the production of mutagenesis, might be controlled. 
These tailored endonucleases induce a double strand break (DSB) at a specific locus within 
the genome: consequently, DNA-repairing mechanisms will take place, resulting in either 
 switching off of the gene’s function via the second DNA
non-homologous recombination end joining (NHEJ)
via homologous recombination (HR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The mechanism of DNA double strand break (DSB) repair. pathways: homologous recombination (left) or nongene replacement, while NHEJ leads to gene inactivation.
-repairing pathway, a process called 
, or replace the mutant form of th
(Figure 7) (Takata et al., 1998). 
DSB is repaired by tw-homologous end-joining (NHEJ) (right). HR can result in  
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Several types of tailored endonucleases have been engineered and used as DNA-targeting 
tools in different studies and include meganucleases (MGNs) (Silva et al., 2011), zinc finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) (Joung and 
Sander, 2013), and clustered regularly interspaced short palindromic repeats (CRISPR) 
(Sander and Joung, 2014, Jinek et al., 2012, Mali et al., 2013) reagents.    
Another advantage of eliminating the internal  TCR expression is that it might provide a 
new strategy to produce “universal” off-the shelf therapeutic antigen-specific T cell products 
from unrelated donors to be administrated to multiple subjects without causing GVHD 
(Torikai et al., 2012). 
In this project, the feasibility of using other endonucleases such as MGN, TALENs and 
CRISPR/Cas9 targeting constant regions of  and/or  chain of TCR was investigated. In the 
next section, a brief description of each gene-editing tool will be discussed. 
1.5.1 siRNA knocking down endogenous  TCR expression: 
As an alternative to protein engineering, a Japanese group reported that small interfering 
RNA (siRNA) has the ability to down-regulate endogenous TCR expression, which leads to a 
decrease in the potential for mis-pairing, thus improving the expression and reactivity of 
introduced TCR. They designed a system that can express therapeutic TCR while silencing 
the expression of endogenous TCRs by using a siTCR retroviral vector. This vector encodes 
the alpha and beta chains for TCR, recognizing the tumor specific antigen named MAGE-A4, 
and siRNA simultaneously targets conserved regions in the wild-type TCR constant domain. 
The results of this study demonstrated that a primary human T cell transduced with a MAGE-
A4-TCR-siRNA vector led to an elevated expression of introduced TCR and reduced, but did 
not eradicate, the expression of endogenous TCR (Ochi et al., 2011). Recent studies 
incorporated siRNA to a Wilms Tumor antigen 1 (WT-1)-specific TCR vector. The 
promising data produced by this study illustrated an increase in anti-leukaemia activity in 
vivo: a reduction in the potential loss of antigen specificity after expansion was also noticed, 
possibly reflecting the diminished generation of mis-paired TCRs(Okamoto et al., 2012). 
These data from RNA interference lend theoretical support to a novel strategy that uses 
genome-targeting technology. 
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1.5.2 ZFNs knocking down endogenous  TCR expression: 
ZFNs are hybrid artificial DNA endonucleases that are comprised of adjusted-design 
(customized) zinc finger DNA binding domains that fuse to non-specific cleavage 
endonuclease domains of a restriction enzyme called Fok1. 
In 2012, Provasi et al. designed zinc-finger nucleases to edit T cell specificity at the DNA 
level by knocking out the endogenous TCR. Although this study yielded promising data, T 
cells were exposed to two rounds of stimulation with CD3/CD28 beads and two viral vectors 
were used to deliver ZFNs and antigen-specific alpha beta TCR genes: adenovirus and 
lentivirus, respectively (Provasi et al., 2012). Consequently, the yield population of 
therapeutic T cells will be highly differentiated and exhausted; unfavorable conditions for 
adoptive immunotherapy. In addition, ZFNs have been criticized in past studies for their 
propensity to cleave off-target sequences, resulting in toxicity (Beumer et al., 2008). 
Moreover, designing highly specific ZFNs targeting a novel DNA sequence can be time and 
resource intensive, limiting the development of additional targeting tools (Isalan, 2012). 
1.5.3 Meganucleases: 
MGN are sequence-specific endonucleases recognizing large and unique DNA sequences 
(12–45 base pairs)(Paques and Duchateau, 2007). Their recognition sites are extremely rare 
within the genome, and consequently the chance of an off-target toxicity effect occurring is 
seldom or almost non-existent. This feature makes meganucleases superior to ZFNs as a 
gene-targeting tool (Meissner et al., 2014). In nature, MGNs promote the propagation of 
mobile genetic elements via a process known as homing. Homing endonucleases can be 
redesigned to target a specific sequence within the genome. The MGNs that are used in this 
study are called I-CreI and belong to the LAGLIDADG family of homing endonucleases. I- 
CreI has been exposed to different mutations in its DNA-interacting region to allow the 
cleavage of a precise sequence within the T cell receptor beta chain gene, resulting in gene 
inactivation (Barzel et al., 2011). 
The process of engineering and designing a novel MGN with high specificity requires 
empirical and selection-based approaches that can be time and resource consuming (Epinat et 
al., 2003). TALENs (see directly below for definition) thus far appear not to be subject to the 
previous limitations suffered by both MGN and ZFNs. 
1.5.4 TALENs: 
Another chimeric molecule known as TALENs, composed of a non-specific cleavage domain 
of endonuclease FokI, and fused to a specifically designed DNA-recognition domain, is 
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becoming an attractive tool for gene targeting and manipulating. Transcription activator like 
effectors (TALEs) are a unique class of DNA-binding proteins that are naturally produced by 
plant-pathogenic bacteria in the genus Xanthomonas. Their main function is to directly 
modulate host gene expression to enhance virulence (ability to cause disease). TALE’s DNA-
binding domain is comprised of a central region of 15.5–19.5 highly conserved units in a 
unique tandem array. Each repeat consists of 33–35 amino acids, which confers DNA-
binding specificity, flanked by an N-terminal domain and a nuclear localisation domain prior 
to being flanked by C-terminal, transcriptional activation domain (Sun and Zhao, 2013, 
Holkers et al., 2013a). The repetitive units’ sequence of TALE is identical except for two 
extremely variable amino acids at positions 12 and 13 known as ‘repeat- variable di-residue’ 
(RVD) that establishes the base-recognition specificity of each unit (Figure 8). In other 
words, each RVD preferentially recognises one of the four bases in the target site. This one-
repeat-to-one-base relationship allows one to predict how the TALE site will bind to a 
specific nucleotide within the genome and easily customises the TALE domain targeting a 
sequence of interest (Miller et al., 2011, Li et al., 2012). Because of this, as well as the 
minimal, off-target cleavage activity of TALENs compared to ZFNs, TALENs have attracted 
great interest as a potential DNA-targeting tool. In December 2015, at the meeting of the 
American Society of Hematology (ASH) in Orlando, a conference paper was presented on 
the first clinical application of “universal” CD19-targeted CAR T cells modified by TALENs 
targeting alpha constant regions to knock out the expression of endogenous T-cell receptors, 
which effectively eliminates the risk of GVHD (Qasim et al., 2015a). The therapy was used 
to treat an infant with refractory, relapsed B-cell acute lymphocytic leukemia under the basis 
of UK special therapy regulations. Although the follow-up period is still quite short, the 
intervention, comprising lymphodepletion and infusion of the universal CD19 CAR T cells, 
has induced molecular remission where all other treatments have failed. 
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1.5.5 CRISPR/Cas9 
The CRISPR/Cas9 genetic engineering tool is comprised of two main compartments: Cas9 
nucleases; the part that is responsible for DNA cleavage; and guide RNAs: small molecules 
that direct Cas9 toward a specific sequence within the genome (Jinek et al., 2012). Clustered 
regularly interspaced short palindromic repeats (CRISPR) are an adaptive defense 
mechanism that evolved by many species of bacteria and archaea to protect them against 
exogenic mobile genetic elements derived from invading  foreign DNA. Once foreign nucleic 
acid is invading these microbes, few fragments of the invader DNA sequence are captured 
and inserted as a “spacer” between identical repeats that are specific to a particular CRISPR 
system. Once the DNA locus is transcripted, a precursor RNA is produced then processed to 
small fragments of one spacer linked to a portion of the repeats sequence. When the same 
virus or parasite infect the host again, the corresponding RNA guides the destruction process 
of the invading DNA or RNA. The production of spacer RNAs and the cleavage of the 
ATATCCAGAACCCTGACCCTGCCGTGTACCAGCTGAGAGA TATAGGTCTTGGGACTGGGACGGCACATGGTCGACTCTCT 
FoK I 
L-TALEs 
R-TALEs 
N-terminal domain C-terminal domain 
N-terminal domain C-terminal domain 
FoK I
L-TALEsN-terminaldomain C-terminaldomain
LTPDQVVAIASHDGGKQALETVQRLLPVLCQDHG
Figure 8: Schematic diagram of a transcription activator-like effector nucleases (TALENs). TALE repeats (top) are represented as coloured rectangles flanked with N- and C-terminal motifs. Bottom diagram exhibits the TALE-derived, DNA-binding domain. The amino acid sequence of a single TALE repeat is expanded with the two hypervariable residues, highlighted in red text. 
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corresponding invading sequence are mediated by Cas proteins (CRISPR-associated) (Sander 
and Joung, 2014, Carroll, 2012). Researchers have discovered that this complex DNA 
cleavage process can be recapped in vitro by using a combination of purified Cas9 and a 
single guide RNA that has minimal features of both spacer and trans-CRISPR activator RNA 
(that is full complementary to the repeat sequence). The cleavage site should be a DNA 
sequence that matches the spacer and a minimum 16 target base pairs are required to ensure 
recognition of the specific sequence within the complex genome. Additionally, a crucial 2 to 
3 base pairs (or more) located just right to the DNA-RNA hybrid region called proto-spacer 
adjacent motif (PAM) is required for Cas9 to recognize target DNA sequence (Jinek et al., 
2012, Wiedenheft et al., 2012). In addition to the simplicity in designing guide RNA 
targeting specific locus and the high efficiency of the system (Yu et al., 2013, Jiang et al., 
2013), CRISPR/Cas9 system is able to target and hit multiple loci within the genome at the 
same time by injecting multiple guide RNAs (Wang et al.). Given all the previous features of 
CRISPR/Cas9, scientists have predicted that this system can potentially be used to replace 
MGNs, ZFNs or TALENs for targeted genomic cleavage in higher organisms (Deltcheva et 
al., 2011). 
 
1.6 Gene delivery to T-cells: 
The further success of gene therapy is partially dependent on the understanding of vector 
biology and of the interaction mechanism between host and delivery agent. Multiple means 
have been explored to deliver a particular gene into human T lymphocytes: 
 
1. 6.1 Non-viral gene delivery system:  
1.6.1.1 DNA Plasmid: 
Naked DNA plasmid can be transferred in T cells by a method known as electroporation or 
nucleoprotein transfection. Transfected T cells can be selected based on the accompanying 
insertion of drug resistant genes. Although the inexpensive cost of this method is a significant 
advantage, it simultaneously suffers from several disadvantages. As naked DNA integrates at 
very low frequency in T cells, this approach is considered inefficient and extended culture for 
several weeks is required to generate sufficient numbers of cells. Consequently, subsequent 
capacity to survive long-term in vivo might be significantly compromised. Moreover, the 
inclusion of antibiotic-resistant genes in T cells might generate immunogenicity leading to 
the premature elimination of these cells in vivo (Jensen et al., 2010). 
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1.6.1.2 Transposons/Transposase systems (Sleeping Beauty and PiggyBac) 
This is a non-viral integration system of gene delivery that relies on two non-viral 
components: i) donor transposon plasmid and ii) helper transposase. This system provides a 
higher integration rate than naked DNA with efficient long-term transgene expression. In 
comparison to some viral vectors, sleeping beauty additionally allows for the insertion of 
larger DNA fragments (Field et al., 2013). 
1.6.2 Viral gene delivery system: 
An optimal viral vector should harness its viral infection and integration pathways without 
pathogenicity or subsequent expression of viral genes, or the formation of infectious, 
replication competent viral particles. Producing a virus vector with the previous features 
requires the deletion of some coding regions, while leaving the sequences that are required 
for in cis functions, such as the movement of the packaging vector genome into the virus 
capsid, or the integrated viral genome into the host DNA (not all vectors genome is able to 
integrate, for example,  recombinante associated adenovirus genome don’t integrate to the 
host genome). Replacement of these sequences with expression cassette allows the 
expression of therapeutic transgenes. Besides having the ability to carry foreign genes and 
express them efficiently and steadily, the production of stable, propagated vectors, and the 
ability to be purified to high titers are some of the additional characteristics required to 
generate an ideal gene delivery vehicle. There are five main popular categories for vector 
engineering: oncoretroviruses, lentiviruses (LV), adenoviruses, adeno-associated viruses and 
herpes simplex viruses (Walther and Stein, 2000). For T cells, gamma RV and LV have been 
most useful. 
1.6.2.1 Gamma-Retroviruses: 
 Because of their ability to stably integrate into the host cell genome, retroviruses are 
considered the most useful vehicle to deliver genes into mammalian cells. Retroviruses are 
RNA viruses with the ability to reverse transcribe their genome into double-strands (ds) DNA 
(proviral). In addition to the stable, long-term expression of the transgene, retroviruses 
possess other features that make them a useful tool for therapeutic applications: for example, 
they have the ability to infect a wide variety of cell types with a low cytotoxic profile 
compared to other virus vectors. Also, they are capable of carrying foreign genes of 
reasonable sizes (8 kilobases (kb)) and of generating viral vectors with significant titres for 
efficient gene transfer. However, a gammaretrovirus like Moloney murine leukemia virus 
(MMLV) has the tendency to integrate near-regulatory sites of the active gene: therefore, if 
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the genes adjacent to integration site are porto-oncogenes, this might lead to insertional 
mutagenesis, which is defined as the chance integration of a provirus adjacent to a cellular 
proto-oncogene, perturbing its expression and thus potentially resulting in oncogenesis. This 
phenomenon has been observed in four patients with severe combined immunodeficiency 
(SCID-X1) and one Wiskott-Aldrich syndrome (WAS) patient who was treated with 
gammaretrovirus and developed T cell leukaemias. The study revealed that the retrovirus 
integrated near the promoter pg LMO2 gene, which is a proto-oncogene related to T cell 
leukemias (Hacein-Bey-Abina et al., 2003). Another drawback feature associated with 
gammaretrovirus vectors is that they can only gain access to the cell nucleus during the cell 
division cycle at the point where the nuclear membrane breaks down: consequently, they 
don’t have the ability to transduce non-dividing cells (Park et al., 2000). On the other hand, 
vectors derived from HIV-1 (lentiviral vectors) have the ability to efficiently transduce both 
quiescent and dividing cells: hence, the possible target cell populations will rise remarkably 
to include haematopoietic cells, muscle cells and neurones. Moreover, lentiviral vectors 
possess other advantages that make them superior to retroviral vectors, including their ability 
to carrying genes up to 10kb (which is accompanied by a decreasing of the titre), and the 
possibility of developing insertional mutagenesis with lentiviral vectors is decreased because 
they do not tend to target promoter regions within the genome. 
 
1.6.2.2 HIV-1 lentiviral vectors: 
1.6.2.2.1) Human Immunodeficiency (HIV-1) Virus structure: 
HIV-1 virus is a lentivirus, which is a member of the retrovirus family. Lentiviruses are 
characterised by a period of latency between the infection and the onset of the clinical 
disease. In a manner common to all viruses, HIV-1 utilises cellular machinery in order to 
reproduce and can only replicate within the host cell. Retroviruses are unique in virology, in 
that they allow the genetic material composed of ribonucleic acid (RNA) to be integrated into 
the host deoxyribonucleic acid (DNA) through the employment of the reverse transcriptase 
(RT) enzyme. However, HIV-1 has a unique structure compared with other lentiviruses: it is 
approximately 120 nanometres in diameter and typically described as spherical. The genetic 
material is in the form of 9749 nucleotides, long, single-stranded RNA molecules, of which 
there are two copies in the centre of the virus, which is in turn surrounded by the conical viral 
capsid (protein shell) composed of the protein p24 (Ratner et al., 1985a). The proteins 
contained in the capsid help to ensure that the virion (the extracellular, viral infective agent) 
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is protected against degradation by nucleases. When the virus fuses with the host cell 
membrane, it utilises the plasma membrane to form a protective layer around itself, 
containing the proteins gp120 and gp41 (glycoproteins), which protrude from the cell surface 
in a characteristic spike pattern. The combination of gp120 and gp41 are known as the env 
protein (envelope protein) consisting of a stem of gp41 (3 molecules) and a cap of gp120, 
although the precise configuration of this arrangement is open to interpretation depending on 
the imaging techniques that are utilised (Zhu et al., 2006). However, by using the host 
membrane as a means of protecting the viral genome, it is possible to evade immune 
detection to a certain degree. 
The two distinct components of the HIV-1 virus are thus: the viral envelope, formed by the 
host cell plasma membrane; and the viral core containing the genetic material. The following 
section will consider the structure of the genomic material in HIV-1, along with the 
characteristic enzymes that ensure successful host cell integration of genetic material and 
evasion of degrading enzymes. 
1.6.2.2.2) HIV-1 genome: 
Although HIV belongs to the retrovireade family, there are some distinct features that 
distinguish HIV-1 from other members in this family. HIV genome has 9 open reading 
frames that give rise to 15 different proteins, with the env gene encoding gp120 and gp 40 
(Watts et al. 2009). Common to all retroviruses are the four essential genes: group-specific 
antigen (gag), polymerase (pol), protease (pro) and envelope (env). In addition to these, HIV- 
1 carries six other auxiliary genes: negative regulatory factors (nef), regulator of expression 
of virion proteins (rev), transactivator of transcription (tat), virion infectivity factor (vif), viral 
protein R (vpr), and viral protein U (vpu) (Turner and Summers, 1999). 
Four fundamental genes are responsible for encoding the virus structure: gag encodes internal 
structure proteins such as matrix (MA), capsid (CA), and neucleocapsid (NC) proteins. Pol 
gene is translated to generate the viral enzymes: for instance, reverse transcriptase (RT), 
integrase (IN) and the RNase H. Gag, pol, pro coding sequence is expressed as a polyprotein 
known as gag-pol-pro, which is self-cleaved by a protease enzyme that encodes via the Pro 
gene. Proteins that are associated with the viral envelop, the trans membrane (TM) and 
surface protein (SU), are expressed by the env gene. The remaining six auxiliary genes are 
accountable for encoding proteins that are involved in a broad spectrum of viral mechanisms. 
The first supplementary gene is nef, which plays a role in modifying the host immune 
response. It encodes nef proteins which reduce the expression of CD4 and Major 
histocompatibility complex I and II (MHCI and II): as a result, the virus can escape from the 
 host immune system. The second auxiliary gene is rev, and this gene is in charge of encoding 
proteins that play a major functio
The third non-essential gene is tat: proteins encoded by this gene are at the helm of regulating 
the viral transcription mechanism while proteins encoded by vpr are responsible for guiding 
the viral compartments to their directions inside the cell via a signal called “the nuclear 
localization signals”. Therefore, vpr assists in transporting the pre
from the cytoplasm toward the nuclear pore. Moreover, it induces the arre
G2 phase of the cell-cycle: thus, the virus can increase its transcription and protein 
production. Vpr also has more than one function, 
budding process of the virus. Finally, vif proteins inhib
APOBEC3G, resulting in the production of an infectious progeny of the virus
2009). 
Once the RNA viral genome is reverse transcripted and integrated in the host’s genome
provirus gene is flanked by two equivalent, non
(LTRs). LTR is comprised of three regions
region incorporates the promoter
transcription of viral genes. O
site. The R region is arranged in repeats at both ends and contains the essential seq
strand transfer during the reverse transcription process (Figure 9).
1.6.2.2.3 Virus life cycle: 
The replication of retroviruses is a multi
journey by attaching their surface glycoprotein to specif
virus is attached to its target, the 
allows virus entry (Dragic et al., 1996)
Figure 9 Schematic of HIV-1 genome encodes the structural genes gag, pol, env.and rev, there are accessory genes, vif, vpr, vpu and nef. The provirus is flanked by two identical, long(LTRs); which are subdivided into U3, R and U5 regions. Moreover, the genome also contaipolypurine tract (PPT) and central PPT (cPPT).
n in regulating the gene expression of other virion proteins. 
-integration complex (PIC) 
st of the cells in the 
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it a defensive cell factor called 
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 and enhancer sequences that are essential for the 
n the other hand, the 3’-U5 serves as a transcription termination 
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coating occurs where the viral particle is disassembled. As a result, the viral RNA genome is 
freed in the host cytoplasm and ready for reverse transcription. Reverse transcription starts at 
the 5’ end of RNA (3’ end of tRNA), where the primer-binding site (PBS) is located. 
Transfer RNA (tRNA) will bind to PBS and use reverse transcriptase (RT) to perform its 
function, which converts RNA to (ds) DNA capable of integration into the host genome. 
Once reverse transcription has taken place, a viral complex known as pre-integration complex 
(PIC) will be generated. In order for retroviral PICs to enter the nuclear membrane, mitosis 
(cell division) should occur; on the other hand, lentiviral PICs have the ability to penetrate 
the host nuclear membrane without requiring cell division; this is one of the reasons behind 
the preference for lentiviral vectors over retroviral vectors. PIC has a larger diameter than the 
nuclear pore, and thus, nuclear entry does not occur via simple penetration of PIC through 
these pores. Although the exact mechanism utilised by lentivirus to enter the nucleus is not 
yet fully understood, it has been suggested that many viral and host molecules contribute to 
driving PIC to the nucleus. Once the provirus is inside the nucleus boundaries, viral integrase 
will play its role by chopping part of the host genome and sealing the provirus genome 
instead. Consequently, viral gene expression patterning will commence using host cellular 
machinery (Haseltine, 1991). 
1.2.2.4 The development of third generation lentiviral vector: 
In the first generation of HIV-derived vectors, the replication-defective, recombinant, 
chimeric lentiviral vector is built up from three different components: the first is the 
packaging plasmid expressing the HIV-1 core proteins, enzymes and accessory factors; the 
second plasmid is the envelop plasmid which carries the G envelop glycoprotein gene from 
another virus called the vesicular stomatitis virus (VSV-G) (Figure 10.D); and the last 
expression plasmid is the transfer vector plasmid that encodes the transgene of interest and 
cis-acting elements for HIV-1 that are essential for packaging, reverse transcription and 
integration.  
Generating a vector derived from the pathogenic human virus carrying all its genes, except 
for env, raises biosafety concerns because it would only require a minimal number of 
recombination events to build a functional virulent viral particle. Therefore, re-designing of 
the packaging system has occurred, resulting in the production of a second generation of 
lentiviral vectors. In the second generation, the four accessory non-essential genes are 
eliminated from the packaging system, leaving the four essential HIV-1 genes, gag and pol, 
for expressing all structural and enzymatic components of the virion, and tat and rev, which 
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are crucial for transcriptional and post-transcriptional functions (Figure 10.B). The deletion 
of vif, vpr, vpu and nef from the packaging system has no effect on the production of high 
titres of lentiviral vectors, but it improves the safety profile. Although this second version of 
the viral vector is widespread and there is no evidence for detecting any recombination 
events, additional alterations have been applied to the lentiviral vector for further reduction of 
the recombination effect and the formation of the replication competent lentivirus (RCL).  
To improve the safety profile of viral vectors, 3rd-generation lentiviral vectors have emerged 
(Figure 10.C). One of the differences in the 3rd-generation design is that it has four separate 
plasmids: two packaging plasmids, an envelope plasmid and a vector transfer plasmid. 
Another improvement in the 3rd-generation system is the replacement of the U3 in 5’ LTR in 
the transfer vector plasmid with an active promoter, removing the need of tat to carry on an 
efficient transcription. Additionally, it has been suggested that expressing rev in trans would 
lead to the production of high-titer vector stock. This gene delivery system conserves only 
three of the nine HIV-1 genes, and has four separate transcriptional units for the production 
of vector particles: thus, it offers a remarkable advantage from the point of view of biosafety 
(Dull et al., 1998). 
To address the unwanted outcome of inserted mutagenesis, self-inactivating (SIN) vectors 
have been engineered (Figure 10.A). SIN is viral vectors that incorporate a deletion in U3 
region at 5 ’ LTR, where viral promoter and enhancer are located. Upon reverse transcription 
and integration, this modification will lead to the inactivation of the viral promoter/enhancer 
elements. At the 5’ region of SIN, U3 can be replaced with strong promoters from other 
viruses such as the spleen focus-forming virus LTR (SFFV), which is widely used due to its 
ability to produce high titers and to provide a constant expression. However, SFFV is not 
preferably used in clinical settings due to two reasons: first, SFFV is derived from the gamma 
retrovirus, thus leading to safety concerns; second, it tends to methylate, silencing the gene 
expression process. As a result, a new, human-derived promoter is required. Human 
phosphoglycerate kinase (PGK) promoter can be used to provide a high level of gene 
expression and has been approved for use in clinics (Cooray et al., 2012). 
In addition to the reduction in the number of HIV-1 genes to improve safety, some elements 
are added for different purposes. A mutant version of the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) has been used to increase vector titre and 
boost gene expression (Higashimoto et al., 2007). 
Lentiviral vectors have been widely used in a large number of clinical trials to treat a range of 
diseases. In 2006, the first clinical trial to treat HIV-1 by lentiviral vector was published. This 
 study has revealed crucial information about the efficiency and safety
Moreover, it builds a solid foundation to assist the following gene therapy stud
lentiviral vectors (Levine et al., 2006)
 
  
 
 
Figure 10: Second and third generation lentiviral vectors. second generation system uses the HIVU3 in the 5’ LTR with Tat independent Rous Sarcoma virus (RSV) cPPT=central polypurine tract, WPRE= Woodchuck hepatitis virus post transcriptional regulSecond generation lentiviral packaging plasmid.CMV= Cytomegalovirus lentiviral packaging plasmid. Rev gene is provided in packaging cell in trans using the RSVEnvelop plasmid with vesicular stomatitis virus glycoprotein (VSV
 
 of using these vectors. 
. 
A. Self-inactivating lentiviral transfer vector. The -1 original U3, while the third-generation packaging system substitutes promoter. RRE: rev responsive element, 
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1.7 Aims of the project  
To investigate the feasibility of generating off-the-shelf, universal, antigen-specific T cells 
from healthy donors that can be administered to multiple patients without causing GVHD. 
The main questions addressed in this project are: 
i. Is it feasible to prevent endogenous TCR expression using nuclease technologies? 
ii. Can TCR knockout cells be redirected against target antigens via lentiviral gene 
transfer of antigen specific receptors? 
iii. Do engineered cord blood T cells retain their naïve phenotype after subjected to 
multiple manipulations? 
iv. Do naïve cord blood T cells tolerate multiple manipulations that require knocking out 
TCR and introducing new receptor better than adult T cells? 
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Chapter 2: Materials and Methods                           
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2.1 Materials: 
All cell culture reagents were supplied by Gibco BRL (Invitrogen) and all general chemicals 
by Sigma-Aldrich. Enzymes for molecular cloning and other restriction digestion reactions 
were supplied by Promega, New England Biolabs and ThermoFisher Scientific. Primers were 
provided by Invitrogen. DNA sequencing reactions were performed by Eurofins MWG 
Opero, while next generation sequencing were completed by MiSeq illumena 
2.1.1 General reagents: 
2.1.2 Buffers: 
10x TAE: 400mM Tris-acetate, 10mM EDTA in H2O  
2x B & W:  10 mM Tris-HCL (pH7.5), 1 mM EDTA, 2 M NaCl 
1x B&W with 0.005% Tween 20:5 mM Tris-HCL,0.5mM EDTA, 1 M 
NACL,0.005%Tween20 
1-Kb plus DAN Ladder Invitrogen 
Agar Invitrogen 
Agarose Melford 
Ampicillin Sigma-Aldrich 
Bovin Serum Albumin (BSA)  Sigma-Aldrich 
Carbenicillin  Sigma-Aldrich 
dNTPs  Applied Biosciences 
Ethylenediaminetetraacetic acid (EDTA)  
Ficoll   GE Healthcare 
Interleukin-2 (IL-2) Proleukin,Chiron 
Interleukin-7 (IL-7) Proleukin,Chiron 
Interleukin-15 (IL-15) Proleukin,Chiron 
Kanamycin Sigma-Aldrich 
LIVE/DEAD fixable blue dead cell stain 
(Tryban blue) 
Invitrogen 
 
MES SDS Running buffer (20x) Invitrogen 
NuPAGE 4-12% Bis-Tris gels Invitrogen 
NuPAGE Transfer buffer (20x) Invitrogen 
SeeBlue® Plus2 Protein standard Invitrogen 
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Laemmli buffer: 60mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 
0.01% bromophenol blue 
MACS buffer: phosphate-buffered saline (PBS), 0.5% bovin serum albumin (BSA), 2 mM 
EDTA. Mix and filter them through 0.45µm Filter. 
2.1.3 Antibodies: 
sc-9100 T cell receptor alpha rabbit IgG 
 
Santa Cruz Biotechnology 
sc-9101 T cell receptor beta  rabbit IgG Santa Cruz Biotechnology 
130-098-
219 
Anti-TCR-biotin mouse IgG2b Miltenyi Biotec 
130-090-
485 
Anti-biotin microbeads Miltenyi Biotec 
 Cre-I (Meganuclease ) rabbit IgG Cellectis  
NXA931 Sheep HRP-linked Anti-Mouse GE Healthcare 
NA934 Donkey HRP-linked Anti-Rabbit GE Healthcare 
   
115-066-
072 
Biotin-SP-conjucated AffiniPure F(ab)’2 
fragment goat anti-mouse IgG, F(ab)’2 
fragment specific 
Jackson Immunoresearch 
laboratorie 
555547 FITC Mouse Anti-Human TCR α/β Becton Dickinson UK LTD  
555335 APC Mouse Anti-Human CD3 Becton Dickinson UK LTD  
LS-
C107386 
PE-Cy7 Mouse Anti-Human CD45RA LifeSpan Bioscience 
305624 Brilliant violet 421 Mouse Anti-Human 
CD95 
Biolegend 
MHCD0431 PerCP Mouse Anti-Human CD4 Thermofisher scientific  
 
557734 Alexa Fluor® 647 Rat Anti-Human 
CD197 (CCR7) 
BD Pharmingen™ 
561914 FITC Mouse Anti-Human CD62L BD Pharmingen™ 
555635 PE Mouse Anti-Human CD8 BD Pharmingen™ 
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2.1.4 Kits: 
Amaxa cell line nucleofector kit V     Lonza 
Amaxa nucleofector kit for human T cells    Lonza 
CD34 microbead kit  and MD columns    Miltenybiotec 
DNeasy Blood & Tissue kit      Qiagen 
Endofree plasmid preparation kit     Qiagen 
Real Assembly TALEN kit       Joung lab 
Mini-elute PCR purification kit      Qiagen 
Mini / maxi Plasmid preparation kit     Qiagen 
Mini-elute PCR purification      Qiagen 
Pierce BCA protein assay kit     Thermo Fisher Scientific 
QiaQuick PCR purification kit     Qiagen 
QiaQuick Gel purification kit      Qiagen 
RNeasy Mini Kit       Qiagen 
Surveyor mutation detection kit     Thermo Fisher scientific 
T7 mScript™ Standard mRNA Production System   Cambio 
The GenElute™ Mammalian Genomic DNA Purification kit Sigam-aldrich 
TCR depletion kit and LD columns     Miltenybiotec 
TOPO TA cloning       Invitrogen 
2.1.5 PCR Primers: 
Unless otherwise stated, all primers were supplied by Invitrogen and most of PCR reactions 
were processed using phusion high-fidelity DNA polymerase (Promega/New Biolab) or Go 
Taq DNA Polymerase (Promega) 
 
Primer name Primer sequence  
CAPNS1 fwd 5’-ACCGCGGCCGCAATTGCAGT-’3 Meganuclease target site 
CAPNS1 rev 5’- AAAGGGGACCAGTGGGTGCTTCG-3’ Meganuclease target site 
oJS2581 fwd 5’-TCTAGAGAAGACAAGAACCTGACC-‘3 TALEN α unit 1- biotin 
adds 
oJS2582 rev 5’-GGATCCGGTCTCTTAAGGCCGTGG-‘3 TALEN α unit 2 
T7 CRISPR 
TRAC fwd 
5’-
TTAATACGACTCACTATAATCCGTCAGGGTTCTG
GATATC-‘3 
Adds T7 promoter  
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T7 CRISPR 
TRAC rev 
5’-AAAAGCACCGACTCGGTGCC-‘3 Adds T7 promoter 
TRAC fwd 5’-AACGTTCACTGAAATCATGGCC-‘3 Meganuclease / TALENs 
target site  
TRAC rev 5’-GCTGGGGAAGAAGGTGTCTT-‘3 Meganuclease / TALENs 
target site 
TRBC1 fwd 5’-CTGTCAGAGGAAGCTGGTCTGG-‘3 Meganuclease target site  
TRBC1 rev 5’- CTTACCATGGCCATCAACACAAG-3’ Meganuclease target site 
TRBC2 fwd 5’-GTGGGAGAGACCAGAGCTACCTG-3’ Meganuclease target site 
TRBC2 rev 5’- CCATTGACCACACAAATAGTAAGG-3’ Meganuclease target site 
 
2.1.6 Cells: 
2.1.6.1 Bacterial cells: 
Most of the transformation process was done using One Shot® Stbl3™ Chemically 
Competent E. coli (Invitrogen, UK).  These cells are excellent host strain to use for cloning 
unstable inserts, such as lenitviral DNA containing direct repeats.  This strain is derived from 
the HB101 E.coli group and its genotype is F- mcrB mrr hsdS20 (rB-, mB- ) recA13 supE44 
ara-14 galK2 lacY1 proA2 rpsL20 (Str ) xyl-5 λ- leu mtl-1r .  
Second bacterial cells called XL1-Blue Competent Cells (Agilent Technologies, USA) were 
used in the transformation process on cloning homemade TRBC TALENs DNA fragment 
into Fok-nuclease expression vector. These cells are designed for routine cloning application.  
The XL1-Blue genotype is recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lacF´ proAB 
lacIq Z∆M15 Tn10  
2.1.6.2 Mammalian cell lines and culture conditions:  
Multiple cell lines derived from hematopoietic origin were used: Jurkat cells are an 
immortalized human, T lymphoblastoid cell line derived from an acute T cell leukaemia, and 
they are suspension lymphoblasts. This cell line was established from the peripheral blood of 
a 14 year-old boy by Schneider et al (Schneider et al., 1977). 
An antigen-processing (Tap) deficient human cell line expresses HLA-A2 named T2 was 
also used.  T2 cells are a mutant human cell line that have a defect in antigen presentation in 
the context of class I major histocompatibility complex (MHC) molecules. As a consequence, 
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the HLA-A2 molecule of these cells can be efficiently loaded with exogenous peptides 
(Amrolia et al., 2003).  
A human, TCR-negative, Jurkat-76 cell line was also utilised in addition to the previous cell 
lines: this is a cloned, human, T cell leukaemia line that is deficient in endogenous TCR 
expression. 
All these cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
(Invitrogen life technologies, UK) and were supplemented with 10% of heat-inactivating, 
foetal-calf serum (FCS) (Sigma Life Sciences, USA) and 1% of penicillin/Sterptomycin 
(Invitrogen Life Technologies, UK). 
Cell line named Sup-T1 was also applied in some experiments. It consists of human, T cell, 
lymphoblastic lymphoma cells that are derived from a malignant pleural effusion taken from 
an eight year-old Caucasian male with T cell lymphoblastic lymphoma. These cells were 
stably transfected with CD19 antigen and they were obtained from Cancer Institute, UCL, 
UK. The SupT1-CD19 cell line was used to evaluate the functionality of a T cell transduced 
with CD19-CAR lentivirus. A non-transfected SupT1 cell line; CD19 negative SupT1, was 
also used as a negative control for these experiments. SupT1 cells were treated in similar 
conditions to those of other cell lines derived from the human T cell population. 
For lentiviral virus production, HEK293T cells were carefully treated and cultured. These 
cells are human embryonic-kidney cells which are grown in Dulbecco's Modified Eagle 
Medium (DMEM) (Invitrogen Life Technologies, UK), supplemented with 10% FCS (Sigma 
Life Sciences, USA) and 1% Penicillin/Streptomycin. They are adherent cells and their 
suitable environment for incubation is at 37oC with 5% CO2. Their proliferative capacity and 
permissibility to transfection make them a good choice as a packaging cell line for virus 
production. 
2.1.7 Cord blood and primary human T cells and culture conditions: 
Cord blood (CB) is a well-established origin for hematopoietic stem cells transplantation.  
One of its immunological advantages is its ability to tolerate antigen mismatch that leads to a 
decrease in GVHD incidence, while maintaining to pursue an anti-tumour effect (Barrett and 
Bollard, 2015). The widespread use of CB-Transplantation is obstructed by the delay in 
hematologic engraftment and by high, treatment-related mortality (Okas et al., 2010).  
CB contains a comparatively higher number of mononuclear cells including T cells, B cells, 
and natural killing cells than peripheral blood (PB) or bone marrow (Harris and Rogers, 
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2007). CB-T lymphocytes are the main concern of this project, so the next paragraph will 
discuss its properties.  
CD3+ percentage is similar in both CB and PB; however, the absolute number of T cells is 
higher in CB than PB. Markedly, the CD4 to CD8 ratio is the same in both CB and PB. CB-T 
cells are naïve CD45RA+CD62L+. Surprisingly, it has been reported that even after exposing 
CB-T cells to stimuli, they maintain their CD45RA compartments and therefore, maintain 
their naïve phenotype (Cairo et al., 2016); a fundamental requirement for a successful 
adoptive T cell therapy.  
The Anthony Nolan Cord Blood Bank, based in the UK, provided us with umbilical cord 
blood units (CB). Adult peripheral blood mononuclear cells (PBMC) were obtained from 
healthy, adult volunteer donors who signed a consent, and they are based at the Institute of 
Child Health, UCL. Both CB-T cells and PBMCs were treated in similar ways: the units were 
diluted in phosphate buffer saline (PBS) (Invitrogen Life Technologies, UK) at a 1:1 ratio 
and incubated for 20–30 min at room temperature. Diluted blood was then gently layered 
onto 15 ml ficoll-paque (GE Healthcare, UK) in 50 ml falcon tubes. After being subjected to 
35 min of centrifugation at 400 gravity, mononuclear cells were collected from the layer 
between the plasma and the ficoll, and washed with PBS three times. After the final wash, the 
harvested monocular cells were resuspended in X-VIVO 10 or 15 medium (Invitrogen, UK) 
and supplemented with 5% AB human serum (Invitrogen, UK), together with 100 units per 
ml of human, recombinant interleukin 2 (IL-2) (Proleukin, Novartis, USA).  Afterwards, cells 
were activated with different stimulators (A detailed discussion regarding T cell activation 
will be presented further in the text) for 48 hours before transduction or transfection. 
2.1.8 Media: 
All starter culture for bacterial growth is made of LB broth: 1% tryptone, 0.5% yeast extract; 
1% NaCl. A 1.5% LB agar is added to the previous recipe to form an agar plate.   
For Mammalian cells, all cell culture media were obtained from Gibco BRL and Invitrogen, 
unless otherwise stated. The medium used for culturing cell lines was supplied with foetal 
calf serum (FCS) (Sigma-Aldrich). For cord blood and primary cells, X-VIVO 10 or 15 
medium (Lonza) was supplied with human AB serum (Lonza).  Dynabeads ® Anti-CD3/anti-
CD28 beads (Invitrogen) were used as a one mean for T cell activation in addition to IL-2 
(100U/ml).  
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2.1.9 Parental plasmids: 
pLNT/SFFV-MCS-WPRE: self-inactivating (SIN), second generation lentiviral backbone 
derived from pHR plasmid. It includes a SFFV promoter followed by a multiple cloning site 
and Woodchuck hepatitis virus post transcriptional regulatory element (WPRE). 
pLNT/SIEW: (SFFV-IRES-eGFP-WPRE) lentiviral vector with the same backbone as 
pLNT/SFFV-MCS-WPRE, with an IRES-eGFP inserted at the multiple cloning site. 
pLNT/SFFV-TRAC-TALENs: expression plasmid encoding the left arm TRAC TALENs, 
under the control of SFFV promoter; cloned into self-inactivating next generation lentiviral 
vector backbone. Provided by Cancer Institute, UCL. 
pLNT/SFFV-TRAC-TALENs: expression plasmid encoding the right arm of TRAC 
TALENs, under control of SFFV promoter; cloned into self-inactivating next generation 
lentiviral vector backbone. Obtained from the Cancer Institute, UCL. 
pCRISPR-TRAC: All-in-one sgRNA expression plasmid encoding TRAC sgRNA under the 
control of U6 promoter and encoding Cas9 under the control of CMV promoter Provided by 
GeneCopoeia.  
pCRISPR-TRBC1: expression plasmid encoding TRBC1 sgRNA under the control of U6 
promoter and encoding Cas9 under the control of CMV promoter. Provided by GeneCopoeia. 
2.1.10 Generated plasmids: 
Sub-cloning is a method in which any DNA fragment, promoters or selectable markers are re-
cloned from one plasmid to another expression plasmid. This technique has been applied to 
move MGN open reading frames (CAPNS, TRBC01 and TRBC02) from their original 
expression plasmid and clone them into lentiviral vector backbone named pSEIW. SIEW is 
self-inactivating (SIN) second generation lentiviral backbone derived from pHR plasmid. It 
includes a SFFV promoter followed by IRES-eGFP and Woodchuck hepatitis virus post 
transcriptional regulatory element (WPRE). 
BamHI and AscI (Promega, UK) restriction enzymes were used to linearize the vector and 
prepare it for ligation. MGN open reading frames were chopped out from their original 
expression plasmid with EcoRI and SacII (Promega, UK) restriction enzymes. Afterwards, 
the digested vector and appropriate inserts were mixed at 5:1 ratio and incubated overnight 
with Ligase (Promega, UK) at 16oC. On the following day, ligation reactions were 
transformed into competent E.coli (Invitrogen) and cultured on ampenicillin culture agar. The 
picked-up colonies were exposed to restriction reaction with EcoRI (Promega, UK) and run 
on 1% gel to define the correct sizes of vector and inserts. 
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2.2 Methods: 
2.2.1 Escherichia coli (E.coli) growth and maintenance:  A single colony of E.coli was picked up and placed in 5 mls LB broth. This starter culture 
was incubated at 37oC with agitation at 250 rpm for 16-18 hours.  Another way that  bacterial 
culture was obtained; was by streaking it out on an agar plate (1.5% becto agar) and 
incubating it in incubator at 37oC overnight.  For selection of transformed E.coli, the same 
media was supplemented with appropriate antibiotics: 50µg/ml Ampicillin or kanamycin, or 
100 µg/ml Carbenicillin was used.  A 15% glycerol was added to the starter cultures in order 
to store bacterial cultures in -80oC. 
2.2.2 Transformation of chemically competent E.coli: 
One vial of component E.coli bacteria was thawed on ice and 1-5 µl of DNA was added. The 
bacteria and DNA mixture was incubated on ice for 30 min.  After 30 min of incubation, the 
bacterial cells were heat-shocked at 42oC for 45 seconds, then cooled on ice for two minutes.  
Afterwards, a 250 µl SOC medium was mixed with the cells and incubated on horizontal 
manner with agitation at 37oC for 1 hour. A 100 µl bacterial culture was plated out in LB 
agar supplemented with appropriate selection antibiotics and incubated overnight at 37oC.  
2.2.3 Plasmid DNA preparation: 
A single colony of E.coli containing plasmid DNA was grown overnight at 37oC in LB broth 
supplied with an appropriately selected antibiotic.  Next, the plasmid was purified and 
extracted by alkaline lysis using a Qiagen Miniprep or Maxiprep kit according to the 
manufacturer’s instructions.  Then, a Nanodrop ND-1000 spectrophotometer at a wavelength 
of 260nm was used to measure DNA concentration.  
2.2.4 Restriction endonuclease digest: 
In order to prepare DNA for traditional cloning procedure or for any other DNA analysis, 
restriction enzymes have been used to cut DNA at a specific site. DNA was digested in a 
reaction containing one or two restriction enzymes (<10% final volume), 0.1mg/ml BSA, 1x 
buffer (supplied by manufacturer) and water to reach a final volume of 20 µl or 50 µl 
reaction. The reaction was then incubated for 1 to 4 hours at 37oC. 
2.2.5 Filling in of 5’ DNA overhangs to form blunt ends: 
The 5’ DNA protruding ends generated by restriction enzyme digests were filled-in using 
DNA polymerase I Large (Klenow) fragment. 1 unit (U) of enzyme per microgram of DNA 
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was mixed with DNA, 1x buffer (supplied by Promega) and 40µM of each dNTP. After 10 
min of incubation at room temperature, the reaction was stopped by heat inactivation of the 
enzyme for 10 min at 75oC. 
2.2.6 Dephosphorylation of 5’ phosphate groups from DNA: 
Prior to ligation and to avoid re-ligation of linearised vector DNA with compatible ends,  5’ 
phosphate groups from DNA were removed. Thermosensitive alkaline phosphatase was 
added directly to restriction reactions at 1U per microgram of DNA. Then, after 15 min of 
incubation in at 37°C, the enzyme was inactivated at 75°C for 10 minutes.  
2.2.7 DNA Ligation: 
1U of T4 DNA Ligase and 1x T4 DNA ligase buffer (supplied by manufacturer) were used to 
ligate insert DNA into plasmid backbone in approximately a 3:1 molar ratio in a final 
reaction volume of 20 µl.  For sticky ends, the reaction was incubated overnight at 4oC, while 
for blunt ends, an overnight incubation at 16oC was considered.  After overnight incubation, 
the reaction was transformed into chemically component E.coli bacteria. 
2.2.8 Agarose gel electrophoresis and purification of DNA fragments: 
One of the standard lab procedures is to separate DNA fragments by size for visualization 
and purification using gel electrophoresis.  Agarose is dissolved in 1xTAE buffer by heating, 
and ethidium bromide or syber green was added to the final concentration of 0.5µg/ml before 
it was allowed to solidify.  Alongside 1kb Plus DNA ladder, samples were loaded onto gel 
after they were mixed with DNA loading buffer.  Negatively charged DNA fragments move 
toward positive electrodes by electrophoresis at 100-150V in 1x TAE buffer and then 
visualised under UV light using a UviDoc gel documentation system. In some cases, DNA 
fragments were cut out from the gel using a scalpel under UV light.  Qiaquick gel extraction 
kits were used to purify them. 
2.2.9 Genomic DNA extraction: 
Before incubating the cell’s lysate at 70oC for 10 min, a cell pellet was resuspended in 200µl 
resuspension solution and mixed with 20 µl proteinase kinase and 200 µl lysis buffer. 
Afterwards, 200 µl ethanol was added and the sample then transferred into a binding column 
and spun in a bench top centrifuge at centrifugal force of 6500 x gravity for 1 minute. The 
column was washed twice by adding 500µl washing solution and finally, DNA was eluted in 
180 µl H2O and stored at -20oC.      
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2.2.10 Topo TA cloning: 
DNA fragment was extracted from 1% agarose gel, then amplified by PCR using Taq-
polymerase enzyme and purified according to the manufacturer’s instructions. The PCR 
amplified DNA fragment was then ligated into pCR™4-TOPO® vector by incubating the 
PCR insert with salt solution, water and vector for 5 minutes at room temperature.  The Topo 
cloning reaction was then placed on ice and used to transform One shot Topo10 E.coli by 
heat shock, which then were plated on ampicillin LB agar and incubated overnight.  The 
insert was sent for sequencing after extracting DNA from some selected colonies.  
2.2.11 Surveyor Nuclease assay: 
The CAPNS1, TRAC and TRBC MGN target sites as well as the TRAC TALENs target sites 
were amplified by PCR using corresponding primers (mentioned in the materials section) and 
PCR product was resolved by electrophoresis through a 1% or 2 % agarose gel.  Then, 15 µl 
(approximately 200 ng) of PCR product (DNA) was denatured in a thermocycle PCR 
machine for 10 minutes at 95oC and cooled down to 85°C with a decrement of 2°C/s then 
85°C to 25°C with a decrement of 0.1°C/s and 4°C to allow re-annealing. Surveyor nuclease 
recognizes and cleaves a mismatched double strand DNA created when NHEJ DNA 
containing mutations re-anneals with the native sequence. Therefore, amplified DNA was 
exposed to 2 µl Enhancer S and nuclease S at 1:1 ratio and incubated at 42oC for 1 hour to 
digest mismatched DNA and producing two bands.  Cleaved DNA was visualized on 2% 
agarose gel with 0.5μg/ml ethidium bromide under UV light. 
2.2.12 mRNA production and In-vitro transcription: 
Reports and studies have proven that delivering gene of interest as mRNA is more effective 
and less toxic to the cells than using a naked DNA plasmid nuclofection system (Mock et al., 
2015). Therefore, it has been suggested that mRNA electroporation might be a reliable 
alternative method as a gene-transferring technique into T cells. T7 mScript™ Standard 
mRNA Production System and RNeasy kit were used to produce mRNA from expression 
plasmid encoding TRAC TALENs. Plasmids; which contain T7 promoter sequence, first 
were linearised by restriction digest using AvrII and then purified using QIAquick PCR 
Purification Kit. Then, the DNA template was subjected to In-vitro transcription (IVT) by 
adding the following reagents: 10x mScript T7 transcription buffer, NTP solution, 100mM 
DTT, RNase inhibitor and finally the mScript T7 enzyme solution and incubated at 37oC for 
30 min.  DNase I was added the previous IVT reaction to remove any DNA template 
residues.  Before capping the In-vitro transcript RNA, it was heat-denatured at 65oC for 10 
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minutes then capped by adding 10U/µl ScriptCap capping enzyme and incubated at 37oC for 
30 minutes.  After capping, mScript™ poly (A) polymerase enzyme was added to the poly(A) 
tails sequence with the desired length. At the end of each reaction, approximately 60 g of 
fully capped and polyadenylated mRNA was produced.  
2.2.13 Quantification of protein by using Pierce BCA protein assay: 
Standard reagents were prepared by diluting the content of albumin standard (BSA) into 
clean vials from 2000µg/ml to25 µg/ml in milliQ water. The volume required for working 
reagents was first determined by the following equation:  
(# standards + # unknowns) × (# replicates) × (volume of WR per sample) = total volume 
WR required, then, in order to prepare the working solution, 50 parts of BCA reagent A 
(supplied with the kit) with 1 part of BCA reagent B (supplied with the kit).  
In a microplate well, 25 µl standard or sample were added in replicates and were mixed with 
200 µl working solution on a plate shaker for 30 seconds. Covered Plate was allowed to cool 
down at room temperature after an incubation period of 30 minutes at 37oC. Finally, the 
absorbance was read on plate reader at or near 562 nm.  
2.2.14 Western blot analysis: 
1x10 6 cells were harvested 24 hours after transfection and lysed using RIPA buffer (Santa 
Cruz Biotechnology, CA). 20µg of protein and SeeBlue Plus2 Pre-stained Standard were 
separated by 4-12% Bis-Tris NuPAGE gel electrophoresis and 1x MES buffer at 200V for 45 
min. Proteins then transferred from the gel onto immobiolon-P PVDF membrane by using X-
Cell II Blot module and 2x NuPAGE transfer buffer plus 10% methanol at 18V for 45 min 
(Merck Millipore, UK).  In order to avoid a non-specific antibody binding, membrane was 
blocked in 4% milk powder in PBST (PBS containing 0.05% Tween-20) for an hour at room 
temperature. Afterwards, membranes were incubated with primary, rabbit, polyclonal 
antibody against I-CreI at 1: 20,000 dilution for meganuclase detection or with 1:5000 for 
anti-TCR alpha and beta rabbit IgG and incubated overnight at room temperature. On the 
following morning and before adding the horse-radish peroxidase conjugated goat anti-rabbit 
secondary antibody (diluted 1:2000 in 4% milk in PBST), the membrane was washed three 
times by adding 20 ml of PBST. After the one-hour incubation of the membrane with 
secondary antibody, it was washed in PBST and the specific protein bands were visualized 
with an enhanced chemiluminescence (ECL) reagent (Thermo Fisher Scientific, USA). A 
rabbit antibody against β-tubulin was used for the loading control. 
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2.2.15 Propagation and storage of mammalian cell lines: 
Adherent cell lines were passaged when they were 80-90% confluent by washing with PBS 
then detaching them by incubating with trypsin/EDTA.  Cells were diluted and maintained in 
fresh warm DMEM, then cultured at suitable concentration into a tissue culture flask. Non-
adherent cells were passaged when the media color changed by transferring a proportion of 
the cells into a fresh and warm medium. All cells were cultured at 37oC in 5% CO2 
incubators. As mentioned above, all media were supplemented with 10% FCS and 1% 
penicillin/streptomycin. In order to create a cell bank, a 1-10x106 cells’ pellet was re-
suspended in freezing medium; which was made up of 90% FCS and 10% DMSO, then 
frozen slowly in an isopropanol freezing container at -80oC overnight. The cells were then 
transferred into liquid nitrogen.  If cells were required, they were moved from liquid nitrogen 
and rapidly thawed in a water bath, then added in drop by drop manner to warm fresh 
complete medium. Cells then were centrifuged to remove DMSO and resuspended in fresh 
warm compete appropriate medium and cultured in a T25 tissue culture flask. 
2.2.16 Cell counting: 
A haemocytometer (0.0025 mm2, Marienfeld, Germany) was used as the counting chamber 
to count the viable cells’ density. A 10 µl cell suspension was mixed with 90 µl Trypan blue 
dye (Sigma Life Sciences, USA) and loaded into the counting chamber. Dead cells ingest the 
Trypan blue dye and are discriminated from intact living cells by using direct-light 
microscopy. The total number of viable cells was counted in the four large squares within the 
haemocytometer and the resulting figures input into the following equation:   
Average of cell number in the 4 squares x 10 (dilution factor) x104= total number of cells/ml 
in the original suspension. 
2.2.17 Isolation of cord blood and primary human T cells and culture conditions: 
The Anthony Nolan Bank, based in the UK, provided us with umbilical cord blood units 
(CB). Adult peripheral blood mononuclear cells (PBMC) were obtained from healthy, adult-
volunteer donors based at the Institute of Child Health, UCL after signing consent. Both CB-
T cells and PBMCs were treated in a similar way: units were diluted in phosphate buffer 
saline (PBS) (Invitrogen Life Technologies, UK) at a 1:1 ratio and incubated for 20 min at 
room temperature. Diluted blood was then gently layered onto 15 ml ficoll-paque (GE 
Healthcare, UK) in 50 ml falcon tubes. After being subjected to 40 min of centrifugation at 
400 x gravity, mononuclear cells (buffy coat) were collected from the layer between the 
plasma and the ficoll, and washed with PBS 3 times. After the final wash, the harvested 
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monocular cells were resuspended in X-vivo 10 or x-vivo 15 medium (Invitrogen, UK) and 
supplemented with 5% AB human serum (Invitrogen, UK), together with 100 units per ml of 
human recombinant interleukin 2 (IL-2) (Proleukin, Novartis, USA). 106 cells per well were 
placed in a 24-well plate or for scale up experiments, 50x106-100x106 cells were cultured in a 
100 ml cell differentiation bag (Miltenyi Biotec, Germany) and activated with different 
stimulators (this section will later discuss the means by which T-lymphocytes are stimulated) 
for 48 or 72 hours before transduction or transfection.  
2.2.18 CB and PBMCs stimulation conditions: 
CB-T cells and PBMCs were activated under three different conditions. The standard way of 
activating human lymphocytes is to use Dynalbeads® ClinExVivoTM CD3/CD28 
(Invitrogen, UK) at a ratio of 1:1. For small scale experiments, 106 CD3/CD28 beads per ml 
were added to 106 CB-T cells or PBMCs; while for large scale experiments, 50x106 or 
100x106 beads per ml were added to 50x 106 or 100x106 CB-T cells, in addition to 100 U/ml 
of IL-2 supplementation every 48 hrs. Another means of stimulation involved the use of a 
combination of cytokines cocktail: 5 ng/ml of human recombinant interleukin-7 (IL-7) 
(Peprotech, USA), 5 ng/ml of human, recombinant interleukin 15 (IL-15) (Peprotech, USA), 
and 100 u/ml of IL-2 were added to the previously isolated CB-T cells and PBMCs. Finally, a 
combination of CD3/CD28 beads and IL-7 and IL-15 cytokines were added to the third batch 
of isolated CB-T cells and PBMCs. After 48 hours of activation, cells were ready for either 
virus exposure or transfection. 
2.2.19 Nucleo-transfer of DNA into cord blood, PBMCs and Jurkat cells: 
Three different means were used to introduce various types of DNA-nucleases to Jurkat cells, 
CB-T cells and PBMCs. After stimulating CB-T cells and PBMCs with anti-CD3/anti-CD28 
beads or cytokines, cell density ranged from 2-5 x 106 cells were centrifuged and resuspended 
in 100 µl human-T cell nucleofector solution for amaxa transfection system, and in E2 buffer 
for neon transfection system.  Afterwards, cells were exposed to different types of gene-
specific nucleases as a DNA: 10 µg of each pair of TRAC TALENs (Cellectis, France) 
(TriLink, USA) (Hamburg, Germany), and   TRAC and TRBC CRISPR/Cas9 (Genecopoiea, 
USA).  DNA was delivered directly to the nucleus of the cells using a Nucleofector II device 
(amaxa) (Lonza, Belgium) with program T-20 or by using the following electroporation 
parameters with a neon-transfection system:  
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Pulse voltages (v) Pulse width (ms) Pulse number  
 
2150 20 1 
  
Following transfection, the cells were immediately transferred to 1 ml of pre-warmed, 
complete X-VIVO 10 or 15 media with IL-2 and cultured at 37oC using 5% CO2. In the same 
experiments with Jurkat cells, cells were nucleofected directly without any stimulation by 
using the x-001 program with amaxa, while with neon transfection, the following 
electroporation parameters were used:  
 
 
After nucleofection, the cells were placed in complete RPMI 1640. The cells were kept in 
culture for 24 and 48 hours prior to analysis for marker genes such as eGFP or red-Cherry 
and for seven days before evaluation of T cell receptor knock out (TCR KO) efficiency. In 
the case of the beads’ stimulation, cells were rested overnight following semi-automated, 
magnetic bead removal using a Dynal ClinExVivo MPC (Invitrogen, UK) prior to analysis.  
2.2.20 mRNA electroporation with BTX electroporation system: 
For delivering mRNA into the cells, the BTX electroporation system was used.  Two days 
after activating the cells or five days after stimulating and transducing, 10x106 cells were 
aliquoted, centrifuged and resuspended in 400 µl electroporation buffer. Then, 20 µg TRAC 
TALENS (10µg/pair) or 500 ng TRAC guide RNA and Cas9 were added to the corner of the 
electroporation cuvettes.  Cells were mixed with the RNA constructs in the cuvettes then 
moved quickly into the electroporation chamber that is connected to BTX machine.  After 
electroporation, cells were transferred quickly into a pre-warmed, completely fresh X-VIVO 
10 or 15 in T12.5 tissue culture flask. Two hours later, 100 U/ml of IL-2 was added.  Cells 
were kept in this culture condition until moved to G-rex10 the next morning for expansion of 
the cells for scale up purposes.  
2.2.21 Production of lentiviral vector: 
Unless otherwise stated, all plasmids were supplied by Plasmid Factory, Germany  
Pulse voltages (v) Pulse width (ms) Pulse number  
 
1350 10 3 
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12-15 x 106 packaging cells; HEK 293T cells, were cultured into 175T tissue culture flasks in 
25 ml of supplemented DMEM and incubated overnight at 37oC in 5% CO2 atmosphere to 
reach ~80% confluency. For second generation lentivirus production, three different DNA 
constructs: 25 µg vector plasmid, 32.5 µg gag-pol packaging plasmid pCMV-dR8.74 (for 
integrating virus), or pCMV-dR8.74 D64V (for non-integrating virus) and VSV-G2 envelop 
plasmid were mixed together in 5 ml OptiMem and sterilized thorough a 0.22µm filter. For 
the production of third generation lentivirus particles, a 25 µg pRSV-Rev fourth plasmid was 
added and filtered in addition to the previous packaging plasmids. The DNA mixture was 
incubated with a mixture of 5 ml OptiMEM and 1 µl 10 mM polyethylenimine (PEI) for 20 
min at room temperature. After washing the packaging cells with warm OptiMEM, 10 ml of 
DNA-PEI mixture were added to each T175 flask and the cells were incubated for 4 hours at 
37oC using 5 % CO2. The medium was then replaced with 30 ml of supplemented DMEM. 
Following overnight incubation of the transfected cells, the culture medium was replaced 
with supplemented DMEM and kept for another period of overnight incubation at 37oC using 
5 % CO2. To harvest the lentiviral vector, 48 and 72 hours after transfection the supernatant 
was collected and filtered through 0.45 µM filter (Merck Millipore,UK) and placed into an 
ultracentrifuge (Sorvall, Thermo Fisher Scientific, USA) for spinning at 23,000 RPM for 2 
hrs. The final stage of the production involved re-suspension of the virus pellet in 100 µl 
OptiMEM, which was incubated on ice for 20 min and eventually stored as 20 µl aliquots    
at-80oC. 
For scale-up lentivirus production, 20x106 HEK293ts cells were cultured in a 5-layer culture 
flask (Millicell HY Flasks, USA) for three days before transfection. 55 µg pMD.G envelop, 
90 µg gag-pol packaging plasmid, 45 µg Rev and 180 µg vector plasmid were mixed together 
in 25 ml OptiMUM and filtered through 0.22 µm filter then incubated with 25 ml of 
OptiMUM containing 5 µl PEI at room temperature for 20 min.  The 50 ml DNA-PEI 
mixture was added to the packaging cells. After 4 hours incubating cells with DNA-PEI 
mixture, the transfection reagent was exchanged with 150 mls completely warm DMEM. 
Unlike the small scale production, there was no medium change on the next day of 
transfection.   For virus harvesting, the 48 and 72 hours after transfection virus was subjected 
to overnight spin at speed of 10.000 g. Finally, the virus pellet was re-suspended in 900 µl 
OptiMEM, which was incubated on ice for 30 min and eventually stored as 80 µl aliquots  at 
-80oC. 
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2.2.22 Virus titration: 
1x105 HEK293ts were plated in 24 wells plate the day before transduction, while for 5x104 
Jurkat or TCR –ve cells, the cells were plated on the same day for virus titration. To define 
the number of functional viral particles per ml, an aliquot of concentrated virus particles was 
used in a serial dilution process using amounts of virus particles ranging from 0,0032 µl to 10 
µl in volume. Viral particles were serially diluted to add 10, 2, 0.4, 0.08, 0.016 and 0.0032 µl 
of the virus stock in 100 µl of OptiMEM per well. The cells were incubated with the dilutions 
prepared at 37oC/5% CO2 for 6 hours in 300 µl volume. Following 6 hours of incubating 
cells with the lentivirus, 700 µl supplemented DMEM was added to each well and the cells 
were kept in the incubator for 3 days. Seventy-two hours later, transduced cells were 
collected and stained with mAb against targeted antigens (Vβ 2.1 PE FC gamma chain of 
CAR-CD19 PE-Cy5 or CD34 QBen-10-APC) for FACS analysis by using an LSR II 
cytometer (Becton Dickinson). Analyses of the results were carried out using FlowJo 
software and to calculate the original, infectious virus units the following equation was 
applied: 
Number of infectious units per ml = ((Percentage of infected cells/100) x number of cells) X 
1000))/amount of virus 
2.2.23 INF-gamma capture assay: 
In a 96-well plate, 1.5 x 106 cells of WT1-TCR transduced CB-T cells (n=3) were seeded 
overnight at 37oC using 5% CO2. The next morning, effector CB-T cells were incubated with 
1.5 x 106 T2 cells at a ratio of 1:1. These cells were loaded for 3–6 hours with 100 µM of 
WT1 peptide, and the remaining 1.5x106 T2 cells were loaded with ADV, a non-specific 
peptide. Cells were then harvested, washed and stained with INF-γ catch reagent (Miltenyi 
Biotech, Germany) and incubated on ice for 5 minutes. 10 ml of pre-warmed RPMI 1640 
supplemented with 1% AB serum was added to the cells and incubated at 37oC on a MACS 
(Miltenyi Biotech, Germany) rotor for 45 min. The cells were washed and stained with anti-
INF-γ phycoerythrin (PE) (Miltenyi Biotech, Germany) and anti-CD8 fluorescein 
isothiocyanate (FITC) (BD Biosciences, UK) for 10 minutes on ice. Flow cytometric analysis 
was performed using the Becton Dickinson LSR II cytometer and FlowJo software. 
2.2.24 51Chromium release assay: 
1.6x106 T2 cells-target cells- were peptide-loaded with 100µM of either relevant peptide, 
WT126p, or an irrelevant ADV peptide and incubated at 37oC using 5% CO2 for 1 hour. 
While for SupT1-CD19 positive and Sup-T1 negative target cells were counted and 1.6x106 
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aliquots were prepared. During the incubation period, 6x105 cells/ ml of effector T cells 
(WT1-TCR- or CD19-CAR transduced CB-T cells), were placed in 100 µl of culture medium 
RPMI 1640 in a 96-well, U bottom plate at different ratios, ranging from 20:1 to 1.25:1. 
Target cells were labelled with 100µCi of 51Chromium (PerkinElmer Las, UK) and incubated 
for one hour at 37oC. Labelled target cells were then washed twice with PBS (Invitrogen, 
UK) and diluted to reach 5x104 cells/ml. 100 µl of diluted target cells were applied to all the 
wells of the previously seeded 96-well plate and spun to facilitate cell-to-cell contact. Six 
wells were plated with triton; toxic reagent, to measure the spontaneous 51Cr release.   After 4 
hours of incubating labelled target and effector cells at 37oC and using 5% CO2, 50 µl 
supernatant were added to 150µl scintillation fluid in 96-well isoplates and incubated at room 
temperature overnight. The next morning 51Cr release effect was measured by beta-counter. 
 The specific killing activity of the cells is calculated as follows: 
Experimental 51Chromium release – spontaneous 51Chromium release 
% specific killing=Maximum 51Chromium release – spontaneous 51Chromium release 
2.2.25 Flow cytometry: 
Fluor-chrome, labelled-monoclonal antibodies were used for staining the cells with indicated 
specificity and for controlling the appropriate isotypes. Samples were acquired through using 
a FACS BD LSRII cytometer (BD Biosciences) and using FACSDiva software. All data were 
analysed using FlowJo software version 7.6.5 or 10. 
Briefly, cells were pelleted by centrifugation then stained with the appropriate monoclonal 
antibody diluted in PBS and incubated for 20 min at 4oC in the dark. Stained cells were 
washed with PBS before resuspending for FACS analysis.  
Viable cells were gated on forward/side scatter; therefore, measuring cell death was based on 
the shift on the forward and side scatter axis as cells became smaller and more complex. 
2.2.26 Transduction of lentiviral T-cell receptor or chimeric antigen receptor constructs 
into cord blood T-cells and peripheral blood: 
In small scale experiments, T-cells derived from cord blood unit and PBMCS were obtained 
by centrifugation through ficoll and plated 1x106 cells per well in 24 well plate on Day 1, 
then activated with different activation methods (explained in detail in chapter 4). Forty-eight 
hours post-activation, donor-derived cord blood T-cells or PBMCs were exposed to a single 
round of lentiviral vectors transduction carrying WT1-TCR or CD19-CAR genes, with 
multiplicity of infection (MOI) 5 or 10. Three days later, transduced T-cells were stained 
with mAbs conjugated to PE targeting the Vβ2.1 region and mCβ-APC to monitor WT1-TCR 
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expression. For evaluating CD19CAR transduction efficiency, different mAbs were used: 
mAB conjugated to a Cy-5-targeted spacer portion (Fc gamma) of CD19-CAR; mAB 
conjugated to APC targeting CD34 as RQR8 (short suicide gene) was linked to CD19CAR; 
and/or indirect staining of Fab fragment of the CAR using streptavidin-PE as the secondary 
antibody.  The expression of WT1-TCR or CD19-CAR transgenes was analysed using flow 
cytometry on an LSR II cytometer, and FACS data were analysed using FlowJo or FlowJo 
software. Throughout the culture period, half of the culture medium was exchanged with 
fresh complete x-vivo 10 or 15 medium, and 100 U/ml IL-2 or other cytokines cocktail 
depending on the way of activation.  Cells were then exposed to different functional assays.  
The scalability of CB-T engineering experiment was performed either within a closed bag 
system or in 10m G-rex as part of feasibility studies for ‘off-the-shelf therapies’ for the 
treatment of haematological malignancies. Forty-eight hours after activation, 50 or 200x106 
activated-CB-T cells were transduced with SIN LNT-SFFV-WT1TCR with MOI 4 in a 
closed bag system or with Lnt-EFLα-RQR8-2A-CD19CAR with MOI of 5. Three days 
following transduction, the cells were stained for transduction efficiency and moved into the 
G-rex10 system in order to expand them. Flow cytometric analysis using a LSR II cytometer 
(BD Bioscience) was conducted and FACS data were analysed using FlowJo software. 
Transduced cells were then sorted and frozen down for functionality and cytoxcity assays. 
2.2.27 TALENs production: 
Engineering of TALENs-recognising sequences from the constant region of TCR (TRAC, 
TRBC): 
A pair of TALENs targeting the constant region of alpha chain of TCR was provided by 
Cellictes, a French company. Another pair of TALENs targeting the constant region of both α 
and β chains of TCR has designed and constructed in-house with the help of information 
contained at www.TALengineering.org (Figure11). The sequence within exon 1 on 
chromosome 14 was chosen to be the target place for TALENs targeting TRAC, while a 
conserved sequence within TRBC1 and TRBC2 genes on exon 1 at chromosome 7 was used 
as a platform to design TALENs targeting TRBC (Figure 12). 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: TALENs pairs targeting sites wiconstant region. Each exon is represented by a block. Black boxes represent coding regions, whereas grey blocks show non-coding regions. One TALENs pair was designed to bind to exon 1 of the TCR a constant region (TRAC) and another TALENs pair binds a conserved sequence on exon 1 of the TCR β constant regions 1 (TRBC1) and 2 (TRBC2). Underlined nucleotide sequences represent the intended binding sequence of each TALEN. 
Figure 11: Process of designing TALENs pairs targeting sites within genomic loci of TCRand TCR-beta constant region (right).
thin genomic loci of the TCR-alpha and TCR 
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One of the suggested, customised graphical plans (Figure 13) has been used as a platform to 
assemble these particular nucleases. 
 
Figure 13: The customised graphical output provided by TALengineering resource.TAL effector repeats are shown as coloured rectangles. Diagram A represents the arrangement of TAL effector repeats to assemble pair of TALENs targeting sites within genomic loci of TCR-a while diagram B represents the arrangement of TAL effector repeats to assemble pairs of TALENs targeting conserved sequences within the genomic loci of TCR-β.  
Using the graphical outputs provided by www.talengineering.org as a guide (Figure 13), 
TALENs were assembled following the next steps: 
To prepare DNA fragment encoding the first TAL effector repeat, 20 rounds of PCR using 
the following primers: oJS2521 (5’-biotin-TCTAGAGAAGACAAGAACCTGACC-3’) and 
oJS2582 (5’-GGATCCGGTCTCTTAAGGCCGTGG-3’) were conducted. The resulting PCR 
products, which are biotinylated on the 5’ end, are then exposed to 40 units of the restriction 
enzyme BsaI-HF (New England Biolab, USA) for digesting and producing 4-base pair 
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overhangs. Afterwards, the digested DNA fragment was purified using a QIAquick PCR 
purification kit (Qiagen, UK) according to the manufacturer’s instructions. 
To prepare DNA fragments encoding the rest of TAL effectors repeats (2nd, 3rd, 4th,... etc), 
10 µg of each plasmid was digested with 50 units of BbsI restriction enzyme (New England 
Biolab, USA) for 2 hours at 37oC, followed by serial restriction digests performed in 
NEBuffer 4 (New England Biolab, USA) at 37oC using 100 units each of XbaI, BamHI-HF 
and SAlI-HF enzymes (New England Biolab, USA), added at 5-minute intervals. These 
restriction digest reactions were then purified using a QIAquick PCR purification kit (Qiagen, 
UK) according to the manufacturer’s instructions. At this stage, the DNA fragments encoding 
DNA TAL effector repeats were ready to be assembled in an iterative fashion on solid-phase 
magneticbeads; the strategy requires restriction digestion, purification and ligation to take 
place, in that order (Figure 14). 
 
 
Figure 14: Graphical overview of the TALENs assembly method. A) Archive of 28 TAL effector repeat-encoding plasmids required to assemble TALE. (B) Schematic overview of the TALE assembly process. A DNA fragment encoding a single TAL effector repeat and labelled on its 5′ end with biotin (purple oval) is initially ligated to a second DNA fragment encoding one specific TAL effector repeat and then attached to a streptavidin-coated magnetic bead (orange sphere). Additional DNA fragments encoding the rest of TAL effector repeats are ligated until an array of the desired length is assembled. The DNA fragment encoding the full-length TAL effector repeat array is then cleaved from the bead by restriction digestion and ligated to TALEN expression plasmid, which encodes wild-type nuclease FOKI, to produce fully functional TAL effector nuclease. 
In a PCR tube set-up, the initial ligation was done by mixing the first biotinylated DNA 
fragment, which encodes the first TAL effector repeat with T4 DNA ligase (Invitrogen, UK), 
QLB (quick ligase buffer) (Invitrogen, UK), and the 2nd TAL effector repeat. The mixture 
was incubated for 15 minutes at room temperature. During the incubation period, anti-
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CD3/nti-CD28 beads (Life Technologies, UK) were washed and placed on a SPRI plate®, a 
96-ring magnet plate (Beckman Coulter, UK) for 3 minutes, then re-suspended in buffer. 
After 15 minutes of incubation, the initial ligation reaction was added to the washed-beads at 
a ratio of 1:1 and incubated for 15 minutes at room temperature. Afterwards, the beads were 
washed again using buffer. For the next ligation, the digestion of bead-bound DNA fragment 
using BsaI-HF (New England Biolab, USA) was performed, followed by a beads-washing 
step, then the ligation of the extension DNA fragment by T4 DNA ligase (Invitrogen, UK). 
The previous steps were repeated to complete the assembly of the entire TAL effector array. 
Finally, the magnetic beads were released from the DNA fragments by using BbsI (New 
England Biolab, USA). Fully assembled TAL effector repeats were then ligated to the 
TALEN expression plasmid vector using T4 DNA ligase (New England Biolabs, USA) to 
produce fully functional TALE effector nucleases. 
2.2.28 Production of CAR CD19 cord blood T-cells with TCR negative phenotype 
(Cellectis protocol): 
T-cells derived from cord blood were obtained through centrifugation using Ficoll as was 
described earlier.  Due do the presence of a high percentage of nucleated red blood cells, 
CD3 staining was carried out to determine the exact number of lymphocytes. Fifty to 100 
x106 cells were activated with anti CD3/CD28 Dynal beads at 1:1 ratio and cultured in 100 ml 
differentiate culture bag (Milteny biotec, UK) at a concentration of 1x106 cells/ml in 100 ml 
completely fresh  X-VIVO 15 and 100 U/ml IL-2.  Two days after activation, the bags were 
coated with retronectin (Takara, Japan) and incubated for 2 hours at room temperature. Later 
the cells were subjected to Lnt-EFLα-RQR8-CD19CAR 3rd generation lentivirus with titer of 
2x108 IU/ml and added to the retronectin-coated bags. Three days after transduction, 500 µl 
of cells were analysed for transduction efficiency by staining the cells for CD19CAR 
expression and flow cytometry. On Day 4 and 24 hours prior to exposing cells to TALENs, 
the cells were counted and re-cultured at a density of 1.7x106/ml to be prepared for 
electroporation. On electroporation day, 10x106 cells were aliquoted in a 15 mls falcon tube, 
centrifuged and resuspended in a 400 µl electroporation buffer.  10 µg TRAC TALENS per 
pair were added to the corner of the electroporation cuvette, then the cells were added and 
mixed by pipetting. Afterwards, cuvettes were transferred to cuvette chamber of BTX 
machine and electroporated with the following program:   
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 Group 1 Group 2 Group 3  
Amplitude 1200 1200 130 V 
Duration 0,1 0,1 0,2 ms 
Interval 0,2 100 2 ms 
Number 1 1 4  
 
     
300 µl of pre-warmed X-VIVO 15 was added to the electroporated cells and they were 
immediately transferred to pre-warmed x-vivo 15 plus 5% human serum medium in T12.5 
flasks and incubated for 2 hours at 37oC before adding 100 U/ml of IL-2. The next day, cells 
were moved to G-rex10 (WilsonWolf, USA); an expansion system that provides cells with 
unlimited neutrinos and unlimited O2, compared to the T-flasks. The cells were allowed to 
expand until Day 17 from activation. During this period and exactly at Day 12, the cells were 
stained with mAB targeting TCR α/β-FITC and CD3-APC to monitor the reduction in TCR 
expression. In the final step, TCR positive (+ve) cells were separated from TCR negative     
(–ve) population by running the cells through an LD column and using a TCR depletion kit.  
2.2.29 TCR depletion: 
In the final step of CD19CAR+ve TCR-ve cell production, cells were collected from G-rex10 
and pelleted by centrifugation at 300xg for 10 minutes. Cell pellet was then resuspended in 
100 µl MACS buffer. The cell suspension was then incubated with 10 µl Anti-TCRα/β biotin 
for 10 minutes in the dark in the refrigerator. The cells were washed in 1-2 mls of MACS 
buffer, and centrifuged at 300xg for 10 minutes, then resuspended in 80 µl buffer.  20 µl anti-
biotin microbeads were added and incubated with biotin labelled cells for 15 minutes at 4oC. 
The cells were washed as previously explained and resuspended in 500 µl MACS buffer and 
proceeded to depletion with LD column.  LD columns were inserted into a midi MACS 
separator, then rinsed with 2 mls of MACS buffer and let it run through. After applying the 
cells onto the prepared LD column, the column was washed twice with 1 mls of MACS 
buffer.  Afterwards, unlabeled cells which passed through the column were collected and 
labelled as depleted TCR negative fraction.  In order to collect TCR positive population that 
trapped in the column, cells were forced out by applying a plunger to the column after 
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removing it from the MACS separator. Finally, the cells were cultured in complete x-vivo15 
in 24 well plate for overnight.  The cells then were frozen down and stored in liquid nitrogen.  
2.2.30 CD34 selection with MS column: 
After transducing T cells - either derived from CB or PBMCs- with CD19CAR lentivirus 
construct that has CD34 RQR8 as a selectable marker - cells were exposed to positive 
selection by using a CD34 microbead kit and MD column.   After adding 100 µL of FcR 
blocking reagent to the 300 µl cell suspension, CD34 positive cells were labelled with 100 µl 
CD34 microbeads and incubated in the dark at 4oC for 30 minutes.  Cells were washed with 
MACS buffer then resuspended in 500 µl MACS buffer before proceeding to magnetic 
separation. MS columns were first rinsed with 500 µl buffer then labelled cells were applied 
onto the column and the through flow was collected to use it as a control of CD34 negative 
population. The column was washed three times with 500 µl buffer. And later separated from 
the separator and placed into collection tube. 1 ml of buffer was added to the column and 
positive fraction cells were immediately flushed out from column by pushing the plunger into 
the column.  Both positively and negatively labelled fraction cells were cultured in X-VIVO  
10 before they were analysed.  
2.2.31 Engineering Cord Blood T cells with CD19CAR: 
T cells derived from different cord blood donors were engineered to express CD19CAR 
construct.  The T cells were separated from whole blood through ficolling, as previously 
described. Two days after T cell activation with 1:1 ratio anti-CD3/anti-CD28 beads, they 
were transduced with third generation Lnt-EFLα-RQR8-CD19CAR.  Cells were moved to 
expand into G-rex10 and throughout the 12 days of culture, the cells were fed with IL-2 every 
48 hours and phenotyped at Day 5 and Day 12. On Day 12, the cells were frozen in freezing 
medium and stored at -80oC then moved to liquid nitrogen.  
2.2.32 High throughput next generation sequencing (NGS): 
Cord blood T cells were activated with CD3/CD28 beads or the cytokines cocktail (IL-7, IL-
15 and IL-2), transduced with CD19CAR lentivirus, electroporated with TRAC TALENs as 
mRNA, and ultimately a TCR negative population was selected.  DNA genomic material was 
extracted by using a DNeasy blood and tissue kit as previously stated from cell pellet of 
genetically altered cells by TALENs. A high generation sequencing process was carried out 
using MiSeq illumina (USA) and DNA samples were prepared with the help of Dr. Claire 
Deakins and Dr. Anastasia Petrova.  An Illumina Miseq Machine was used to perform the 
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NGS procedure. Raw sequencing data was analysed using software named CRISPR-GA; 
where the raw sequencing reads were uploaded and then underwent quality control by 
trimming to discard the results that contained any sequencing errors. The software then 
mapped the reads to the reference sequence (TRAC). The mapping was done by a specialised 
BLAT platform, which is suitable to support indels (deletions and insertions). The software 
processes the mapped BLAT results to detect the insertions and deletions. It then uses pattern 
matching to compute the number of reads matching the expected sequence or generating 
variants. This information is then integrated to create plots and reports. Pattern matching is 
used to calculate the number of reads matching the expected sequence and other variants 
generated. NHEJ and HR are estimated by computing specific equations. The final result 
consists of three parts. First, the results report the analysis of indel sizes. Second, they 
illustrate the analysis of indel locations within the edited genomic locus. Lastly, they show an 
integrated plot representing indels, NHEJ and HR. Furthermore, a FASTA file is created with 
all reads containing indels, as well as an XML text output with HR, NHEJ values and the 
indel relative location in genomic locus. 
2.2.33 Phenotyping Assay to determine T cell subset: 
As the project proceeded, new phenotyping panels were improved and used: 
After activating and transducing T cells either derived from cord blood or adult peripheral 
blood with different vectors, the cells were subjected to phenotyping staining to determine 
their characteristics. In the first panel, cells were stained with the following markers: CD4, 
CD8, CD27, CD25 and CD45RA. Later on, another panel was used to characterise T-cell 
subsets: CD4, CD8, CD45RA, CD62L, CD95 and CCR7. In addition, Fab fragment of 
CD19CAR stain was also added to characterise cells in a more specific manner. 
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Chapter 3: Engineering Cord Blood T cells for Tumor Immunotherapy  
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3.1) Introduction: 
Although adoptive-T cell immunotherapy has led to remarkably successful outcomes in 
treating cancer and viral infections, the inability to isolate and expand a sufficient number of 
high-avidity, specific T lymphocytes for therapeutic purposes poses a fundamental limitation 
for this therapy (Rooney and Leen, 2012). An alternative approach is to generate genetically 
modified T lymphocytes expressing an exogenous specific TCR and , or an artificial 
protein-fusion derived chimeric receptor known as CARs, aimed at targeting specific tumor 
associated antigens (Morris et al., 2003, Ghorashian et al., 2015). The limitations associated 
with this fast-growing field are mainly time and the high expense of manufacturing the 
patient-specific therapeutic product. In addition, endogenous TCR chains in the allogeneic 
infused T-cells might lead to GVHD (Torikai et al., 2012). One of the possible solutions to 
overcome this hindrance is to use a third party donor that would be easily accessible and have 
suitable application for more than one recipient. We hypothesised that this could possibly be 
achieved by engineering unrelated cord blood T-cells towards specific antigens (Serrano et 
al., 2006).  
Unrelated cord blood transplantation (CBT) has in recent years become an attractive therapy 
for hematological disorders. This is due to the fact that CB-T cell permits HLA disparity 
between the recipient and the donor, and a noticeably lower risk of graft-versus-host disease 
(GVHD) for a given degree of mismatch, compared to hematopoietic cell transplantation 
(HCT) from adult donors (Rubinstein et al., 1998, Rocha et al., 2001, Hiwarkar et al., 2015).  
In fact, the absence of memory T cell fraction may be the reason for the low incidence and 
severity of GVHD that is noticed in cord blood transplantations  (Kloosterboer et al., 2004). 
Additionally, the majority of cord blood T cells possess a naïve phenotype, which is 
characterized by expressing CD45RA, CCR7 and CD62L. Consequently, the rate of 
persistence and survival of the genetically engineered CB-T cells after engraftment might be 
higher than the engineered adult T cell (Eisenthal et al., 2003, Frumento et al., 2013). Also, 
CB-T cells preserve their long telomeres. Consequently, they have  higher telomeres activity, 
which  is a good indicator of higher proliferative activity (Weng, 2012). These factors, in 
addition to the ethnic diversity and relative ease of collection, have made CB-T cells amongst 
the best candidates for adoptive T cell therapy to generate an allogeneic universal therapeutic 
product (Shpall et al., 2011). 
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Here we hypothesised that CB-T cells possess attributes that are fundamental for the 
generation of a universally genetically modified therapeutic T cell product. We investigated 
the advantages of engendering genetically engineered CB-T cells over adult donor engineered 
T-cells. This chapter describes the outcomes of redirecting the specificity of cord blood T 
cells through expression of: 1) Recombinant TCRs using exogenous antigen specific T-cell 
receptors against Wilm’s tumour antigen (Wilm’s tumour antigen is the tumour associated 
antigen over-expressed by leukemic cells); and 2) Chimeric antigen receptor (CAR) targeting 
CD19 antigen molecule expressed by normal and neoplastic B cells.  WT-1 TCR and second 
generation CD19CAR were introduced to the activated CB-T cells via lentiviral vector 
transduction ensuing second and third generations lentiviral vectors were produced. 
Interferon gamma and 51Chromium release assays were used as a means to evaluate 
cytotoxic activity and specific-target specificity of the genetically engineered cells in order to 
assess the functionality of the genetically engineered CB-T cells. Engineered CB-T cell 
properties were explored via investigating the expression profile of naïve chemokines by 
phenotyping assay.  
3.2) Engineering CB-T cell with WT1-TCR: 
3.2.1) Vector Production and Characterisation: 
Lentiviral vector stocks were produced by transient transfection of HEK293T cells with 
lentiviral vector plasmid, a second generation lentiviral packaging plasmid p8.74 and VSV-G 
envelope plasmid, pMDG.  Lnt-PGK-eGFP construct was used to produce GFP virus for use 
as a control. Virus particles were harvested at forty-eight and seventy-two hours after 
transfection and concentrated by ultracentrifugation. The titre of each virus batch was 
quantified by transducing the appropriate type of cells with serial dilutions of virus stock and 
the expression of the desired antigen-receptor was analysed by flow cytometry seventy-two 
hours after transduction.  After that, the number of infectious units per ml was calculated.  
Plasmid encoding WT1-TCR alpha and beta genes used in this project were originally cloned 
from an allo-restricted, cytotoxic T lymphocyte line specific for the WT1 antigen-derived, 
HLA2-2 presented peptide pWT126. WT1-TCR is comprised of a Vα1.5/Vβ2.1 heterodimer 
(Xue et al., 2005). In addition to fusing murine constant-region genes (mCα and mCβ) to the 
cloned, variable-region genes of WT1-TCR, cysteine residues were introduced to the WT1-
TCR construct. The WT1TCR construct was previously ligated to a lentiviral vector with an 
SFFV in an internal promoter (Figure 15.A).  FACS analysis was performed on a TCR-
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negative Jurkat cell line and was used for virus titration (Figure 15.B). A typical titre of 7.1 x 
108 infectious units (IU) per ml was achieved.  
 
A) Lnt-SFFV-WT1-TCR modified construct 
 
B) Virus titration of Lnt-SFFV-WT1-TCR 
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Figure 15: Lnt-SFFV-WT1-TCR virus titration. A) Schematic map of Lnt-WT1-TCR modified construct. B) FACS plot data demonstrated WT1-TCR transduction efficiency using serial dilutions of concentrated LNT-SFFV-WT1-TCR virus supernatant on the Jurkat negative cell line.  
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Forty-eight hours after activating CB-T cells with anti CD3/CD28 Dynal beads at a 1:1 ratio, 
the activated cells were transduced with lentiviral vectors containing human, Vα1.5/Vβ2 
TCR genes and murine, constant α/β genes at MOI of 10. Three days post transduction; the 
transduced cells were harvested for further analysis including transduction efficiency, 
evaluation and some functional assessment. This experiment was conducted on five cord 
blood units and the following section will discuss the outcome of editing the specificity of 
these cells toward WT1 antigen. 
3.2.2) WT1-TCR Transduction Efficiency of all Five Cord Blood Donors after 
Activation of CD3/CD28 Beads and Transduction with LNT-WT1-TCR (MOI 10): 
Three days after transduction, cells were stained with anti-Vβ2.1 and anti-mCβ (murine 
constant ) antibodies to determine the transduction efficiency. Gating on the viable cells on 
the LSR II cytometer, a significant increase in the percentage of the T cells-expressed 
Vβ2.1/mCβ led to between 49–95% gene transfer (mean=60%, n=5) compared to the non-
transduced T cell population in the CD3/C28 beads stimulation condition was detected 
(Figure 16).  This result indicated that WT1-TCR was successfully transduced into CB-T 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Expression level of WT1-TCR after transducing activated cord blood T cells (n=5) with Lnt-SFFV-WT1TCR. Ggrouped graph show a summary of the expression levels of WT1-TCR on the surface of activated cord blood T cells (n=5) post transduction with MOI 10 of WT1-TCR lentiviral vector. A considerable proportion (49-95%) of WT1-TCR cells in WT1-TCR transduced T-cells were positive for staining with mAb to Vβ1 and mCβ in comparison to non-transduced CB-T cells. Student T test was calculated to be p<0.0001  
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Figure 17: Expression level of WT1-TCR on CD3/CD28 beads + IL-2 activated CB-T cells. Representative FACS blot of one CB donor displaying the percentage of activated T-cells expressing both Vβ2 and mCβ and the level of antigen expression is indicated by mean fluorescent intensity (CD3/CD28 beads +IL2 stimulation condition). Plots in the first row exhibit the percentage of viable CD4+ and CD8+ cells. The percentage of CD4+WT1-TCR+ T cells are shown in the FACS plots in the second row, while the last row illustrates the FACS plots of CD8+WT1TCR+ T-cells.  
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To assess the function of WT1-TCR CB-T cells, antigen-specific cytokine production from 
the WT1-TCR transduced T-cells and the antigen- specific cytotoxicity were examined.  
INF-γ capture assay: 
WT1-TCR transduced CB-T cells of three donors were stimulated by T2 cells loaded with the 
modified WT126 peptide or irrelevant ADV peptide for six hours and examined for 
production of IFN-γ. The cells were then harvested and stained with INF-γ catch reagent then 
with anti-INF-γ phycoerythrin (PE) and anti-CD8 fluorescein isothiocyanate (FITC) before 
flow cytomeric analysis of INF-γ release. The FACS plots suggested that WT1-TCR 
transduced cells stimulated with the WT126 peptide produced IFNγ, whereas cells stimulated 
with the irrelevant peptide (ADV) did not do as well as non-transduced cells.  INF-γ release 
percentages from WT1-TCR transduced cells of 6.3%, 12.5% and 2.3% for donors 1, 2 and 3 
respectively, were detected by the LSRII flow cytometric machine. Conversely, a percentage 
of less than 1% of INF-γ was produced by the non-specific peptide (ADV).  Both negative 
and positive controls were used in parallel to the genetically engineered cells and their INF-
γrelease results were reasonable and supportive of the assay (Figure 19). Un-transduced cells 
were mixed with T2 cells to act as the negative control group. To simulate a positive control, 
one drop of superantigen named staphelylococcal enterotoxin B (SEB) was mixed with the 
un-transduced cells and T2 cells. 
A representative FACS plot of CB-T cells obtained from the 3rd donor showed that the 
functional cytokines secretion of the WT1- TCR transduced cells activated by CD3/CD28 
beads was 2.30 % of the Vβ2.1 positive cell population (Figure 18). 
A summary of the functional INF-γ secretion of the WT1-TCR-transduced cells activated by 
CD3/CD28 beads is explained in figure 19. The bar chart shows that WT1-TCR-transduced T 
cells were able to recognise and kill peptide-loaded T2 cells in an antigen-specific manner 
without affecting or killing the non-specific peptide-loaded cells. 
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Figure 18: antigen-specific responses of WT1-TCR transduced CB-T cells. The WT1-TCR construct (indicated at the top) was transduced into CB-T cells and its functional activity was determined. An antigen-specific interferon γ (INF-γ) production determined after 6 hrs of stimulation with specific PWT126 peptide or non-specific ADV peptide. Representative FACS plot data of intracellular INFγ staining are shown. 
pg. 93  
                    
The previous data might suggest that WT1TCR-transduced CB-T cells are highly capable of 
recognising their target antigens and discriminating them from non-target cells. To further 
confirm this observation, an in vivo trial is required.  
 
51Chromium Release Assay: 
The in vitro, antigen-specific functionality of WT1-TCR-transduced CB-T cells was also 
demonstrated in antigen-specific killing activity in a 51chromium release cytotoxicity assay 
using a relevant and non-relevant peptide loaded onto target cells (T2 cells). As demonstrated 
in figure 20, the human, TAP-deficient T2 cells were killed after being coated with pWT126 
(specific peptide), but not after being coated with ADV peptide (control, non-specific 
peptide). The  increase in the percentage of the killing activity; or of 51Cr release, of CB-T 
cells that expressed WT1-TCR was found to be 85% compared with the killing activity of 
non-transduced T cells, and the killing behaviour of WT1-TCR CB-T cells against target 
cells loaded with non-specific peptides (Figure 20).  
The previous data might suggest that WT1- TCR transduced CB-T cells are highly capable of 
recognising their target antigens and discriminating them from non-target cells. To further 
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Figure 19: Summary of INF-gamma secretion produced by three CB-T cells transduced with Lnt-SFFV-WT1-TCR after stimulation with specific peptide (pWT126) or irrelevant peptide (ADV).Bar graph demonstrates the level of INF- γ secretion of WT1-TCR transduced CB-T cells (n=3) in response to specific and non-specific antigen. Student t test was calculated to be equal to 0.0147 (p<0.05).  
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confirm this observation, an in vivo trial is required. Moreover, it has been noticed that levels 
of killing reflect the levels of gene transfer. 
                     
 
3.2.3) WT1 TCR transduced CB-T cells show naïve phenotype post activation and of 
lentiviral transduction: 
Phenotype classification of transduced CB-T cells, such as naïve, effector and memory T 
cells is useful in determining the fate and the exhaustion status of the cells prior to 
transferring them into a patient’s body. The first panel of phenotyping used in this project 
was staining the cells to determine the expression of CD4, CD8, CD27 and CD45RA. The 
cells were categorised as “naïve” if they possessed a CD4+CD8+CD45RA+CD27+ 
phenotype; as a “memory” if they lost the expression of the CD45RA marker; or as an 
“effector” if they were negative phenotypic for both CD45RA and CD27.  The expression of 
these surface markers was detected by flow cytometry after staining the cells with mAbs and 
targeting them.  The following table demonstrates the percentages of each T cell subsets in 
detail for the three donors: 
 
 
Figure 20: Percentage of specific killing of Lnt-SFFV-WT1TCR CB-T cells. WT1-TCR engineered CB-T cells (n=5) recognised their specific tumour antigen and selectively kill their target, cancerous cells but not non-specific control targets in vitro. 
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 As Table 5 shows, CB-T cells from donor 1 and donor 3 behaved in almost the same manner 
and exhibited similar percentages of CD27 and CD45RA expression.  CB-T cells in any of 
the three conditions (un-activated, un-transduced or WT1TCR transduced) from both donors 
appear to express a higher percentage within the naïve category compared to the memory and 
the effector subsets. By contrast, CB-T cells from the 2nd donor behaved in a different 
manner. The activated cells either transduced or un-transduced, expressed CD27 in higher 
percentages (62.2%-79.3%) than CD45RA.Thus, they were classified as memory T cells, but 
the un-activated T-cells were categorised as naïve T cells based on their expression of the 
surface markers, CD27 and CD45RA (Figure 21). 
The results from this assay might suggest that CB-T cells could conserve their naïve 
phenotype even after activation and lentiviral transduction. The naïve phenotype is a crucial 
requirement for T cell immunotherapy in which infused engineered T cells live longer within 
the patient’s body, and it might also show better results in the homing process.  
As it appears from the previous results, cells from different donors behave in various manners 
and produce different results. For this reason, and because the phenotyping panel was so 
basic, results from this assay might not be precise. A more advanced phenotyping panel was 
used for the future experiments and it will be discussed in the next chapters. 
  Naive Effector Memory 
 
Donor 
1 
Donor  
2 
Donor 
3 
Donor 
1 
Donor 
2 
Donor 
3 
Donor 
1 
Donor 
2 
Donor 
3 
Un-activated 70% 77.2% 61.8% 12.6% 1.3% 5.33% 1.18% 10.44% 1.69% 
Un-Td 68% 13.7% 69.7% 23.6% 5.7% 6.13% 1.56% 62.2% 0.73% 
WT1TCR-Td 71% 0.16% 47% 0.7% 0.23% 19.4% 18.1% 79.3% 3.6% 
Table 5: The percentages of CB-T cells different subsets prior and post activation and transduction. 
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 After these promising results, the production of substantial numbers of engineered cord blood 
T cells was discussed.  
3.2.4) Scale-up Experiment to Engineer CB-T Cells with WT1TCR in a Closed Bag 
System: 
In the scalability experiment relating to CB-T cell engineering, performed with 200 x106 CB-
T cells in a closed bag system, the ficolled CB-T cells were activated with anti-CD3 and anti 
CD28 in a 100 ml differentiation bag. Two days later, activated T cells were transduced with 
Lnt-SFFV-WT1TCR (MOI 4) and kept in culture for ten days with IL-2 supplemented every 
forty-eight hours. On Day five of the experiment, cells were collected and stained with anti-
V2.1 and anti-murine constant  chain to evaluate the transduction efficiency by 
flowcytometry.WT1-TCR-transduced CB- T cells demonstrated a remarkable increase in the 
percentage of the positive WT1-TCR cell population, compared with non-transduced cells. 
The FACS plot in figure 22 illustrates that up to 58.5 % of CB-T cells express TCR 
composed of Vβ2.1 and mCβ chains targeting WT1 antigens. 
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Figure 21: Classification of WT1TCR transduced CB-T cells prior and post activation (n=3). The frequency of CD27 and CD45RA cells in CD4+ T cells and CD8+ T cell populations from three donors. CB-T cells were isolated from three CB units and then stained with anti-CD4, anti-CD8, anti-CD27, and anti-CD45RA mAb. The mean percentage and SD of each condition in each subset are shown. 
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WT1-TCR transduced cells were later selected based on the existence of murine constant 
region within the introduced TCR that were expressed by the cells. WT1-TCR transduced 
cells were stained with anti-mC-APC mAbs then labeled with anti-APC microbeads. The 
cells that expressed WT1-TCR were then positively selected or enriched by using MS MACS 
column. 70x106 positive selected cells were frozen down in 90% FCS and 10% DMSO for 
further analysis.  
 
 
Figure 22: Expression of WT1-TCR in closed bag system for scale up purposes. 200x106 CB-T cells were activated with CD3/CD28 beads and transduced with LNT-SFFV-WT1TCR (MOI 4). A) Gating on the viable cell population, B) FACS plots data demonstrated the remarkable efficiency of WT1-TCR on CB-T cells after transduction. 
 3.3) Engineering CB-T cell with CD19CAR:
3.3.1) Vector production and c
Two lentiviral vectors were utilised
The first lentiviral vector expressing CAR
was produced by PULE LAB
inactivating (SIN), second generation
includes a SFFV promoter, followed by a RQR8 sort suicide gene (CD34 marker) connected 
to CD19CAR via foot and mouth disease 2 like peptide (FMD
titration of Lnt-CAR-CD19 with an SFFV 
CD19CAR-negative-SupT1 cell line.  The FACS analysis provided a titre of 1.8 x 10
ml. 
 
A) Lnt-SFFV-CD19-CAR construct
      B) Virus titration of Lnt-SFFV 
 
Figure 23: Lnt-SFFV-CD19-CAR virus titration.plot data demonstrated CD19CAR transduction efficiency using different amounts of concentrated LNTCD19CAR virus on a CD19CAR-negative SupT
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-CAR virus titration. A) Schematic map of Lnt-t data illustrate CD19-CAR transduction efficiency using -EFLα-CD19-CAR virus on a Jurkat cell line.
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3.3.2) CD19-CAR transduction efficiency after activation of CB-T cells with CD3/CD28 
beads and transduction with LNT-SFFV-CD19CAR (MOI 10): 
One unit of CB was ficolled and 2x106 cells were cultured in X-VIVO 15 + 5% HS, 100 units 
of IL-2 and CD3/CD28 Dynal beads at a 1:1 ratio per well were placed in 24 well plate. Two 
days later, activated cells were exposed to a Lnt-SFFV-CD19CAR vector at MOI of 10.  
Three days post transduction; transduced cells were harvested for further analysis, including 
transduction efficiency evaluation and some other functional assessments, such as 51Cr 
release assay. To investigate the transduction efficiency, both transduced and non-transduced 
cells were stained with antibodies that are designed to target the spacer/linker region of 
CD19-CAR, named scFv-APC mAb, for flow cytometry analysis. The flow cytometric 
characterization of CD19CAR-CB-T-cells revealed a remarkable increase in the percentage 
of T cells-expressed as CD19CAR – up to 70%, compared with non-transduced cells in the 
CD3/CD28 beads stimulation condition (Figure 25). 
 
               
 
 
 
3.3.3) CD19-CAR T cells generated from cord blood have the potential for significant 
and specific in vitro lysis of their target: 
The functionality of the CD19CAR transduced CB-T-cells was also investigated by 
determining the specific killing behavior of the transduced CB-T cell population against 
Figure 25: Expression level of CD19CAR transgene after lentiviral transduction of CB-T cells. FACS blot on the left demonstrate the level of CD19CAR expression in the un-transduced population (0.427%); which is considered as the background. FACS blot on the left illustrate the clear population of the transduced cells that expressing CD19CAR (69.8%).  
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target cells expressing CD19 on their surfaces (SupT1-CD19 cell line).  CD19-CAR CB-T 
cells generated after lentiviral transduction were incubated for four hours with a 51Cr labeled 
target. The SupT1-CD19 cells stably transfected with the CD19 antigen, or SupT1 cell line 
that served as positive and negative controls, respectively. Manufactured anti-CD19-CAR 
CB-T cells were able to kill their targets in a CD19-specific manner with a remarkably high 
percentage of killing activity (70%). More impressively, very high levels of cytotoxicity were 
appreciated even at very low effector-to-target (E:T) ratios. In contrast, the corresponding un-
transduced controls demonstrated little cytotoxicity (Figure 26). The previous data might 
suggest that CD19CAR transduced CB-T cells are highly capable of recognising their target 
antigens and discriminating them from non-target cells. To further confirm this observation, 
an  in vivo trial is required. Moreover, it has been noticed that levels of killing reflect the 
levels of gene transfer. 
 
        
Figure 26: Percentage of specific killing of Lnt-SFFV-CD19-CAR CB-T cells. LNT-SFFV-CD19CAR-transduced normal donor CB-T cells killed CD19-SupT1 cells expressing CD19 on their surface, but not CD19 negative-SupT1 cells (control target).  
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 Experiments using the lentiviral vector with a SFFV promoter were conducted only on one 
cord blood unit, while the other vector that utilizes EFl as a promoter was used to edit the 
specificity of more than one CB-T cell donor. In the following section, we will discuss the 
outcome of editing the specificity of these cells towards a CD19 antigen. 
3.3.4) CD19-CAR Transduction efficiency after activation CB-T cells with CD3/CD28 
beads and transduction with LNT-EFL-CD19CAR (MOI 5): 
After the promising outcome of the preliminary data, a scale-up plan to manufacture large 
quantities of engineered CB-T cells was discussed. On the first day, up to 100 x106 CB-T 
cells (n=5) were activated in 100 ml differentiation bags with anti-CD3/anti-CD28 beads. 
Two days later, the activated cells were transduced with Lnt-EFl-CD19CAR lentivirus 
vector at MOI 5. After transduction, the cells were moved to be cultured in G-rex 10m flasks 
for ten more days. The G-rex expansion system is considered to be one of the most robust 
systems to multiply cell growth rate by providing unlimited gas exchange and nutrition via its 
gas permeable membrane. Finally, the cells were harvested to analyse their killing activity 
and to investigate their naïve phenotype, and some cells were frozen for in vivo assay. 
Before proceeding to the final step, two donors were subjected to a positive selection of 
CD34 in order to have a pure population of cells expressing CD19CAR alone using the 
MACS separation system for positive selection. However, the number of positive selected 
cells was not reflective of the high percentages of transduction efficiency. In fact, the 
numbers of the positive cells were very low. It had been later discovered that CD34 was 
expressed by the cells for only a short period of time, and then it disappeared in an 
unexplainable manner. One of the notions that had been suggested regarding the reason of its 
disappearance was that CD34, or to be more specific RQR8, was recycled by the cells, so it 
may have been subjected to a period of disappearance. Nevertheless, to date the exact reason 
behind the disappearance of the RQR8 region after a short time of transduction remains 
unclear.  
To determine the levels of CD19-CAR expression on the cell surface, cells were stained with 
CD34-APC monoclonal antibodies (mAb) and/or anti-Fab antibody for flow cytometric 
analysis two days after transduction. Flow cytometry detected RQR8 and/or Fab on up to 
75.9% CD19CAR transduced CB-T cells,  and less than 1% background detected on un-
transduced cells (27%-75.9%, mean=52.14) (Figure 27) 
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A) Percentage of CD19CAR expression 
 
B) FACS blot represent the expression of CD19CAR 
 
Figure 27:CD19CAR expression levels on five different donors of CB-T cells. A) Grouped dot graph illustrates the percentages of CD19CAR expression in 5 different CB units transduced with Lnt-EFl-CD19CAR. Un-transduced cells from the same donors were used as a control group. A significant increase in CD19CAR expression levels were observed within the transduced group, compared to the percentages within the un-transduced batch (P value ≤ 0.01). B) Representative FACS plots that explain the flow cytometric characterisation of CD19CAR expression of CB-T-cells from donor number 4. FACS plots show 58% of the transduced cells are expressing CAR19 with 1% background detected within the control group by staining with anti-Fab-PE and anti-CD34-APC antibodies. 
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3.3.5) CD19CAR Engineered T cells Phenotype Post Activation and Transduction  
(n=3): 
Twelve days post activation and after engineering the cells with CD19CAR, the cells were 
stained with CD4, CD8, CD45RA, CD62L and CCR7 to investigate the effect of CD19CAR 
on them, as well as to determine their fate after being engineered. As shown in the bar chart 
display in Figure 28, there is a slight difference in the percentage of the naïve population 
between the engineered cells and the un-transduced cells. Un-activated cells were used as a 
control and the results resembled the un-engineered cells. It may be concluded from this 
assay that CB-T cells still retained their naïve phenotype and it is feasible to expand the naïve 
CB-T cells ex vivo. 
 
 
 
 
CD4+
Naiv
e
CD8+
Naiv
e0
20
40
60
80
100
CD
45R
A+C
D62
L+C
CR
7+ UnactivatedUn-Td Td
Figure 28: Phenotypic analysis of CAR19 engineered CB-T cells.Bar chart demonstrates the expression of naïve markers: CD45RA, CD62L and CCR7 on CD4 and CD8 subsets of CB-T cells transduced with CD19CAR lentiviral vector. 
 
 3.3.6) Ability of CAR19 Engineered 
A Sup-T1-CD19 cell line was used as the target cells to investigate the functionality of the 
CD19CAR engineered T cells. The specific ki
against their target was determined after incubating them with a 
cell for four hours. The SupT1 cells that negatively express CD19 were used as a negative 
control. The engineered CAR19 CB
target cells and rarely showed killing behavior against the negative control cell line.
to the killing activity of the un
19CAR transduced CB-T cells are highly capable of recognising their target antigens and 
discriminating them from non
is required. Moreover, it has been noticed that levels of killing reflects 
transduction efficiency (Figure 29)
 
 
 
 
 
    
Figure 29 : Percentage of specific killing of Lnttransduced normal donor CB-T cells CD19 negative-SupT1 cells (control target). P valuebetween untransduced CB-T cells and CD19CAR CBkilling behavior between CAR19 cells against SupT1expressing CD19. 
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3.4) Discussion: 
Graft-versus-host-disease (GVHD) is the end of a complex interplay of donor and host 
factors that leads to massive tissue damage and impaired immunological recovery. Despite 
decades of research studies examining GVHD’s role in delaying immune reconstitution, it 
remains a fundamental cause of morbidity and mortality after allogeneic transplantation and 
limits the success of this therapeutic approach (Parmar et al., 2014). Umbilical cord blood 
cells have become a major source of hematopoietic stem cells that are utilised for the 
treatment of patients with high-risk hematologic diseases lacking a human leukocyte antigen 
(HLA)-matched bone marrow donor (Eapen et al., 2007). Cord blood lacking memory T cell 
subsets is responsible for the low incidence and severity of GVHD after allogeneic 
hematopoietic stem cell transplantations (HSCT) from CB. Additionally, the naïve phenotype 
of CB-T cells, ease of accessibility and the prolonged survival rate after engraftment, 
amongst several other characteristics, have made CB-T cells an optimal source to generate 
allogeneic universal “off-the-shelf” pharmaceutical T cell products. 
Although unrelated cord blood transplantation has proven to be a great source of 
hematopoietic stem cells for patients with B-lineage acute lymphoblastic leukaemia (B-ALL), 
a T cell-subset in circulating CB-T cells prevents tumour identification that might lead to 
disease-relapse. In 2006, a scientific group hypothesised that using a single-chain chimeric 
immunoreceptor targeting specific antigen (i.e. CD19), will overcome this limitation. 
Therefore, CD19CAR derived from CB-T cells has already been generated and tested 
successfully in a murine model (Serrano et al., 2006), providing a solid foundation to 
generate universal off- the-shelf genetically engineered CB-T cells, which is the main goal of 
this chapter. 
In order to achieve our aims, we have investigated the feasibility of genetically engineered 
CB-T cells for direct anti-tumour therapy using lentiviral transfer of both WT1-αβ TCR and 
CD19-CAR. The self-inactivating lentiviral vectors expressing an optimised TCR targeting 
Wilms’ tumour antigen 1 (WT1-TCR) or the CD19-specific chimeric antigen receptor 
(CAR), were produced and tested on TCR-negative Jurkat T cells. CB-T cells were activated 
with anti-CD3/-CD28 beads in the presence of interleukin-2 and exposed to a single round of 
lentiviral transduction. Three days after transduction, a flow cytometric analysis found 
between a 49–95% gene transfer (mean=60%, n=5) with high levels of viability and 
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functional integrity. Engineered CB-T cells exhibited antigen-specific interferon-γ release 
and mediated appropriate, target-specific cytotoxicity in chromium release assays. The 
scalability of CB-T engineering was confirmed in a closed-bag system appropriate for 
therapeutic use as part of feasibility studies for ‘off-the-shelf therapies’ to treat  
haematological malignancies. Findings related to engineering CB-T cells with third 
generation CAR CD19 reveal high gene transfer percentages found between 27–75% 
(mean=52.14%, n=5) with high viability. In the primary in vitro 51Chromium release 
experiment, anti-tumour activity of genetically altered CB-T cells was observed to be highly 
specific in targeting the CD19 antigen expressed by the SupT1 cell line. Interestingly, the 
levels of chromium released by the antigen-specific engineered cells reflect the percentage of 
gene transfer. These findings suggest that naïve CB-T cells have a high potential to be 
engineered and manipulated towards a specific antigen with a great anti-tumour effect and 
high specificity. 
In adoptive T cell therapy, it has been shown that the circulating, infused engineered adult T 
cells undergo memory-effector differentiation in a rapid manner, which is linked to a 
reduction in the survival rate and anti-tumour efficacy after engraftment. Furthermore, 
immune exhaustion of engrafted T cells is associated with a late differentiated phenotype 
(Klebanoff et al., 2005a, Gattinoni et al., 2005b).  
Here our findings suggest that engineered CB-T cells retain their less differentiated 
phenotype, naive and stem cell memory T cell subsets after in vitro activation with genetic 
manipulation, which is favourable for immunotherapy. In summary, the outcomes of this 
chapter may suggest that CB-T cells are more amenable to alteration and more easily lend 
themselves to transduction. This would lead to an accessible and fixable production of off-
the-shelf therapeutic, antigen-specific T lymphocytes that are ready for infusion into multiple 
recipients without the risk of GVHD occurring. However, the potency of the anti-tumour 
effect of these engineered cells should be evaluated in an in vivo mouse model before being 
applied in clinical trials. For further work, CB-T cells should be evaluated to reject B-cell 
lymphoma (Raji cells line) in a xenograft tumour model in the immunodeficient mouse strain 
NOD/SCID/IL2rnull (NSG). Another issue is that the endogenous  TCR will still be 
expressed by the engineered T cells, resulting in a possibility that this endogenous TCR 
might lead to some problems, such as GVHD or a pairing with the exogenous newly 
introduced TCR leading to the production of unspecific TCRs (Heemskerk, 2010). One of our 
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aims in this project is to disrupt the expression of the endogenous TCR-CD3 complex by 
using engineered nucleases as part of genome editing technology. The outcome of these 
experiments will be discussed later in the text. 
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Chapter 4: Comparison of CB-T Cell Activated with 
CD3/CD28 Beads and IL-2 versus CB-T Cell 
Activated with Cytokines (IL-7 and IL-15) and IL-2 
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4.1) Introduction: 
The age-related differences in engineered T-cell differentiation, activation, adhesion, and 
exhaustion status have had a major influence on their ability to achieve fully competent anti-
tumor activity in adoptive immunotherapy (Harris et al., 1992).  As it has been mentioned 
earlier, one of the fundamental keys for successful adoptive T cell therapy against cancer is 
the expansion, persistence and long survival of the tumour-directed therapeutic T cells after 
infusion. Ordinarily, T-cells from ficolled blood are activated via cross-linking of anti-CD3 
and anti-CD28 conjugated beads prior to transduction or transfection. Once the gene transfer 
process is performed, cells are usually expanded by adding c chain cytokine IL-2 every 
forty-eight hours (Savoldo et al., 2011). The T cells’ activation signal is triggered via the 
TCR-CD3 complex. The T cell expansion and proliferation, co-stimulatory CD28 is 
responsible for this function (Frauwirth and Thompson, 2002). Anti-CD3/anti-CD28 
conjugated beads are considered to be a strong stimulant; therefore, cells will divide and 
differentiate in a rapid manner towards effector-memory T cells (TEM) and expressing 
CD45RO chemokine with less than 10% of CCR7 and CD62L co-expression. As a 
consequence, these cells may have short persistence in vivo after engraftment. Although 
effector-memory T cells have a robust anti-tumour activity, only central-memory T cells and 
other less differentiated T-cell subsets, such as naïve and the recently defined “T-memory 
stem cells,” are critical for in vivo expansion, survival, and long-term persistence (Gattinoni 
et al., 2011, Xu et al., 2014). 
Interesting reports have suggested that activation of adult T cells via common-γ cytokines 
such as IL-7 and IL-15 will preserve the stem cell memory T cells subsets, a subpopulation 
that is favorable for adoptive T cell therapy due to its high survival rate and efficient anti-
tumour activity (Xu et al., 2014, Gattinoni et al., 2009). These chemokines implant due to 
their activation mechanism that has been reviewed in the literature. For example, IL-15 
promotes proliferation of naive CD8+ subsets, endorses T cell survival via up-regulation of 
Bcl-2 and also blocks the inhibitory effect of regulatory T cells and effector-memory T cells; 
while the induction of homeostatic expansion of naïve T cells is one of the roles of the IL-7. 
Most interestingly, CB-T cells don’t lose their CCR7+ expression after being activated with 
IL-7 and IL-15; suggesting that using a cytokines cocktail as a stimulant might be a better 
alternative to activate CB-T cells prior to viral transduction for adoptive T cell therapy. 
In this project, the gene transduction efficiency of CB-T cells activated with CD3/CD28 
beads was compared to cytokine cocktail-activated CB-T cells. Prior to transduction, ficolled 
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cord blood was subjected to either anti-CD3/CD28 beads at a 1:1 bead ratio or to a cytokines 
cocktail composed of IL-7, IL-15 at a concentration of 5ng/ml and IL-2 (1 00U/ml). The 
functionality and the anti-tumour activity of these transduced cells were also examined. 
4.2) Cytokines (IL-7 and IL-15) Titration: 
In order to determine the ideal combination of the cytokines cocktail that produced a robust 
activation of CB-T cells with a reasonable survival rate, a cytokines titration experiment was 
performed. Different concentrations of IL-7 (0, 0.5, 5, 50 ng/ml) were mixed with 100 U/ml 
IL-2 and with different concentrations of IL-15 (0, 0.5, 5, 50ng/ml) to activate 2x106 CB-T 
cells in a 24-well plate.  Three days post-activation, a third generation CD19CAR lentiviral 
vector was used to transduce these activated cells.  Forty-eight hours after transduction (Day 
5 after activation), the cells’ viability and CD19CAR expression level were investigated by 
flow cytometry after staining the cells with mAb targeting the RQR8 portion (anti-CD34) of 
the CD19CAR construct. The interleukins were topped up every 48 hours for each condition. 
IL-2 was added to all conditions at a concentration of 100U/ml and topped up every 48 hours. 
The first column of table 6 demonstrates the effect of different concentrations of IL-7 & IL2 
(100U/ml) as a stimulator on CD19CAR transduced CB-T cells by measuring the expression 
levels of CD19CAR. The second column illustrates the consequence of different 
concentrations of IL-15 & IL2 (100U/ml) alone as a stimulator on CD19CAR transduced CB-
T cells by measuring the expression levels of CD19CAR. The third column shows the 
percentage of CD19CAR expression levels on CB-T cells that were activated with various 
dosages of IL-15, 5 ng/ml of IL-7 and 100 U/ml of IL-2.  
The final results suggest that 5 ng/ml of IL-7 + 5 ng/ml of IL-15 + 100 U/ ml of IL-2 is the 
ideal condition to stimulate activation of cord blood T-cells (Table 6).  Surprisingly, the data 
suggested that the highest percentage of CD19CAR expression is reached when the cells are 
activated with IL-15, in combination with IL-2, but not IL-7 (Figure 30).  We chose to use 
IL-7, IL-15 and IL-2 as the most suitable conditions for the survival and function of T cells. 
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 IL-7+IL-2 (100 U/ml) IL-15+IL-2 (100U/ml) IL-7 (5ng/ml)+IL-15 
IL-2 (100U/ml)  
0 ng/ml 3.90 % 1.68 % 5% 
0.5 ng/ml 5.9% 15.9 % 7.3% 
5 ng/ml 6.14 % 20% 17% 
50ng/ml 10.60 % 12% 8.40% 
Table 6: Transduction efficiency of CB-T cells transduced with 2nd generation Lnt-SFFV-CD19CAR and cultured under various concentrations of IL-7, IL-15 or both. 
 
 
 
 
 
 
 
 
 
 
 
4.3) Comparison of WT1-TCR and CD19CAR transduction efficiency of CB-T cell 
stimulated with different conditions before transduction: 
Cord blood T cells were activated using different stimulators, either CD3/CD28 antibodies 
(n=5) and IL-2 (100 U/ml), or a combination of IL-7 (5 ng/ml), IL-15 (5 ng/ml) (n=3) and IL-
2 (100 U/ml).  Forty-eight hours post activation, the activated T cells (with either condition) 
were transduced with lentiviral vectors containing human, Vα1.5/Vβ2 TCR genes and 
murine, constant α/β genes (MOI 10), or lentiviral vectors carrying scFv CD-19CAR genes 
(MOI 10).  Three days after transduction, the cells were stained with anti-Vβ2.1 and mCβ 
antibodies or an antibody targeting the spacer portion of the CD19-CAR molecule (Fcγ). 
Gating on the viable cells on the LSR II cytometer, a significant increase in the percentage of 
T cells-expressed Vβ2.1/mCβ led to between a 49–95% gene transfer (mean=60%, n=5) 
0 ng
/ml
0.5 n
g/ml 5 ng
/ml
50ng
/ml
0
10
20
30
40
50
Concentration (ng/ml)
Tra
nsd
ucti
on e
ffec
ienc
y %
IL-7IL-15
IL7 (5ng/ml)+IL-15
Figure 30: The percentage of CD19CAR expression level of CB-T cells after activation with different combination of various dosages of IL-7 or/and IL-15 stimulators in addition to 100 U/ml of IL-2 with all conditions. Plot demonstrates CD19CAR transduction efficiency percentage at Day 5 after activation of CB-T cells with different concentrations (0, 0.5,5,50 ng/ml) of different cytokines. 
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compared with the non-transduced T cell populations in the anti-CD/anti-C28 bead 
stimulation condition (Figure 31). Comparing this result with the transduction efficiency of 
the T cell population stimulated with cytokines alone, CB-T cells showed T cells-expressed 
in 26–47% gene transfer (mean=38.5%, n=3) on the basis of Vβ2.1/mCβ expression (Figure 
31). Representative FACS plots of one cord blood donor displaying the percentage of 
engineered CB-T cells expressing both V2β and mCβ is illustrated in Figure 32.  
Previous studies on peripheral blood found less than around 30% gene transfer levels in 
cytokine-stimulated cells. WT1-TCR transduced cells were utilised in some functional assays 
such as INF-gamma and 51Cr release or cytotoxic assay as well as CD19CAR transduced CB-
T cells.  
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Figure 31: Expression of WT1-TCR in five human cord blood donors. Lnt-SFFV-WT1TCR modified construct was transduced into CB-T cells and its expression was analysed by anti Vβ2, and mCβ antibody staining. Graph shows comparison of WT1-TCR transduction efficiency of CB-T cell stimulated with different conditions before transduction; five CB-T cells stimulated with CD3/CD28 beads +IL- 2, while three other CB-T cells were stimulated with a combination of IL-7 and IL-15. 
 Figure 33 illustrates the expression level of CD19CAR on the surface of five different donors 
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this result with the transduction efficiency of the T cell population stimulated with cytokines 
alone, CB-T cells showed T cells
on the basis of CD19CAR expression.
levels of CD19CAR on CB-T cells 
explained in figure 34.  
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Figure 33: Expression level of CAR19 in five human cord blood donors. Lnt-SFFV-CD19CAR or Lnt-EFl-CAD19CAR vectors were transduced into CB-T cells and CAR19 expression was analysed by anti-scFv or anti-CD34 and/or anti-Fab antibody staining. Graph shows comparison of CD19CAR transduction efficiency of CB-T cells stimulated with different conditions before transduction; five CB-T cells stimulated with CD3/CD28 beads +IL- 2 (100U/ml), while three other CB-T cells were stimulated with combination of IL-7 (5ng/ml) and IL-15 (5ng/ml) in addition to IL-2 (100U/ml). 
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4.4) CB-T Cells engineered with WT1
their targets: 
The antigen-specific killing activity of the cord blood that was transduced with WT1
was evaluated in cytotoxicity assays
target cells (T2 cells). As demonstrated in 
were killed after being coated with pWT126 (specific peptide),
with ADV peptide (control, non
activated with beads, a substantial increase in the percentage of the killing activity of T cells
expressed WT1-TCR was found to be 85% compared with the killing activity of non
transduced T cells and the killing 
with a non-specific peptide. In comparison to the specific killing activity of beads
WT1-TCR CB-T cells, the specific lysis 
cells showed a percentage of 40% specific killing activity, in keeping with the lower 
transduction efficiency in these cells (p<0.0005)
Figure 34: FACS analysis of CD19CAR CBa remarkable increase in the percentage of T cellstransduced cells in the CD3/CD28 beads population activated with IL-7, IL50 % vs. with non-transduced cells (lower  
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Figure 35.B illustrates the specific killing behavior of two different donors of CB-T cell that 
transduced with two different lentiviral vectors expressing CAR-CD19 and activated under 
two different conditions: with CD3/CD28 beads+IL-2 (100U/ml) and with a cytokines 
cocktail (IL-7 (5ng/ml) +IL-15 (5ng/ml)+IL-2 (200U/ml)). The specificity and anti-cancer 
activity of CD19-CAR T cells was analysed by using target cells expressing CD19 on their 
surfaces (SupT1CD19 cell line) and as a negative control, SupT1 cells that do not express 
that CD19 was used (SupT1 cell line). An Lnt-SFFV-CD19CAR vector was used to 
transduce the first donor and a high percentage of killing activity (70%) was observed in 
CD19-CAR T cells stimulated with anti-CD3/CD28 beads. T cells stimulated with cytokines 
showed a significant killing activity, compared with the killing activity of the non-transduced 
T cell population (48%) (Figure 35 B.i). Again, both groups had levels of killing reflective of 
the levels of gene transfer. The second donor CB-T cells were transduced with Lnt-EFl-
CD19CAR and a significantly high percentage of anti-tumor activity was detected in both 
bead stimulated T cells (43%) and cytokines stimulated T cells (49%). In both experiments, 
CAR19 engineered T cells did not recognize the SupT1 cells and, as a result, no cytotoxic 
activity was noticed from these cells (Figure 35 B.ii).  
The previous data may imply that either bead stimulated engineered CB-T cells or cytokines 
activated CB-T cells, are able to recognize their target cancerous cells and kill them in a 
perfect manner.  
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A) Specificity of WT1-TCR transduced CB-T cells toward their target (PWT126):   
 
 
 
 
 
 
 
 
 
 
 
 
B) Specificity of CD19CAR transduced CB-T cells toward their target (CD19) in two 
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ii) 
 
4.5) Compression of expression levels of INF-γ secretions of WT-TCR transduced 
CB-T cells stimulated with CD3/CD28 beads vs. cytokines cocktail: 
The in vitro, antigen-specific functionality of WT1-TCR-transduced T cells was also 
demonstrated using intracellular cytokines staining applied to three CB-T cells donors (n=3). 
The first two CB-T cells were exposed to a CD3/CD28 activated condition, while the third 
donor’s CB-T cells were exposed to two differently activated conditions: using CD3/CD28 
beads and IL-2 (100U/ml) or with IL-7, IL-15 and IL-2 cytokines. After six hours of 
stimulation with relevant, (PWT126) or irrelevant (ADV), peptide-loaded T2 cells, INF-γ 
secretion was observed in response to PWT126 peptide only. A representative FACS plot of 
CB-T cells obtained from the 3rd donor showed that the functional cytokines secretion of the 
WT1- TCR transduced cells activated by anti-CD3/anti-CD28 beads was observed to be 
Figure 35: WT1-TCR or CD19CAR can recognise their specific tumour antigen and selectivity kill their target, cancerous cells but not non-specific control targets in vitro. A) LNT-SFFV-WT1TCR transduced normal donor CB-T cells killed T2 cells loaded with WT1 peptide but not non-specific control targets (ADV). B) i.LNT-SFFV-CD19CAR-transduced normal donor CB-T cells killed CD19-SupT1 cells expressing CD19 on their surface, but not CD19 negative-SupT1 cells (control target). * p value refers to the significant differences between the antiCD3/antiCD28 stimulation condition and the cytokinesstimulation condition. ii. Engineered-T cells stimulated with cytokines cocktail show a higher percentage of anti-cancer activity toward specific target SupT1-CD19 than CB-T cells anti-CD3/anti-CD28 beads. Both groups demonstrate little cytotoxic activity toward negative control SupT1 cells, which is almost similar to the anti-tumour activity of the un-transduced cells toward SupT1CD19 cells. P ≤ 0.005 reflects the significant levels of antitumor activity of engineered CB-T-cells stimulated with cytokines cocktailtoward SupT1CD19 cells, versus the negative control. P value ≤0.05 reflects the difference of killing behavior between CAR19 cells stimulated with anti-CD3/anti-CD28 beads against SupT1-CD19 and CAR19 cells against SupT1 not expressing CD19.  
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2.30% of the Vβ2.1 positive cell population. The same percentage of activity has been 
detected in the WT1TCR CB-T cells stimulated with cytokines (2.10% INF-γ secretion) 
(Figure 36). The outcome of both negative and positive controls supported the results of the 
experiment. The previous data might suggest that WT1TCR-transduced CB-T cells are highly 
capable of recognising their target antigens and discriminating them from non-target cells 
either stimulated with anti-CD3/anti-CD28 beads, or with the cytokines cocktail. To further 
confirm this observation, an in vivo trial is required. 
 
 
 
Figure 36: Antigen-specific responses of WT1-TCR transduced CB-T cells. The WT1-TCR construct (indicated in chapter 3) was transduced into CB-T cells and its functional activity was determined. A) antigen-specific interferon γ (INF-γ) production determined after 6 hrs of stimulation with specific PWT126 peptide or non-specific ADV peptide. Representative FACS plot data of intracellular INFγ staining are shown. FACS plots in the top row illustrate the percentage of INF-γ secretion of the controls that used in the experiment. FACS plots on the bottom row demonstrates the percentage of INF-γ secretions of WT1-TCR CB-T cells stimulated with anti-CD3/antiCD28 beads + IL-2 (100U/ml) (right) versus WT1-TCR CB-T cells stimulated with cytokines cocktail+IL-2 (100U/ml) (left).  
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4.6) CB-T cells stimulated with IL-7(5ng/ml) IL-15 (5ng/ml) IL-2 (100U/ml) show more 
naïve phenotype characteristic than cells stimulated with anti-CD3/anti-CD28 beads: 
The presence of naïve-like phenotypes engineered CB-T cells were detected by staining the 
cells (n=3) with the following markers: CD8, CD4, CD45RA, CD62L and CCR7 antibodies.  
Flow cytometric analysis demonstrated that cytokine stimulated cells acquire a higher 
percentage of naïve phenotype than engineered cells that were activated with anti-CD3/anti-
CD28 beads. Un-activated cells were stained after being exposed to liquid nitrogen for 
freezing purposes. These cells were not stained with CD4 and CD8 because they lack the 
expression of these two markers. The expression of the naïve like markers was determined by 
flow cytometry. Cytokines stimulated CB-T cells appeared to express the naïve markers 
(CD4+ subset: 44%-73%, mean=58.2, n=3 /CD8+subset: 25.5%-75%, mean= 52.6%,n=3), in 
a high percentage similar to the naïve markers on the surface of un-stimulated cells (76%-
77%, mean= 76.5%, n=3).  On the other hand, a lower percentage of CD45RA,CD62L and 
CCR7 was detected on the surface of the bead stimulated CB-T cells (CD4+subset: 0.32%-
49.5%, mean= 24%, n=3/ CD8+subset: 60.1%-47%, mean= 34%, n=3) (Figure 37 A,B). It 
could be concluded from the previous data that using cytokines to stimulate the cells before 
transduction might be better than anti-CD3/anti-CD28 beads in terms of conserving the naïve 
phenotype of the cells and retaining the cells with their naïve-like markers. However, the 
level of cell survival and the number of cells at the end of the experiment is not very 
promising in the case of cytokine stimulating conditions. 
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Figure 37: Comparison of expression levels of CD45RA, CD62L and CCR7 on the surface of CD19CAR transduced CB-T cells that were stimulated with anticharacterizes the percentage of naïve like phenotype cells in two different groups: CAR19 engineered CBactivated with anti-CD3/anti- CD28 beads vs. CAR19 engineeredincluding IL-7, IL-15 and IL-2. The latter group show group. Un-stimulated cells were used as a control.Top plots illustrate the gating process and the percentage of the CD45RA+CD62L+CCR7+ cells in the uncells. Gating on the live cells then on CD45RA positive population, FACS are naïve. The lower plots demonstrate the expression of CD45RA, CD62L and CCR7 on the cell surface of engineered CB-T cells that were stimulated with beads versus cytokines stimulated CD
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4.7) Discussion: 
One of the main cornerstones of an effective adoptive T cell therapy is the ability to generate 
a high number of antigen-directed therapeutic T cells. Hence, it is crucial to provide the 
optimal activation condition that will ensure the best proliferation and the maximum 
transgene expression while T cells are being cultured ex vivo (Ritchie et al., 2013). The 
outcome of this chapter might indicate that using anti-CD3/anti-CD28 beads as an activation 
condition surplus IL-2 generates a strong signal that may lead to fully differentiated T cells. 
However, as a result, T cells will be exhausted and they will reach their apoptotic fate fairly 
soon after in vivo infusion. On the other hand, stimulating naïve CB-T cell precursors with 
IL-7, IL-15 and IL-2 and continuous feeding of the cells with the cytokines cocktail every 
forty-eight hours, retains the cells in the naïve like phenotype for a long period of time, 
promising an in vivo expansion and persistence. In addition, cells activated with the 
interleukins show high percentages in transduction efficiency and have proved their ability to 
recognise their targets and kill them in specific manner.  
In light of these findings, the only advantage of using cytokines over anti-CD3/anti-CD28 
beads as stimuli would be the ability to preserve the interleukins stimulated naïve T-cells 
within their naïve phenotype and not shift them toward the terminal phenotype. 
Consequently, the naïve-like engineered T cells might provide better anti-tumour responses. 
Although stimulating CB-T cells with the interleukins cocktail provided naive-like 
engineered cells with high transgene expression and high anti-tumour activity, expanding 
these cells ex vivo was the biggest obstacle. 
It has been noticed that the numbers of cells and their survival rate dropped as the experiment 
continued over twelve days. This might be due to the absence of a strong signal, which is the 
key to allowing T cells to survive and proliferate; however, CAR19 should provide the 
transduced T cells with a strong survival signal. Some recent reports have suggested that in 
order to preserve CAR19 T cells in culture and expand them ex vivo, the naïve T cell 
precursors should be activated with anti-CD3/anti-CD28 Dynalbeads, and engineered cells 
should be kept in culture in the presence of IL-7 and IL-15 (Cieri et al., 2013).  
Another group has proposed that exposing CAR19 T cells to serial antigen stimulation and 
culturing the cells in the presence of IL-7 and IL-15 will reduce the CD8+ cell death rate and 
increase the survival rate of CD19-CAR T cells. Moreover, this group highlighted the 
importance of CD8 positive subsets after demonstrating that CD8+CD45RA+CCR7+ is the 
only cellular group that expanded after repetitive stimulation with the CAR-antigen, 
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advocating that it’s the only subset that should be preserved to encounter multiple tumour 
cells in vivo (Xu et al., 2014).  
Optimising culture conditions of naïve T cell precursors to generate an immense number of 
effective engineered T cells with a high transduction efficiency and high anti-tumour activity, 
while preserving their naïve or stem cell memory phenotype is an important goal for the 
future.  Two other different stimulation conditions  could be suggested:  The first method is 
to activate the cells with anti-CD3/anti-CD28 beads in the presence of IL-7 and IL-15 and 
with IL-2 (using the same concentrations that were used in this project). The second process 
is to follow Xu and colleagues’ method by challenging the cells with plate bound-OKT3, then 
re-stimulating them with irradiated Raji cells and keeping them in a culture in the presence of 
IL-7 and IL-15. It would also be useful to investigate the importance of the CD8+ population 
by positive selection or by isolating CD8+ cells prior to activation and transduction in order 
to demonstrate if these cells in any way benefit the optimisation and expansion of naïve or 
stem memory engineered T cells.  
In conclusion, the transduction efficiency and cellular anti-tumour activity of cultured CB-T 
cells from five different cord blood units were compared after activating them using either 
anti-CD3/anti-CD28 beads plus 100 U/ml of IL-2 or cytokines cocktail (including: 5ng/ml  
IL-7+ 5 ng/ml IL-15  and 100 U/ml IL-2). The data from this chapter might prove that CB-T 
cells activated with an interleukins cocktail provide favourable data regarding generation of  
effective and robust, naïve engineered T cells that have high potential to kill their target with 
high levels of transgene expression. However, these cells could not be cultured and expanded 
in vitro like the beads activated cells, which show a very high survival and expansion rate.  
Future studies should explore how  to overcome this main obstacle and to obtain a robust 
expansion of the engineered CB-T cells, while preserving their naïve or stem cell memory 
phenotype. 
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Chapter 5: Disruption of Endogenous T-Cell Receptor with Site Specific DNA Nucleases.             
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5.1) Introduction: 
An innovative type of gene therapy technique that might overcome some of the obstacles of 
current gene therapy protocols is genome editing or DNA targeting nuclease technology 
(Alwin et al., 2005) . Genome editing includes repair technology, a precise gene correction 
strategy in which the mutant version of the gene is replaced with the normal functional copy 
at the exact site of the endogenous gene; the consequence being that the gene restores its 
normal function.  By targeting the specific locus of the desired gene, unpredictable genetic 
effects, such as the random integration of the transgene, and the production of mutagenesis, 
might be controlled.   Recently, nucleases including: meganuclases (MGN), zinc-finger 
nuclease (ZFN), transcription activator–like effector nucleases (TALENs) and the clustered 
regularly interspaced short palindromic repeat (CRISPR)-associated nuclease Cas9 
(CRISPRCas9), have become attractive genetic tools for gene targeting and manipulating 
(Cox et al., 2015).   
Nucleases-based genome editing technology enables precise genetic changes by delivering a 
double strand break (DSB) at specific genomic loci. DSBs subsequently generate lesions 
within the specific site which may be repaired either by non-homologues end joining (NHEJ), 
our mechanism of interest, or by homology-direct repair (HDR) depending on the aim of the 
genomic editing, cell status, and the presence of the repair template. 
The NHEJ mechanism to repair the lesion involves the direct joining of the two DSB ends in 
a process that does not require a repair template. NHEJ-mediated DSB eventually results in 
the creation of a small insertion or deletion mutations (indels) connecting the break locus. 
The indels introduced into the coding sequence of a gene can lead to frame-shift mutations 
that consequently lead to mRNA degradation by non-sense-mediated decay, or result in the 
production of non-functional truncated proteins. Thus, NHEJ may be used to disrupt gene 
function, as it may also lead to permanent inactivation by introducing loss-of- function 
mutations into the gene in targeted cells (Byers, Rouet et al., 1994). 
To date, there are two broad categories of nuclease systems that have been developed to 
enable site-specific genome editing. The first group includes MGNs and their derivatives, 
ZFNs and TALENs where their mode of DNA recognition is based on protein-DNA 
interaction. The second group includes CRISPR-Cas9. In this group, specific DNA binding is 
achieved via guiding Cas9 to the targeted DNA sequence by short RNA guide molecules that 
base-pair directly to the target DNA and by protein-DNA interactions (Miller et al., 2007, 
Cade et al., 2012, Boissel et al., 2014, Cong et al., 2013).  
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Meganucleases (MGNs) are endonucleases with large (>14-bp) recognition sites. The DNA 
binding domains which are also responsible for cleavage of target sequences (Smith et al., 
2006). ZFNs and TALENs are chimeric enzymes consisting of a DNA binding domain fused 
to the sequence-agnostic FokI nuclease domain (Wolfe et al., 2000, Moscou and Bogdanove, 
2009). CRISPR Cas9 technology is based on an enzyme called Cas9 that relies on a guide 
RNA molecule to home it on its target DNA, then edit the DNA to disrupt genes or insert 
desired sequences (Mali et al., 2013). Re-engineering meganusleases and ZFNs requires   
protein engineering, while a complex molecular cloning is essential to re-targeting TALENs 
(Isalan, 2012, Sun and Zhao, 2013). In contrast, the Cas9 protein is invariant and can be 
easily re-targeted to new DNA sequences by changing a small portion of the sequence of an 
accompanying RNA guide in those base-pairs directly with the target sequence. Another 
potential advantage of Cas9, in addition to its ease of  accessibility and its low cost, is its 
ability to introduce multiple DSBs in the same cell via expression of distinct guide RNAs 
(Yin et al., 2014). All four types of engineering nucleases have been shown to accomplish 
efficient genome editing in a wide range of model organisms and mammalian cells, which 
make them a valuable reagent in the field of targeted gene therapy. Efforts are underway in 
both industry and academia to develop these tools as therapeutics reagents (Cox et al., 2015). 
The main aim of this chapter is to assess the efficiency of different types of the gene-specific 
nucleases, meganucleases, TALENs and CRISPR/Cas9, at disrupting the TCR locus within 
the genome. Editing the genetic sequence of the endogenous T cell receptors may lead to the 
production of T cells devoid of allo-reactive TCRs by targeting the constant region of the 
TCR  and/or  chain (Provasi et al., 2012). Introduction of antigen-specific receptors or 
chimeric antigen receptors into such TCR-disrupted cells could yield populations of 
“universal T cells” that are suitable for infusion into multiple HLA disparate recipients 
without the risk of GVHD (Torikai et al., 2012).  
To test the feasibility of generating such a disrupted T cell, we started by testing the 
effectiveness of meganucleases in disrupting the genetic sequence of the constant region of a 
T cell receptor; followed by evaluating TALENs as an alternative platform for knocking 
down TCR expression with less toxicity. Then CRISPR/Cas9 nuclease, which is designed to 
target the constant region of the TCR alpha chain, was also involved in the experimental 
process to investigate its ability to disrupt its specific site within the genome.  Finally, a 
comparison between TALENs and CRISPR/Cas9 from the prospective of genome disruption 
and cell toxicity was also evaluated. 
 5.2) Meganucleases: 
5.2.1) Expression of Meganucleases
cells: 
Three different specific meganucleases expression plasmids
the genome were generated by
 Two are mutated meganucleases
the beta chains constant region of T cell recepto
The third construct is targeting a housekeeping gene called 
(CAPNS1) and is used as a control.  
TRBC01, TRBC02 or CAPNS1, were introduced 
amaxa nucleofection system according to the manufacture
were kept in a culture for seven
confirm the expression of meganuclease protein from the plasmid using anti
As Figure 38 shows, there was a highly specific band 
the transfected population, but not in the non
expression of beta-tubulin protein
constructs is 39 kilodalton (kDa)
       
 
5.2.2) Detection of Meganuclease’s
To endorse the molecular signature of meganuclease within the genome of the transfected 
cells, a surveyor mutation detection assay was used.  This enzyme mismatch cleavage system 
uses plant single-strand specific endonucleases of the S1 nuclease famil
Survoyer nuclease - that cleave heteroduplex DNA at mismatches and extrahelical loops 
formed by single or multiple nucleotides. Surveyor nuclease technology involve
following steps:  DNA samples were extracted from the transfected c
Figure 38: Western blotting using Antinucleofected cells were used as a control. Beta
 by Amaxa Nucleofection of coding DNA into Jurkat 
 that target specific sites within 
 Cellectis (France).  
 that are targeting a conserved sequence within the genes of 
r; β1 and β2 (called TRBC01 and TRBC02). 
calpain, small subunit 1 
Two µg of DNA of meganuclease expression plasmids
to the nucleus of Jurkat cells by using 
r’s instructions.  Transfected cells 
 days before being harvested.  Western blotting was used to 
containing the correct size present in 
-transfected cells. As a control
s was also verified. The molecular weight of all three 
, but the beta-tubulin molecular weight is 50 kDa.  
 molecular signature within transfected Jurkat ce
y named
-CreI on meganuclease transfected Jurkat cells-tubulin was used as a loading control.
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 meganuclease specific-site (target DNA) was amplified by PCR. The PCR product was then 
used to form heteroduplex by being exposed to 
Afterwards, the annealed DNA was treated with Surveyor Nuclease S to
of the miss-matched DNA binding feature of 
was analyzed using conventional gel electrophoresis platform to detect any 
effect (Figure 39 A) (Vouillot et al., 20
Another mechanism to evaluate mutation in the genome after the delivery of the engineered 
nuclease is by traditional Sanger 
cloning vector.  The DNA sequences were analysed by vector NTI software w
aligned with the 20 base pair target sequence (the specific site of meganuclease) and the 
original sequence (obtained from NCBI). 
Although the western blot has show
molecular signature of genome disruption could not be confirmed as both DNA sequencing 
and nuclease assay failed to detect genomic breaks
 A) Surveyor mutation detection assay:                  
 
 
 
 
 
 
a denaturation and hybridization process. 
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15). 
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n a well expressed meganuclease
 (Figure 39 B). 
 
pg. 129 
detect the presence 
TCR knockout 
a topo-
here they were 
 as a protein, the 
 B) DNA Sequencing: 
 
Figure 39: The molecular signature of meganuclease transfected jurkat cells show a failure of meganuclease to cleave their target sequence.mismatch-selective endonucleases assay on DNA, amplified from transfected Jurkademonstrated the expected size of the intact amplicon, which is 400 bp in all transfected samples, instead of showing the nuclease cleavage product of heteroduplexes carrying the mismatch, which should be two bands of 254 and 146 in size. PCR unsequencing of the same MGN-transduced Jurkat cells has confirmed nuclease assay results. Alignment of MGN targeted sequence, original sequence (downloaded from NCBI) and DNA sequenccells (test sequence). No disruption can be detected within the targeted sequence.
5.2.3) Cloning Meganuclease (vector: These three meganucleases were cloned into a 2nd generation self
backbone that expresses the trans
an IRES-eGFP at  a multiple cloning site (pLNT/SIEW).They were also cloned in the same 
plasmid, but without the eGFP
produce a lentivirus vector by transient
envelope VSV-G plasmids (pMDG) and gag
MGN-CAPNS1 with an SFFV 
illustrated a titre of 0.31 x 10
TRBC01 and MGN-TRBC02, 
typical titer of 0.1x107 IU per ml w
1.1x108 IU per ml was produced for LNT
SFFV-TRBC02-IRES-eGFP. 
 A) Amount of targeted gene disruption measured by a 
-specific bands were detected in the control lane. B) DNA 
 
MGNs) constructs into a 2nd generation Lentivirus 
-inactivating lentivirus 
gene under the control of an SFFV promoter
 (Figure 40 A,B).  The generated plasmids were used to 
 transfection of HEK293Tcells 
-pol packaging plasmids. The v
promoter was tittered on a Jurkat cell line and FACS analysis 
7 IU per ml.  For the two other vectors that express 
a TCR-negative Jurkat cell line was used for virus titration. 
as produced for LNT-SFFV-TRBC01
-SFFV-TRBC01-IRES-eGFP as well as for Lnt
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Figure 40: Schematic maps of the cloned meganuclease into diffeSchematic map represents successful cloning of different includes IRES-eGFP.  B) Representativewithout IRES-eGFP. 
5.2.4) CD3 Expression levels and cell viability after t
Lnt-SFFV-MGN: 
Jurkat cells were transduced with three different rates of infection (MOI’s) (0
Lnt-SFFV-MGN virus, and cultured in com
the MGNs knock-out effect of endogenous TCR within the transduced cells was evaluated by 
measuring the reduction in the percentage of CD3 expression by FACS analysi
cytometric analysis demonstrated that the 
dramatically compared to the no
CD3 expression reduction that
The previous results may suggest that 
lack of activity observed. The results suggest that an alternative platform may be required
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rent lentivirus vector backbonesMGNs into lentivirus vector backbone that  map of meganucleases cloned into lentivirus vector backbone 
ransduction of Jurkat cells with 
plete RPMI. Seven days following transduction, 
viability of MGN-transduced cells was reduced 
n-transduced cells (Figure 41 A), and there was 
 could be detected within MGN-transduced cells
MGN is toxic to the cells and this might explain the 
 SFFV  MGNs  IRES  eGFP  WPRE
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B) CD3 level expression of Jurkat cells transduced with various constructs of 
 
                 
Figure 41: Unsuccessful attempts using Mdemonstrating the percentage of CD3 expression within transduced and nonJurkat cells. There is no significant decreasnon-transduced cell population. B) Bar charts demonstrating the percentage of viable Jurcells following transduction with the LNTdrop in the viability of the cells after transduction can be concluded from the graph. 
nsduced with several constructs of MGNs
GNs to reduce CD3 expression. A) Bar Chart -transduced e in CD3 expression between the transduced and 
-MCS-MGN virus at different MOIs. A significant  (n=1)
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 5.3) TRAC-TALENS 
To disrupt the expression of the 
sequence found within the constant
obtained from Cellectis (Paris, France)
Cellectis provided TRAC TALENs 
second generation, SIN, lentiviral vector ba
Cancer Institute, UCL).  Each pair of TALENs was connected to 
identify the expression level of TALENs within the transfected cells. V5 is attac
right pair of TRAC TALENs
(Figure 42).   
 
 
 
 
              
 
 
 
 
 
 
 
Figure 42: Schematic figure of TALENslentiviral vector backbone. Each pair of TALENs is connected to tag molethe expression level of TALENs within the transfected cells.V5 is attached to the right pair of TALENsTRAC (top), whereas, MYC is ligated to the left pair of TALENsepitope tag derived from a small epitope (Pk) present on the P and V proteins of the paramyxovirus of simian virus (SV5).  MYC= is synthetic peptide (EQKLISEEDL), derived from the Chuman c-mycprotein . Amaxanucleofection system was used to deliver the Tagged TARC TALENsto three various cell types: Jurkat cells, primary cells and cord blood T cells18-22 amino acid sequence- that is readily cleaved as translation occurs, separating the two proteinsWPRE= Woodchuck hepatitis virus post traregion of a vector to increase vector titre and gene expression  
endogenous TCR, a pair of engineered TALENs targeting a 
-region genes of the alpha chain of TCR was
 and Fehse labs in Hamburg (Germany)
as expression plasmids and they were cloned into 
ckbone by Gordon Weng-Kitn (Pule Laboratory, 
a tag molecule
, whereas, MYC is ligated to the left pair of TRAC TALENs 
-TRAC constructs ligated to 2nd generation, SIN, cule; which helps identify 
-TRAC (bottom). V5= is synthetic 
. 2A= self
nscriptional regulatory element added at the 3’ non.  
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5.3.1) The Effect of TRAC TALENs plasmids on Jurkat cells: 
Although viral vectors, particularly, lentiviral vectors, are very attractive tools for the transfer 
of nucleic acids to a variety of mammalian cells, the delivery of TALENs is prevented by 
repetitive elements of the individual TAL effector nuclease. To avoid this problem, TRAC 
TALENs were tested as plasmid rather than viral vector (Mock et al., 2014).  2x106Jurkat 
cells were nucleofected or TALENised with a 5µg of TRAC TALENs (each pair) as DNA 
construct using x-001 program on an amaxa nucleofection instrument and nucleofection 
solution of Lonza kit V according to the manufacturer’s instructions. As a control, cells were 
nucleofected with each pair alone. Forty-eight hours after nucleofection, the TALENs-tag 
expression was analysed by staining the cells with 0.5µl of Anti-V5-Daylight 405 and 0.5µl 
of Anti-Myc-AlexaFloura 647 mAb. The control cells were stained with Anti-V5-Daylight 
405 or Anti-Myc-AlexaFloura 647 mAb alone.  Seven days after TALENisaition, the cells 
were stained with anti-TCR α/β-FITC and/or anti-CD3-APC to gain knowledge about the 
percentage of the TCR negative population after nucloefection.  
This experiment was conducted three times to estimate the efficiency of TRAC TALENs in 
editing TCR gene expression and the monitor cells’ viability before applying the same 
conditions to adult or naïve T cells.   
The flow cytometric analysis suggested that the tag expression percentage is aligned with the 
percentage of the TCR negative population percentage. The first experiment showed that 
25% of the cells had expressed TALENs and there was a 27% reduction in the TCR positive 
population. The FACS plots from the second experiment showed that 11.2% of the 
nucleofeceted cells had expressed tag-TRAC TALENs, and 19% of the TCR negative 
population was detected. The third experiment showed that the TCR negative population had 
increased by 16 % in Jurkat TALENised, compared to the non-TALENised population; and 
13 % of the cells exposed to TRAC TALENs had expressed tag V5 and tag Myc on their 
surfaces (Figure 43 A,B) (Figure 44). TALENised cells’ viability was reduced by 4.5 fold on 
day two (Figure 45).  
This promising data led to the next step of testing the effect of TRAC TALENs on the adult 
and cord blood T cells. The next section will discuss the results of knocking-out the 
expression of TCR from primary and cord blood T cells, as well as some optimisation to the 
protocol to provide better outcomes.  
 
 
 A) Myc and V5 tag Expression JurkatCells:  
 B)  Percentage of TCR negative population leveTALENised Jurkat cells   
Figure 43: Representative FACS construct. A) Gating on viable cellsthe percentage of tag expression in both TALENised and control group at Day 7 after nucleofection and gating on the viable cells, FACS negative population that produced after TALENisationpopulation.  
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plots of Jurkat cells TALENised with TRAC-TALENs as a DNA ; FACS plots represent the levels of TALENs expression by showing Day 2 of the experiment. B) plots represent the percentage of TCR  of Jurkat cells in comparison with non
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 Figure 44: Bar chart exemplifies the correlation between TRAC TALENs tag expression levels and the increase in the percentage of TCR negative population after TALENising Jurkat cells with TRAC TALENs as a DNA via amaxa nucleofection system. The bar chart shows, an approximately similar percentage between tag expression levels and the percentage of TCR negative group in TALENised population and in the control group as well. P value was calculated by GraphPad software (P<0.01).  
 
Figure 45: The effect of TRAC TALENs as a DNA construct on the viability of Jurkat cells and on the percentage of TCR expression. Bar charts represent the consequence of TRAC TALENs (as DNA)    on the cell viability and the expression of TCR on Jurkat cells in both treated and non-treated populations. There is a significant increase in the percentage of TCR negative population within the TALENised 
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population in comparison to the un-TALENised cells (P<0.01). There is no significant difference between TALENised and un-TALENised cells in cell viability. 
 The previous preliminary data had suggested that TRAC TALENs are effective albeit with 
reduced cell viability and the TCR knock out effect. Thus, the same experiment was 
conducted on both adult and cord T cells before considering a scale-up process.   
5.3.2) Comparison of the Effect of TRAC TALEN on PBMCs and CB-T Cells: 
Mononuclear cells were collected from peripheral blood or cord blood units after separation 
of blood layers using Ficoll. For small scale experiments, 2x106 cells were activated with 
anti-CD3/CD28 Dynal beads at a 1:1 ratio and incubated for 48 hours before TALENisation 
in a 24 well culture plate.  5µg of TRAC TALENs DNA (each pair) was introduced to naïve 
or adult T cells via an amaxa nucleofection system using the Lonza human T cell kit 
according to manufacturer’s instructions.   Two days later, the tag expression of TRAC 
TALENs was analysed by flow cytometry after staining the cells with anti-Myc and anti-V5 
antibodies.  For cord blood T cells, FACS blot results suggested that 22.3% of the 
nucleofected cells had expressed TALENs on their surface with 2.53% of the background 
detected on the non-nucleofected population. Down regulation of TCR expression was 
detected seven days after TALENisation; the cells were stained for TCR using anti-TCR α/β-
FITC and anti-CD3 APC and analysed by flow cytometry. Interestingly, the percentage of the 
TCR negative population was correlated with the percentage of the cells that were expressed 
TRAC TALENs.  These results showed that the TCR-negative population had increased 
approximately by three-folds within nuclofected cells, compared to non-treated cells. 
Whereas, FACS plots revealed that 33% of TCR-negative cells were detected by flow 
cytometry within treated cells with an 11.8% background detected within the non-treated 
cells (net of TCR negative population=21.20) (Figure 46). Regarding the cell survival 
percentage, the FACS plots showed that cell viability of nuclofected naïve cells was reduced 
by only 10% compared to the non-nuclofected cells at Day 7, since beads activation and Day 
5 from nucleofection.  
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This data might have suggested that naïve cells are more prone to transfection with a better 
result of cell viability compared to adult T cells.  Also, it might prove that TRAC TALENs 
has the ability to cause a disruption in TCR alpha constant region genes leading to the down 
regulation of its expression. This result might be promising for showing the effect of 
TALENS on TCR expression, but not for cell viability and DNA toxicity to the cells. For that 
reason, most of the experiment has shifted to use mRNA instead of DNA in transfection 
process.  
In the next section, the feasibility of delivering TRAC as mRNA and its effect on cell 
viability and TCR expression will be discussed.  
5.3.3) Delivering TALENs as mRNA:  
Tag-TRAC-TALENs mRNA was tested on Jurkat cells and then on PBMCs using 
nucleofection. 10 µg of TRAC TALENs per pair as mRNA were delivered to 5x106 Jurkat 
cells using the BTX electroporation system (voltages as in the methods chapter). The cells 
were incubated in warm, complete RPMI for seven days before FACSing for observation of 
TCR expression. The TALENised cells were stained with anti-TCR α/β and anti-CD3 to 
evaluate the efficiency of TRAC TALENs as mRNA in down-regulating the TCR expression 
and in maintaining the viability of the cells within a reasonable percentage. The results 
proposed a remarkable increase in the TCR-negative population after electropotration with 
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Figure 46 : The differences of cell viability and TCR TALENs KO efficiency within nucleofected -CB-Tcells and nucleofected PBMCs. Grouped graph demonstrates the differences of two factors: cell viability and TCR TALENs KO efficiency within nuclofected CB-T cells (N-CB-T cell) and nucleofected PBMCs (N-PBMCs).Un-nucleofected cells were used as a control (Un-N-cells). Graph shows a remarkable difference in cell viability between the two groups. It appears from the blot that TRAC TALENs has approximately the same effect on both N-CB-T cell and N-PBMCs since both of them showed a similar TCR negative population percentage. The statistics applied to this data include unpaired t-test and Mann-Whitney test. T test result (p >0.99) suggested there are no significant differences between the two groups.  
 mRNA compared to the non-electroporated population with 
The FACS plots of mRNA electroporated
TCR+CD3+ quadrant toward TCR
cells with a 13.4% background
around 37.4%. Regarding cell viability and based on gating the viable cells, 
demonstrated that TRAC TALENs mRNA 
fold reduction in viable cell percentage
electroporated group (Figure 47)
 
 
                  
The adult T cells were first 
TALENs mRNA at a volume of 1
viability and down-regulation of cell surface expression of TCR α/β and CD3 was determined 
by FACS analysis after staining 
on viable cells, the outcomes of this test proposed that within the 49% 
Figure 47: FACS plots of mRNArepresentative FACS plots are illustrating the status of Jurkat cells with and without delivering TRAC TALENs as an mRNA. The upper treated cells, while the lower plotsun-electroporated cells. Data from upper viability between the treated and the control group. Gating on the viable cells, lower that there is an increasing TCR negative population by un-electroporated cells.  
reasonable viability percentage
 Jurkat cells showed a 50.8% shift from 
-ve CD3-ve quadrant compared to the 
. This makes the pure net of the TCR-neg
are not toxic to the cells since there was only
s in electroporated cells compa
. 
activated with anti-CD3/CD28 beads then exposed to TRAC 
0 µg per pair and incubated for seven days.  
them with anti-TCR α/β and anti-CD3 mAbs. 
of 
-TRAC-TALENs electroporated Jurkat cells.
plots represent the viability of the treated and the non show the TCR knock out efficiency in electroporated cells vs plots suggest that there is no significant difference in cell 
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there was no significant difference in cell viability between TALENised and non
cells (Figure 48). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.4) Comparison of the TRAC TALENs Effect as mRNA Vs DNA on PBMCs:
In order to compare the effect of TRAC T
and cell viability, the same experiment using the same donor’s cell
DNA TRAC TALENs parallel to mRNA TRAC TALENs
The data showed a three-fold 
of TCR/CD3neg nucloefected PBMCs compared to the control population
Furthermore, nucleofected cells were stained with Anti
expression level of TALENs within the cells; 
Figure 48: FACS plots of mRNAplots are illustrating the status of activated PBMCs cells before and after delivering TRAC TALENs as an mRNA. The upper plots represent the viability of treated and nonshow the TCR KO efficiency in nuclsuggest that there is no significant difference in cell viability between the treated and the control group. Gating on the viable cells, lower 21.2% in nucleofected cells comparpopulations from the double positive quadrant to the double negative quadrant.
had increased 
. The data from the adult T cells
ALENs as DNA or mRNA on TCR knock down 
s was conducted using 
 (mentioned above)
decline in cell viability and an 18% escalation in the percentage 
-MYC and anti-V5 to measure the 
the FACS plots suggested that 17%
-TRAC-TALENs electroporated PBMCs cells.
-treated cells, while the lower eofected cells vs. un-nucleofected cells. Data from upper 
plots propose that there is an increasing TCR negativeed to un-nucleofected cells because of the shift of the cell  
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 population by 
 were able to express TALENs
TCR-neg population.  
A)    
 
In conclusion, this data might suggest that delivering TALEN
toxic to the cells leading to enormous cell loss,
ability to disrupt the specific site within the genome.  In addition, it might 
nucleases in the form of mRNA could be a better alternati
higher cell viability (Figure 50)
 
Figure 49: Delivering TRAC TALENs as DNA in 2nd TRAC TALENs, cells were stained with 0.5 µl antithe viable cells, while lower plots show the percentage of TRAC TALENs expression by TALENised cells. Results show that 17% of the treated cells are expressing both V5 and Myc; which are the markers for TRAC TALENs expression, on their surface with 0.7% of background in the nonDay 7 after nucleofection, nucleofected and unexpression. Upper plots show the gating strategy of the viable cellscells that are expressing TCR α/βand CD3. Cell viability has decreased from 60% of un18.4% of the TALENised population. For the evaluation of the efficiency of TRAC KO, TCRneg population was monitored. As the gates on the FACS population by 27.6 % with 9.62% background in the non
 (Figure 49.A), which was equivalent to the percent of 
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s as a DNA construct c
 but it has no effect on the TALENs 
ve for a more stable expression and 
. 
donor PBMCs. A) TWO days after nucleofection with -Myc and 0.5 µl anti-V5. Upper plots
-nucleofected cells were collected and stained for TCR and CD3 ; lower plots show the percentage of the viable -
plots in the lower part illustrate, there was an increase in the TCRnegative-TALENised group. 
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 Nowadays the focus of most research
nuclease named CRISPR Cas9 in relation to targeted genome editing platforms. Due to its 
ease of use and its ability to target multiple specific sequences at the same time, it has been 
seen as an attractive tool in the field of genome engineering 
section, the potential of CRISPR
the beta constant region will be investigated.
5.4) TRBC and TRAC CRISPR
CRISPR/Cas9 nuclease constructs targeting
generated for TRAC, TCAGGGTTCTGGATATCTGT and TRBC 
GCAAACACAGCGACCTCGGGT (GeneCopoeia US)
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Figure 50: Comparing the effect of deliverdisruption of alpha constant region within the cells' genomewith mRNA show better viability than cells TALENised with DNA. spotted in the actual effect of TRAC TALENs on disruption mRNA or DNA. U npaired t test was conducted on this data and showed within the data (p>0.99)  
Figure 51: Illustration figure of constant region of TCR. 
ers and scientists has shifted towards a new designer 
(Cong et al., 2013)
 Cas9 in targeting a specific sequence within the alpha and 
 
/Cas9: 
 the constant regions of TCR either α or β were 
(Figure 51). 
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 5.4.1) Delivering CRISPR/Cas9 into Jurkat cells as a DNA construct:
During a seven day experiment, the ef
within the Jurkat cells genome w
µg of TRAC and/or 5 µg of TRBC 
on the amaxa nucleofector machine. Two days later, the 
analysed by detecting the expression level
manifested that the levels of the mCherry expression within the nucleofected c
demonstrated that up to 21% of the nucleofected cell population was able to express 
CRISPR/Cas9, in a comparison with the non
stained with anti-CD3 conjugated to APC flourochrome
CRISPR/Cas9 in order to examine the ability of 
their specific site within the genome. Notably, 
CRISPR/Cas9 or TRBC CRISPR
population (21.5% or 20.5%)
CRISPRs/Cas9 TRBC and TRAC (CD3neg=13.2%).  As a control, some cells were exposed 
to the same nucloefection conditions
of 5% was detected within this control group and also among the non
cells’ viability was not as promising as the 
dropped dramatically within the cell
compared to the control group
Figure 52: Expression of TRAC and TRBC live cells population (upper plots)marker within treated and non-treated cells. Background was detected to be around 1.09% in control group, while for nucleofected cells, mcherry level was elevated up to 14.6% within cells exposed to both TRAC and TRBC CRISPR/Cas9, up to 21% in TRAC with TRBC CRISPR/Cas9 alone, mCherry level was 16.7%. As upranged between 10.7%-14.4% for nucleofected group, whereas for control group, cell viability was 35%.
 
ficiency of CRISPR/Cas9 in disrupting their target sites 
as determined. On Day one, 2x106 cells were 
CRISPR/Cas9 as DNA construct using programme x
CRISPR/Cas9 expression was 
s of mCherry on flow cytometry
-nucleofected cells (Figure 
 after seven days of
CRISPRs in recognising and breaking up 
the cells transfected with TRAC 
/Cas9 alone showed a higher percentage of 
, in comparison to the cells that were transfected with both 
, but without adding any DNA constructs. A background 
-treated group.  
knock out efficiency data.
s exposed to transfection (either with or without DNA) 
 (Figure 53). 
CRISPR /Cas 9 construct within Jurkat cells.; lower plots illustrate the percentage of Jurkat cells in expressing mCherry 
CRISPR/Cas9 nucleofected cells and within cells nucleofected per plots exemplify, cell viability was 
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 Due to the low percentages of 
further functional experiments
DNA constructs, and then test 
efficiency.   
 5.4.2) Delivering CRISPR/Cas9 as mRNA:
A T7 promoter sequence was
CRISPR/Cas9 map, the T7 promoter
RNA (sgRNA). For this reason, 
construct ahead of the sgRNA sequence by PCR
sgRNA was produced after following 
Following Zhang’s laboratory protocol (
for the purpose of gene disruption
mRNA was mixed with 100 ng/µl of Cas9 mRNA (TriLink, US
electroporation.  Afterwards, 2x10
electroporation condition using 
anti CD3-APC mAb to detect the percentage
data was analysed by FlowJo and 
the control and the TRAC CRISPR
expression, lower plots of electroporated
with 26.7% and a 2.77% background detected within 
nucleofected group (Figure 54
Figure 53: The effect of CRISPR/Cas9 TRAC and/or TRBCcells Upper FACS plots demonstrate the gating on the viable cells and they show the dramatic reduction in cell viability percentage. Lower plots show the shift in the CD3 expression level from positive to negative phenotwithin the treated group compared to the 
cell viability, it was not feasible to keep the 
. It has been suggested to produce mRNA from 
their effect on the cell’s viability in addition to TCR 
 
 included within the CRISPR plasmid.  According to the 
 sequence was found just behind Cas9
the T7 promoter sequence was added to the previous 
 cloning. In the end, 1.5 µg of mRNA of the 
the MEGAscript kit protocol for mRNA production. 
See reference) in delivering CRISPR
 by NHEJ, 50 ng/µl of sgRNA of CRISPR
A) in the cuvette of 
6Jurkat cells were added to the nucleases and exposed to 
the BTX system. Seven days later, the cells we
s of the CD3neg population. The f
there was no noticeable difference in cell viability between 
/Cas9 electroporated cells. For evaluating TCR surface 
 Jurkat cells show a shift toward 
the CD3neg gate of 
). 
 (as a DNA construct) 
non-treated group. 
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In summary, data illustrates in figure 
might be toxic to the cells and lead to immediate cell death. On the other hand, mRNA 
constructs seem to cause no harm to t
percentage after electroporation
 
 
 
 
 
 
 
 
 
 
Figure 54: the effect of TRAC surface of Jurkat cells. Upper control group show a cell viability percentage of 62.4% and for the percentage of viable cells is 59.7%. Lower shifted toward CD3neg gate; while for nonCD3neg population.  
 
 
55 shows that delivering CRISPR/Cas9 TRAC as DNA 
he cells and maintain cell viability within a reasonable 
, with a decent percentage of a TCR-disrupted population
CRISPR/Cas9 as mRNA construct on TCR expression on the plots display the percentage of viable cells by gating on live Jurkat; CRISPR/Cas9 electroporated cells plots show that 26.7% of the electroporated cells have -electroporated cells, there was only 2.77% background of 
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5.5) TRAC TALENs vs TRAC 
In addition to the pair of TRAC TALENs that were obtained from 
(London-TALENs or Cellectis
laboratory in Hamburg (Ge
Hamburg TALENs in knocking out the expression of TCR was compared to the previous pair 
of TRAC TALENs and to TRAC 
nucleofected with 5µg DNA of TRAC London
TRAC CRISPR/Cas9 and incubated for seven days before analysis. Surprisingly, FACS 
showed that both TALENs have the same knock out activity on 
TRAC CRISPR/Cas9 showed
Hamburg, appear to increase the percentage of 
comparing to un-TALENised cells, whereas FACS 
CRISPR/Cas9 show 9.03%  
stated, DNA might be toxic to the cells which could be the reason 
the nucleofected cells (Figure 
 
Figure 55: Comparison between the effectssurface expression and cell viability of Jurkat cells.reduction in cell viability within the DNA treated group but not approximately similar to the control labeled bar. Regarding TCR KO efficiency, highest percentage of TCR-neg population among the other groups (unCRISPR/Cas9 as DNA).  
 
 
CRISPR/Cas9: 
the UCL
-TALENs), another pair was provided by Dr.
rmany) and was named Hamburg-TALENs. The effect of 
CRISPR/Cas9. As previously stated, 2x10
-TALENs, TRAC Hamburg
the TCR expression, while 
 less knocking out activity. Both TRAC TALENs; London and 
the TCRneg-CD3neg population by 13.4% 
plots of cells nucleofected with TRAC 
of the cells in the TCRneg-CD3neg quadrant.  As previously 
for low cell viability within 
56).  
 of TRAC CRISPR/Cas9 as a DNA construct vs as mRNA on TCR  In comparison with the control group, the chart shows a notable in mRNA electroporated cells; which show a percentage the bar labeled with mRNA show-electroporated cells and cells treated with TRAC 
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 Cancer Institute 
 Boris Fehse’s 
6Jurkat cells were 
-TALENs and 
plots 
s the 
  
The same experiment was conduc
were used. TRAC-Hamburg mRNA was produced in order to conduct this experiment.
DNA was first linearised by using an AvrII enzyme, later it was used as a template to 
produce 60 µg of mRNA. 10µg mRNA 
used to electroporate 5x106 Jurkat cells, while for TRAC 
electroporated with 50ng/µl of mRNA sgRNA plus 100ng/µl Cas9 mRNA. The 
electroporation process was performed usi
were assessed by flow cytometry seven days later. The FACS 
viability percentage within treated cells in compar
mRNA TRAC TALENs obta
out activity by showing a sharp shift of the cells toward the TCR
FACS plots after gating of the viable cells.  35.5% 
the viable cells’ gate of TRAC TALENs
exposed to TRAC CRISPR/Cas9;
(Figure 57). 
  
Figure 56: Comparison between the effects of various kinds of nucleases in knocking out TCR expression on the surface of Jurkat cells.to TRAC TALENs London, TRAC TALENs Hamburg and TRAC represent the gating on the viable cells,percentage of TRCneg-CD3neg population. 
ted again, but instead of using DNA, mRNA constructs 
of TRAC TALENs, either London or Hamburg, was 
CRISPR/Cas9, the Jurkat cells were
ng the BTX electroporation system and the cells 
plots showed a remarkable cell 
ison to the un-electroporated cells. 
ined from Cellectis were shown to produce the highest knock 
-negative quadrant in the 
TCR-negative cells were detected within 
-Hamburg electroporated cells and within cells 
 the percent of the TCR-negative population was 21.9%
 Representative FACS plots of Jurkat cells that CRISPR/Cas9 as a DNA. Upper  while lower plots demonstrate nucleases activity by showing the  
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To conclude, this data might suggest that TALENs show a slight
activity than CRISPR/Cas9. Moreover, it appears that delivering nucleases as a
produces a higher cell viability percentage and superior knock out activity than delivering 
them as DNA. 
5.6) Discussion: 
A large number of strategies have emerged and investigated the efficacy of genome
technology rather than the conventional gene therapy approach. Molecular reagents 
including: meganuclase, zinc
attractive genetic tools for gene targeting
under evaluation for becoming a broad spectrum in gene therapy application. In the field of 
adoptive T cell immunotherapy, ZFNs and TALENs were applied to knockout the expression 
of endogenous T cell receptors either 
therapeutic T cells can be applied to multiple non
(Qasim and Thrasher, 2014). 
This section of the thesis discusses
endogenous TCR locus by several different gene
TALENs and CRISPR/Csa9.  Meganucleases are engineered
locus (C1 and C2) in the Jurkat cell line.  TALENs and 
Figure 57: Comparison between different nucleases activity for knocking out TCR expression on the surface of Jurkat cells. Representative FACS plots of Jurkat cells that Hamburg and TRAC CRISPR/Cas9 as an mRNA. Upper demonstrate nucleases activity by showing the percentage of TRCneg
ly better 
-finger nuclease, TALENs and CRISPR/Cas9 are  becoming 
 and manipulation (Kay, 2011). 
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the sequence within the TCR alpha constant region in Jurkat, PBMCs and CB-T cells and the 
results are described. The outcome of the experiments conducted in this chapter suggested 
that meganuclease might be toxic to the cells and that this is due to the acceleration in cellular 
death rate after they had been subjected to the meganuceleases plasmid. In general, 
introducing nucleases as an extrachromosomal DNA to the cells will lead to reduction in cell 
survival and this is because the DNA will be introduced directly to the cells at the nuclear 
level. This could prove to be toxic to the cells. For this reason, most of the therapeutic 
genome editing tools have been transformed to an mRNA species where the electroporation 
is acquired at the cytoplasmic level. Nevertheless, the same results were achieved by using a 
lentiviral vector as the transferring vehicle of megnaucleses to the respective cells.  
TALENs and CRISPR/Cas9 were selected to be the new platforms to suppress the expression 
and inactivate the function of TCR. Several attempts were performed to assemble in-house 
TALENs targeting both constant chains of TCR (TRAC and TRBC).  A positive result was 
accomplished in building the right arm of  the TALENs designed to target the beta constant 
chain; whereas for the left arm, no success was achieved despite all attempted endeavors. 
Building and assembling TALENs fragments through complex digestion and cloning 
procedures was not as easy as designing them. The process of digesting one TAL effector 
fragment to be ligated to the following TALE effector fragment was a labour-intensive and 
tedious procedure with a very dismal percentage of success. Commercially applied TALENs 
were used to conduct the experiments.  
TRAC TALENs from different sources were utilised to disrupt alpha constant regions of 
TCR on Jurkat cells, CB-T cells and adult T cells. The emerging data was outstandingly 
promising given that the percentage of disrupted-TCR reached 70% after being TALENised 
with TRAC TALENs as mRNA. CRISPR/Cas9 was also designed to target TRAC, but its 
efficacy was not as remarkable as the efficacy of TALENs in knocking down the expression 
of TCR. However, experiments aiming to compare the efficacy of CRISPR/Cas9 to TALENs  
were only conducted once. Consequently, more experiments are required to achieve a solid 
conclusion. The CRISPR/Cas9 plasmid required an optimization due to the presence of a 
large number of accessory elements such as mCherry. Additionally, the alteration of the DNA 
plasmid into mRNA demands optimization in order to achieve high quality and purity.  
 Despite the numerous successes and remarkable excitement surrounding genome editing 
based therapy, it poses several challenges that require further work. Off-target cleavage of 
genome editing tools is one of the main safety concerns for clinical application. Most of the 
studies that evaluate the target specificities of ZFNs, TALENs, and CRISPR/Cas9 have 
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concluded that TALENs have the lowest incidence of off-target cleavage compared to ZFNs 
and CRISPR/Cas9  (Pattanayak et al., 2011, Guilinger et al., 2014, Fu et al., 2013, Veres et 
al., 2014). Therefore, the understanding of the specificity of engineered genome editing 
nucleases needs to be improved.  Another major obstacle facing genome targeted technology 
is the means to introduce these designer nucleases to the respective target cells.  Currently, 
the electroporation method to deliver extrachromosomal DNA-based nuclease expression 
vectors, mRNA or proteins might be consider the most popular method to transiently express 
nucleases within the cells (Gaj et al., 2012). Although using integration-competent and 
integration-deficient lentiviral vectors as a delivering system was successful and a more 
potent method of delivery than electroporation, they are still under consideration because 
they may lead to constitutive expressions resulting in producing more off-target activity 
(Weber et al., 2008, Mock et al., 2014).  
Recently, an Adeno-associated virus (AAV) vector proved its efficiency in delivering 
designer nucleases into different tissue types such as the liver and the brain (Holkers et al., 
2013b). Although this class of life-changing medicine is still in its infancy, genome editing 
presents alluring opportunities for tackling a number of diseases that are beyond the reach of 
previous therapies. However, their efficacy, safety and specificity require them to be 
optimized until they can be considered for use in human clinical applications. 
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Chapter 6: Generation of “off-the-shelf” universal engineered CAR19 Cord Blood T cells  
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6.1) Introduction: 
In recent years, promising data has emerged from many studies investigating the ability of 
editing T cell specificity towards a variety of malignancies such as B-cell malignancies.  
Engineering autologous T cells to express chimeric antigen receptor (CAR) against CD19, a 
leukemic antigen on B-cells, has recently been shown to be highly effective as a cell-based 
therapeutic tool for relapsed leukaemia. Harvesting an adequate number of autologous T-cells 
from heavily treated cancer patients or from small infants may be not feasible to manufacture 
a sufficient number of therapeutic engineered CAT19 T-cells. Utilising donor T cells from 
allogeneic HLA matched haematopoietic stem cell donors as part of transplant strategy might 
be feasible. However, in some circumstances it is not possible to find HLA matched 
allogeneic hematopoietic stem cell donors. It has been proposed that generating “off-the-
shelf” engineered CAR19 T cells from non-matched donors might be an attractive alternative 
approach, but it must overcome HLA-barriers.  It is important to engineer T cells with the 
ability to evade host-mediated immunity, and to provide anti-leukemic activity without graft-
versus host disease. The endogenous TCR  on the infused allogeneic T-cells might cause 
graft-versus-host disease by recognising minor and major histocompatibility antigens in the 
recipient (Torikai et al., 2012). In order to preclude TCR-mediated deleterious recognition of 
normal tissues after adoptive transfer, and to reduce the time and expense to manufacture 
patient-specific T-cell as a therapeutic product, our goal is to generate universal “off-the 
shelf” T-cells expressing CD19 CAR from allogeneic healthy cord blood donors. 
Consequently, it can be administrated to HLA non-matched patients without causing GVHD.  
CD19 is a tumour specific antigen that is constitutively expressed on most acute and chronic 
B-cell malignancies. Therefore, to target malignant B cells, we have produced third 
generation lentiviral vectors to express a second generation CD19 CAR (designed with CD28 
as a costimulatory molecule) and also the vector incorporated an abbreviated sort/suicide 
gene RQR8, comprising a 136 amino acid cell surface protein inclusive of a CD34 epitope 
for clinical applications. This same approach has been used in clinical trials to treat acute 
lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) by Cellectis, a 
biopharmaceutical company focused on developing immunotherapies using universal 
allogeneic adult T-cells engineered to target CD19 marker on malignant cells. In June 2016, 
Cellectis announced that the first patient had been treated in the Phase I study of UCART19 
in paediatric acute B-lymphoblastic leukemia (B-ALL) at the University College of London 
(UCL). 
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To test the feasibility of generating universal allogeneic CD19-CAR+CB-T cells, the 
culturing process for generating CD19 CAR+ T cells was modified to include the editing of 
the genome of CD19-CAR+ T cells to irreversibly eliminate the expression of the 
endogenous αβ TCR. After activating CB-T with either anti-CD3/anti-CD28 beads or with a 
cytokines cocktail; which includes IL-7 + IL-15 and IL-2, CB-T cells were transduced with a 
lentiviral vector expressing CD19CAR with a remarkably high transduction efficiency.  
Later, to knockout the alpha TCR loci, the transcription activator-like effector nucleases 
(TALEN)s was used targeting genomic sequences in the constant regions of the endogenous 
α subunits of the TCR. The TALENs mediated genome editing by catalysing the formation of 
a DNA double strand break (DSB) in the genome. Targeting a DSB to a predetermined site 
within the coding sequence of a gene was previously shown to lead to permanent loss of the 
functional target gene expression via repair by non-homologous end joining (NHEJ), an 
error-prone cellular repair pathway that results in the insertion or deletion of nucleotides at 
the cleaved site (Cade et al., 2012). 
Here we demonstrate that cord blood T cells are highly prone to multiple manipulations by 
delivering significantly high transduction efficiency and show a high TCR knock out 
efficiency. Moreover, we demonstrate that TALENs targeting the alpha chain of endogenous 
TCRs in CB-T cells resulted in the desired loss of TCR expression. As expected, these 
modified CD19CAR TCR negative CB-T cells maintained their CAR-mediated redirected 
specificity for CD19. 
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6.2) Manufacture of Universal CD19CAR T (TCRnegCAR19pos) Cells using the G-rex 
Expansion System: (Figure 58)  
CB-T cells were activated with antiCD3/anti-CD28 beads (n=5) or with a cytokines cocktail 
composed of 5ng/ml IL-7, 5 ng/ml IL-15 and IL-2 (n=3) and cultured at a concentration of 
1x106 cells/ml in a 100 ml differentiation bag (Miltenyi Biotec) for two or three days in a 
cytokines activation condition.   On the day of viral transduction, the 100 ml differentiation 
bags were coated with 10 mls of retronectin and incubated at room temperature for a couple 
of hours. Later, activated cells were exposed to self-inactivating third generation lentiviral 
vectors carrying CD19CAR as a transgene under the control of an internal EFL alpha 
promoter and linked to the sort/suicide gene RQR8 at MOI of 5 (Figure 24.A). Transduced 
cells were stained with anti-CD34 and/or anti-Fab antibodies for transduction efficiency and 
assessment. Flow cytometric characterization of transduced cells showed that cells expressing 
CD19CAR between 32.7%-75.9% (n=5, mean=52.92) for anti-CD3/anti-CD28 beads 
activated cells, while for cytokines activated cells, the CD19CAR expression level ranged 
between 15.8%-48.6% (n=3, mean= 29.1) (Figure 59). 
After transduction and prior to electroporation, transduced cells were prepared for receiving 
TRAC TALENs by culturing them at a concentration of 1-1.7x106 cells/ml in complete X-
VIVO 15.  
After analysing the transduction efficiency, cells were exposed to 20 g of mRNA encoding 
TRAC TALENS (10g/arm) and electroporated using the BTX system, then cultured in G-
rex m10 for expansion for seven days. Twelve days after activation, the down expression of 
endogenous TCR was assessed by evaluating the percentage of CD3negative and/or TCR-
negative population by flow cytometry. Flow cytometry analysis revealed that up to 60% of 
the bead activated cells lost their TCR/CD3 surface expression (22%-60%, n=5, 
mean=40.28), although for cells activated with the cytokines cocktail, TCR/CD3negative 
percentages ranged from 12%-56% (n=3 mean=36.2)(Figure 60). To enrich the 
TCR/CD3negative population, a depletion column and negative selection using anti-TCR 
paramagnetic beads was used and more than 99% enrichment was achieved.   
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Figure 58: Schematic Presentation of the generation of "offencoding mRNA was electro transferred 5 days after stimulation and transduction of CBwith 200 IU/ml of IL-2 and/or 5ng/ml of IL-flask, as indicated. CD3 and/or TCR expression was analysed by flow cytometry on 17, TCR negative population was negatively selected to be separated out from TCR positive cells
Figure 59: Expression of CAR19 in five human cord blood donorsCAD19CAR vectors were transduced into CBscFv or anti-CD34 and/or anti-Fab antibody staining. Graph shows coefficiency of CB-T cell stimulated with different conditions before transduction; five CBwith CD3/CD28 beads +IL- 2 (100U/ml), while three other CBIL-7 (5ng/ml) and IL-15 (5ng/ml) in addition to IL
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Figure 60: Down-regulation of CD3/TCR expression after electrotransfer of mRNA encoding the TCR alpha/beta targeted TALENs. Day 7 after electrotransfer of the indicated doses of mRNA coding for TRAC targeted TALENs pairs, TCR αβ-CD3 expression was analysed by either TCR  or by co-staining TCR and CD3. A) Bar chart shows TCR/CD3 expression in T cells cultured with anti-CD3/anti-CD28 beads (n=5) vs. T cells cultured in interleukins cocktail after TRAC TALENs transfer (n=3). B) Representative flow data at Day 7 after TALENs electrotransfer is shown. Flow cytometry data are gated on cells viable cells. Percentages in the lower half represent the percentage of TCR negative cells in T-cell populations. 
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 6.3) Enrichment of TCR negative CB
Isolating the TCR-disrupted population is an essential requirement for future clinical 
application to prevent GVHD in human leukocyte disparate recipients.  To address this issue, 
TCR/CD3 negative cells were 
and a LD depletion column. Flow cytometry analysis show
validating the elimination of the TCR positive population (F
 
 
    
Figure 61: TCR negative CBpopulation. TCR/CD3 expression after depletion using TCRcytometry reveals expression of TCRCD3/anti-CD28 beads (10 days after TRAC TALENs transfection). quadrant represents the percentage of TCR 
-T cells: 
negatively selected using anti-TCR  p
ed >80% of TCR
igure 61).  
-T cells can be enriched by depleting TCR positive T cells -specific paramagnetic beads. Flow  and CD3 in CB-T cells 17 days after activation by antiPercentage in the bottom/CD3neg T cells.
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6.4) Disruption of the αβ TCR-CD3 Complex on T cells using TALENs Targeting 
TRAC: 
To confirm that electroporated CB-T cells had been genetically modified at the intended 
TRAC TALENs target sites, a surveyor nuclease assay was performed using specific 
oligonucleotide primers flanking target sites within TRAC. TCRnegCD19CARpos cells 
TCRposCD19CARpos cells and bulk, non-selected TCR CD19CARpos cells (that stimulated 
with cytokines) were exposed to PCR to amplify the TRAC TALENs-target site, then they 
were exposed to Nuclease N mutation detection enzyme. The Nuclease N digestion products, 
representative of genetic changes induced by the TRAC TALENs, were present only after 
electrotransfer of the TCR-specific TALENs pairs on a 1% agarose gel. To evaluate the 
efficiency of TRAC TALENs by this enzyme, two fragments at size of 300 and 200 base 
pairs should be detected on the gel. As the gel demonstrates, two fragments of the right sizes 
(very faint band at the size of 200 bp) were observed in the TCRnegCD19CARposcells, but not 
in the TCRposCD19CARpos population, as only one band could be seen (Figure 62). It could 
not be confirmed if the very faint two bands that appeared at the cytokines activated cell lane 
were products of Nuclease N enzyme, as they appeared as a smear of a DNA.  
This experiment on naive T cells confirmed that TALENs designed to target TRAC lead to 
permanent disruption of αβ TCR expression, as assessed by the Nuclease mediated surveyor 
assay and confirmed by flow cytometry analysis of TCR/CD3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
6.5) Next Generation Sequenci
As a confirmation of the efficacy of TRAC TALENs in editing its specific target, genomic 
DNA of the manipulated CD19CAR T cells were subjected to next generation sequencing. 
The first run was conducted by Dr.
negative population (after 
stimulated CD19CAR CB-T cells were amplified by PCR then exposed to deep sequencing 
using an Illumina Miseq Machine. NHEJ was detected at a frequency of >70% of
locus for pure negative TCR population.
detected NHEJ events at a frequency of < 1% of TRAC locus
control non-modified cells.  NGS interrogation followed by
TRAC target sites of cytokines stimulated CD19CAR CB
NHEJ signatures for TRAC and the  high efficiency of TRAC TALENs in gene editing 
(>50%) (Figure 63) (Table 7).
 
 
 
Figure 62: Surveyor nuclease assay to detect TALENssites in CB-T cells. CB-T cells activated with antiwere selected for TCR) or with cytokines cocktail (the bulk of TCR negative population). Arrows indicate the fragments produced by a surveyor nuclease digest of amplicons bearing a mismatch at the intended site of TALENs cleavage in the TRAC locus.
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Table 7: Summary of next generation sequencing data of the genome of TRAC TALENised CB-T cells. Table summarises how many reads were accounted for by the un-mutated sequence and how many mutated sequences were detected within the genome of TALEN-manipulated CB-T cells, as well as un manipulated population. It also describes how many reads were passed at the various stages of filtering and trimming of sequence reads. FACS plots represent percentages of TCR-disrupted T cells in both stimulation conditions and the result is almost consistence with the NGS outcome. 
 
 
 
Neg ctrl TCR neg TCR pos Cytokines
Total analysed reads 1595473 975598 1458492 1004869
Proportion of reads accounted for by expected sequence 99.74% 22.50% 99.71% 22.04%
Number of non-matching sequences detected 130 2273 137 2013
Number of raw reads 2002521 1577976 1812864 1631300
Number of reads after first anchoring step (first 6nt) 1917659 95.8% 1500034 95.1% 1746596 96.3% 1561718 95.7%
Number of reads after Q30 filtering 1616164 80.7% 1093441 69.3% 1478741 81.6% 1128061 69.2%
Number of reads after second anchoring step (7nt before 
cleavage site) 1600894 79.9% 980523 62.1% 1463845 80.7% 1009227 61.9%
Number of reads after matching read 1 and read 2 1595473 79.7% 975598 61.8% 1458492 80.5% 1004869 61.6%
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 Figure 63: Next generation sequencing data Histograms illustrate summary of Next generation sequencing data of DNA extractedcord blood T-cells (n=1) that has been stimulated with anti(IL-7+IL-15 and IL-2).  A) Histogram demonstrates the percentage of the similarities between the original sequence of TRAC and the DNA seqpercentage of similarity between the original TRAC sequence and CBexposed to TRAC-TALENs. B) Histogram demonstrates thewithin the genome. As the graph shows; there is a high percentage of nonwithin the genome of the manipulated cells with the genome of the un-manipulated cells
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Two other donors’ genomic DNA extracted from TALENised-genetically edited CD19CAR 
CB-T cells were also subjected to next generation sequencing using a CRISPR-GA pipeline 
plaform in an experiment performed by Dr. Anastasia Petrova using an Illumina Miseq 
Machine. Raw sequencing data was analysed using software named CRISPR-GA; where the 
raw sequencing reads were uploaded and then underwent quality control by trimming to 
discard the results that contained any sequencing errors. The software then mapped the reads 
to the reference sequence (TRAC). The mapping was done by a specialised BLAT platform, 
which is suitable to support indels (deletions and insertions). The software processes the 
mapped BLAT results to detect the insertions and deletions. It then uses pattern matching to 
compute the number of reads matching the expected sequence or generating variants. This 
information is then integrated to create plots and reports. Pattern matching is used to calculate 
the number of reads matching the expected sequence and other variants generated. NHEJ and 
HR are estimated by computing specific equations. The final result consists of three parts. 
First, the results report the analysis of indel sizes. Second, they illustrate the analysis of indel 
locations within the edited genomic locus. Lastly, they show an integrated plot representing 
indels, NHEJ and HR. Furthermore, a FASTA file is created with all reads containing indels, 
as well as an XML text output with HR, NHEJ values and the indel relative location in 
genomic locus (Güell et al., 2014). 
The batch was subjected to detailed release characterization to quantify and exemplify 
deletions and insertions at the intended target site. Next Generation Sequencing (NGS) 
detected on-target events consistent with NHEJ (Insertions, Deletions and Indels) at a 
frequency of >60% for (36-61%) TRAC locus and for similar events at a frequency of just 
0.096-0.11% for control non-modified cells (Figure 64). 
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 Figure 64: NGS TRAC target site sequences.(>60%) of events consistent with NHEJ repair of double straconsistent with the flow cytometric quantification of genelocus is subject to allelic exclusion. A) Control group represented by unblot (top) shows the percentage of CD3 negative population before genome editing using TRAC TALENs. NGS data (bottom) estimated the frequency of NHEJ (right) in the normal condition of the cells as well as the analysing indels sizes and their respective frequencies (left). B) Flow cytometric analyscharacteristic (top). NGS data was consistence 1base pair also have around 3250 insertions of 1base pair; most of the100base pair of the reference sequence (bottom100bp of our target sequence and NHEJ percentage is 61% percentage of TCR-disrupted engineered T cells (top) which is consistence with the NHEJ frequency that determined by NGS (bottom). Right graph demonstrates the NHEJ frequency 21% while graphs on the left illustrate indels sizes and their respective frequencies and their location within your reference locus; there are > 60,000 deletion of 1base pair and around 1000 insertions of 1 base pair; concentrated around 60-100 base pair of the reference  
       
 NGS TRAC target site sequences found a high frequency nded DNA scission. The results were -editing considering that expression at the TRAC -manipulated CB
and their location within your reference locus es demonstrated that 60% of T cell population hawith flow results where there are around 11000 deletions of  indels are concentrated around -left).we have around 50000 indels concentrating around (bottom right). C) FACS blot demonstrate 
most of the indels are sequence (bottom-left). 
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6.6) TCR-disrupted CD19CAR CB-T Cells Appear to Retain Naïve Phenotype 
Characteristics  
In order to assess differentiations of disrupted CB-T cell populations by flow cytometry, a 
panel of the following markers was used: CD45RA, CD62L, CCR7 as well as T cell subtype 
CD4 and CD8. After isolating TCR negative cells from the TCR positive population, the cells 
were stained with the CD4, CD8, CD45RA, CD62L and CCR7 to determine the percentage 
of naïve cells. Our data suggests that the TCR negative population was co-expressing naïve 
markers in a more abundant manner (n=3, CD4+:43%-60%, mean= 53%/ CD8+:23%-45%, 
mean=35.6%) than the pure TCR positive population (n=3, CD4+:25%-31%, mean= 27.6% / 
CD8+:25%-37%, mean=29%). The un-activated cells were thawed and analysed right away 
at the same time and included with the other samples (n=3, 26.6%-31.7%, mean=28.4%) 
(Figure 65). Although the data outcome from the un-activated cells was not as expected, it 
helps in gating the cells in an accurate manner once analysed by the FlowJo software. 
 
 
Figure 65: Co-expression of naive phenotype markers on CAR19 CB-T cells. Bar chart illustrates phenotypic analysis of CB-T cells product after being transduced with Lnt-EFl-CD19CAR, TALENised with TRAC TALENs mRNA and TCR depleted (n=3). Un-manipulated cells (unactivated) were used as a control to gate the cells correctly on FlowJo software. Disrupted TCR cells (TCR negative population) show higher percentages of naïve like phenotypic features than TCR positive fraction. 
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Another phenotypic panel to determine the immunological naivety is displayed by a stem cell 
memory T cell (TSCM) subset. The expression of additional protein surface markers, including 
the death receptor CD95 (also known as FAS), in the context of naive-appearing T cells was 
recently found to delineate a new memory T cell subset in humans and mice (Gattinoni et al., 
2011). TSCM has superior survival potential and efficiently engrafts in allogeneic transplant 
models resembling naive T cells in that they are CD45RA+CD45RO-, and they express high 
levels of the co-stimulatory receptors CD62L and CCR7. Stem cell memory T cells have a 
high proliferative capacity and are both self-renewing and ‘multipotent’. They are able to 
differentiate into other T cell subsets, including central memory T cells and effector memory 
T cells. These properties define their ‘stem cell-like’ abilities (Gattinoni et al., 2011). 
Antibodies targeting CD95 were used in addition to anti-CD45RA and anti-CD62L to define 
the phenotype properties of disrupted-CAR19 engineered T cells after being negatively 
selected for TCR expression.  FACS plots indicated that the negatively expressed TCR group, 
especially the CD4 subset, is significantly superior in expressing stem cell memory T cells 
markers than the pure TCR positive population (Figure 66).  
 
 
Figure 66: Co-expression of stem cell memory T cell phenotype markers on CAR19 CB-T cells. Bar chart illustrates phenotypic analysis of CB-T cells product after being transduced with Lnt-EFl-CD19CAR, TALENised with TRAC TALENs mRNA and TCR depleted. Un-manipulated cells (unactivated) were used as a control to gate the cells correctly on FlowJo software. Disrupted TCR cells (TCR negative population) show higher percentages of naïve like phenotypic features than TCR positive fraction. 
It was later suggested that phenotyping data might be more useful and more precise if the 
cells were stained with anti-Fab marker in addition to the other T cells differentiation 
markers. Thus, the exact phenotype of only CAR19+ cells will be determined. Bulk amounts 
of CD19CAR+ CB-T cells (n=2) that had been exposed to TRAC TALENs (Td-TRAC 
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Talenised) were stained with another phenotypic panel: Fab, CD45RA, CD62L and CCR7 
antibodies.  Flow cytometric results showed that TALENised CD19CAR+ T cells were 
superior to non-TALENised non-engineered CB-T cells in preserving the CD45RA+CCR7+ 
CD62L+ population in  ex vivo expanded CAR-T cells (Figure 67).  
 
Figure 67: Co-expression of naive phenotype markers on Fab positive CAR19-enginereed CB-T cells. Bar chart illustrates phenotypic analysis of CB-T cells product after being transduced with Lnt-EFl-CD19CAR and TALENised with TRAC TALENs mRNA. Un-manipulated cells (unactivated) were used as a control to gate the cells correctly on FlowJo software. Disrupted TCR cells (Td-TRAC Talenised) show remarkably high percentages of naïve-like phenotypic features, in comparison to the un-transduced and un-talenised cells.  
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6.7) Discussion: 
Clinical trials involving the usage of chimeric antigen receptors targeting CD19 as a targeted 
immunotherapy for B-cell malignancies show a high therapeutic potency with a complete 
remission rate of >90 % (Nguyen et al., 2008, Maude et al., 2015). However, expertise and 
additional support from clinicians, researchers, pharmaceutical companies and investors are 
required for this therapy to have a solid infrastructure. Consequently, it emerges as a 
powerful tool to treat B-cell malignancies. Moreover, the low number of T cells from some 
individuals might limit its potency as a therapy (Qasim and Thrasher, 2014, Humphries, 
2013).  It has been proposed that generating pre-manufactured or engineered T cells might be 
a robust alternative approach, but it should overcome the HLA barrier and preclude the 
undesired  TCR on the infused T cells from leading to GVHD. In this chapter, the 
specificity of naïve T cells (cord blood T cells) was redirected towards the CD19 antigen by 
delivering chimeric antigen receptors targeting CD19 to the cells. In addition, it has been 
proven that they can be genetically edited by TRAC TALENs to eliminate the expression of 
the endogenous αTCR. This has a therapeutic implication in regards to donor-derived T 
cells that are infused to achieve an antitumor effect without causing GVHD.  
The TCR  assembly requires it to be a heterodimer in order to form a functional receptor 
on the cell surface. In this manner, disrupting either TRAC or TRBC will be sufficient to 
eliminate the expression of TCR . Recent studies have shown that a mutation in the TRAC 
genome sequence has led to the loss of TCR  expression (Morgan et al.). 
TALENs have been demonstrated to interrupt target gene expressions as an outcome of error-
prone DNA DSB repair by a non-homologous end joining (NHEJ).This in most cases leads to 
a frame shift mutation resulting in a premature stop of translation. TALENs target a specific 
sequence within the genome and thus disrupt gene expression at the genomic level, which is 
an advantage over techniques that involve transcriptional repression and require sustained 
expression of the inhibiting factor ( i.e.  the enforced expression of shRNA to mediate TCR 
down-regulation). Due to the ability of TRAC TALENs to create a permanent disruption in 
the gene expression after transient delivery and expression, it enabled us to use ex vivo 
transcribed mRNA in a “hit-and-run” manner for electrotransfer of TRAC TALENs into CB-
T cells. 
As an alternative to allogeneic bone marrow transplant for hematopoietic reconstitution, an 
un-related human umbilical cord blood (CB) sample has been used successfully in various 
haematological disorders. This clinical application is approached because CB is readily 
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available and has a rich source of hematopoietic stem cells with exceedingly proliferative 
capacities (Hiwarkar et al., 2015). There are some reports that suggest that CB is comprised 
of phenotypically and functionally immature cytotoxic T lymphocytes (CTLs) with decreased 
alloantigen-specific cytotoxicity. In contrast to the CTLs in peripheral blood, the CTLs 
derived from cord blood show a high expression of CD45RA (a naïve T cell marker) and a 
low expression of CD45RO (an activated T cell marker).It has been proven by several studies 
that cord blood may be used for immunotherapy to treat a variety of hematopoietic disorders 
(Lee et al., 2011). 
In this project, the strength of products from both CB-T cells and TALENs, were combined 
together to produce universal “off-the-shelf” engineered CB-T cells targeting CD19 antigen 
that are expressed by B-cell malignancies. The human application of “universally” 
engineered CD19-CAR+ CB-T cells that have been genetically modified with TRAC 
TALENs will rely on efficacy as well as safety. The genetically edited T cells have a specific 
cytotoxic behaviour toward primary targets and cell lines. Their therapeutic potential is also 
dependent on persistence after adoptive transfer. The second generation CAR designed for 
this study activates CB-T cells through chimeric CD28 and CD3-ζ. It remains to be 
determined in side-by-side clinical trials whether other CAR designs, such as signalling 
through CD137 and CD3-ζ, are superior. Safety depends on selective elimination of 
endogenous TCR and minimizing TALENs-mediated enzymatic activity at off-target sites. 
We did observe that the efficiency of enzymatic activity at TRAC TALEN  genomic loci was 
approximately 22-60% (mean=40.28%) for CB cells activated with anti-CD3/anti-CD28 
beads, while for cytokines stimulated CB cells, the percentages of TCR-disrupted T cells was 
12-56% (with mean= 36.3%) after a single electrotransfer of an mRNA species coding for 
TRAC TALENs pairs. However, continued cell-surface expression of TCRs from HLA-
disparate unrelated CB-T-cell donors may cause GVHD after adoptive immunotherapy. 
Therefore, to prevent GVHD after infusion we used TCR-specific paramagnetic beads to 
deplete and re-deplete T cells with residual expression of TCRs.  
Most importantly, we also identified that the genetically edited CD19CAR-CB-T cell were 
retained in the expression of the naïve CD45RA isoform CD62L and CCR7, which might be 
the subset that correlates with in vivo expansion of TCR negative CD19CAR-T cells in 
lymphoma patients (Xu et al., 2014).  
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CD95 is another marker that was under investigation in this study. It has been suggested to be 
associated with a subset named “T-memory stem cells”. Moreover, our data from genetically 
edited CD19CAR-T CB-cells subsequently generated from healthy CB donors, show that the 
subset of CAR-redirected CD45RA+CCR7+ also co-express CD95, further indicating that 
this antigen-experienced population is indeed closely related to “T-memory stem cells” as it 
retains both phenotypic and functional elements of “naïvity” or “stem-ness.” 
In conclusion, it has been demonstrated that TCRnegative-CD19 CAR+ CB-T cells can be 
generated using a genetic approach to diminish the expression of the undesired endogenous 
TCR with TALENs using a robust electrotransfer  platform and to introduce CD19 CAR 
using a lentiviral vector gene delivery system.  Our approach abolishes the danger of GVHD 
caused by adoptive transfer of large numbers of allogeneic T cells, while maintaining the 
desired effector functions mediated by CD19RCD28 CAR to target malignant B cells. This 
strategy provides an important step to developing a “universal” CD19CAR+ T cell, which 
can be manufactured from one unrelated CB donor and administered on demand to multiple 
patients. Subsequent studies are focusing on preventing rejection of the infused allogeneic 
TCR-negative CD19CAR+ CB-T cells by the recipient's immune system recognizing 
disparate HLA. For example, this may be accomplished by using genetic modifications 
including a nucleases-mediated knockout of HLA. Other issues require focus on the future 
studies for finding a robust means to extract T cells out from a CB-unit. Consequently, the 
activation process will be done accurately without adding an excessive number of beads. This 
can be achieved by using various, but specific kits, such as anti-CD3 or anti-CD62L 
paramagnetic beads before activating the cells with anti-CD3/anti-CD28 beads. 
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7)  Discussion: 
Therapeutic success following allogeneic HSCT is defined as achieving a GVL effect without 
risking the potentially lethal effects of GVHD. Several strategies have been tried with the aim 
of addressing the separation of GVL and GVHD after engraftment of allogeneic 
hematopoietic stem cells, such as adoptive transfer T-cell therapy (Walter et al., 1995). 
Although adoptive-T cell immunotherapy has led to remarkably successful outcomes in 
treating cancer, the inability to isolate and expand a sufficient number of high-avidity, 
cytotoxic-specific T lymphocytes (infiltrating T lymphocytes) for therapeutic purposes is the 
biggest obstacle to the success of the therapy (Pardoll, 2003). An alternative approach to 
generating large numbers of potent and specific T cells is to genetically engineer T 
lymphocytes to express an exogenous tumour antigen specific TCR or an artificial receptor 
known as CARs targeting precise TAA (Kapp et al., 2009, Willemsen et al., 2003) 
The high risk involved with generating GVHD by the endogenous TCR in allogeneic settings 
after HSCT, the potential generation of harmful, unpredicted TCR specificities and the 
suboptimal activity toward their specific target in both autologous and allogeneic settings are 
the major drawbacks of antigen-specific TCR gene transfer therapy. Furthermore, the 
cytokines release storm is a serious adverse event that’s associated with CAR T cell therapy 
(Gross and Eshhar, 2016, Klebanoff et al., 2016). 
Here, we used TALENs mediated cord blood T cell engineering coupling with lentiviral 
transduction to produce universally applicable CAR19 T cells that can be administered to 
multiple patients without causing GVHD.These strategies could form the basis of a new gene 
therapy treatment against haematological malignancies and this discussion illustrates some of 
the aspects that must be further considered before application of this technology. 
7.1) Delivery and processing of cord blood units:  
Cord blood units should be as fresh as possible to ensure the presence of high numbers of 
efficient viable T-cells. Cord blood units used in this study were supplied by the Anthony 
Nolan Cord Blood Bank and delivered to our facility from Nottingham. As a result, in some 
events the time between collection and processing of the blood might have been over forty-
eight hours, which might led to a huge loss of the desired cells. Likewise, it is a challenging 
task to extract the buffy coat out from the ficolled old blood. Another issue associated with 
cord blood is the existence of enormous immature nucleated red blood cells, or “red blood 
cell contamination”.  Cord nucleated red blood cells might be counted false positively as 
lymphocytes leading to miscalculation of the amount of anti-CD3/anti-CD28 beads that are 
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required to activate T-cells at 1 bead: 1 cell ratio.  The addition of excessive beads may result 
in producing highly differentiated and exhausted engineered cells that may not be able to 
survive and enter the apoptosis phase in a quick manner. For these reasons, several strategies 
are required to eliminate the superfluous red blood cells that might lead to undesirable 
effects.  Staining the cord blood mononuclear cells with anti-CD3 prior to activation was 
used as one tactic to determine the definite percentage of lymphocyte. Automated calculation 
of lymphocytes using the C-max machine was also considered as one technique to mitigate 
red blood cell amounts. Another strategy to eliminate red blood cell contamination might be 
to positively select out red blood cells from the mononuclear cells by using MACS system 
and immunological beads against red blood cells. All these techniques have not yet proven 
their efficiency and need more optimization. A more proficient approach might be a positive 
extraction of the naïve lymphocytes by using microbeads to select CD62L or CD45RA 
positive cells.  
7.2) Optimisation of culturing and expansion system for engineered universal CAR19 
CB-T cells: 
Culturing the genetically altered cells in an optimal environment to have a large number of 
cells is a crucial requirement to generate off- the- shelf T cells as a therapeutic product (Hodi 
et al., 2010). Recently, the G-rex expanding system has emerged as one of the most effective 
culturing techniques in adoptive immunotherapy (Bajgain et al., 2014).  This culture 
container provides the cells with unlimited gas exchange via a gas transmembrane. Although 
the effectiveness of this device has been proven in many experiments; here, following 
electroporation, TALENised and CD19CAR modified T cells were not be able to expand as 
much as expected.  Several factors might account for this: treated cells that have been 
activated with anti-CD3/anti-CD28 beads may have been exhausted and entered the apoptosis 
phase rapidly and therefore, could not tolerate 17 days in culture (Wherry, 2011). In the other 
case; where cells that were stimulated with the cytokines cocktail alone, the stimuli may not 
have been considered to be not strong enough to generate survival signals in order to keep the 
naïve cells viable. As well as modified CD19CAR cells expressing CD19CAR, they carry 
RQR8, a compact/marker suicide gene moiety transcriptionally linked to CAR19 and it is an 
epitope from the CD34 molecule (Philip et al., 2014). Following lentiviral transduction, 
uncoupling of RQR8 from CAR19 of detectable cell surface expression of CD34 presumably 
resulted in reduced sensitivity to select CD34 CAR19 T cells after transduction. 
Consequently, a number of cells that would be selected based on the expression of CD34 will 
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be affected.  New strategies need to be considered. Interestingly, one study suggested that 
naïve lymphocytes are required to be activated at Day one with anti-CD3/anti-CD28 beads, 
later kept in culture with the presence of IL-7 and IL-15; gamma cytokines responsible for 
proliferation and expansion of T cells (Cieri et al., 2013). Another advantage of culturing 
modified cells in the presence of IL-7 and IL-15 is the significant lower levels of Tregs; a 
favorable condition for adoptive T cell therapy,  when compared to culturing the cells in IL-2 
culture condition (Cha et al., 2010).  
7.3 ) Viral vectors:  
The fact that self-inactivating second generation WT1 TCR coding LV vector and a third 
generation CD19- CAR coding LV vectors have been used to transduce the CB- T cells 
appears not to imitate the transduction efficiency. The only main differences between these 
two viruses concern safety issues. In addition, both viruses were coated with the VSV-G 
envelope glycoprotein, therefore should be able to infect CB-T lymphocytes with the same 
efficiency (Ratner et al., 1985b). The only concern regarding viral vectors is the possible 
variation that could be introduced into data as a result of using different preparations of 
lentiviral vector. However, preparing enough vector stock to perform all the experiments 
could help to eliminate this. 
7.4) Engraft of antigen-specific CB-T cells in NOD/SCID mice: 
In anticipation of further testing of our results relating to the use of CB-T cells as an off-the-
shelf therapy, an in vivo assessment is essential. In future research, a SCID/NOD mouse will 
be injected with  tumour cells  (BV173 leukaemia cells or SupT1 cells), leading to the 
production of specific cancerous cells expressing TAA. A large number of expanded CD19-
CARs or WT1-TCRs CB-T lymphocytes will be injected intravenously into the mouse 
followed by the monitoring of the elimination of cancerous cells without causing 
axenoreactivity. 
An in vivo experiment to investigate the anti-tumour activity of engineered cord and adult 
CD19CAR T cells was conducted by Dr.Christos Georgiadis and Mr.Roland Preece using 
NOD SCID gamma male (NSG) mice. PBMCs or CB (effector cells) were processed by 
Ficoll for the isolation and culture of T cells. Cells were activated using Dynal beads (1:1 
based on lymphocyte count; therefore, 3:1 based on CD3 count) in X-VIVO 15 media 
supplemented with 5% HS and 100 units/ml of r-IL2. Cells were transferred to retronectin 
coated bags the following day and transduced at an MOI of 5 with pCCL-EF1a-CAR19 
vector. Cells were transferred and expanded in G-Rex 10 flasks for twelve days and 
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phenotyped for transduction efficiency evaluation using anti-Fab; Fab expression was 50% 
for both naïve and adult cells. Cells were cyropreserved in 5x106/ml or 10x106/ml aliquots in 
90% FCS/10% DMSO. Both UT and TD populations were cultured and expanded in the 
same manner.  
For in vivo studies, male NSG mice were ordered at 4 weeks for use at 6 weeks. 5x105 
Luciferace transduced Daudis were inoculated intravenously (IV) via tail vein on Day 0. 
Animals were imaged by in vivo imaging instrument (IVIS) on Day 1. On Day 2, effector T 
cells were thawed and counted for IV infusion. Cell numbers required were 4x106 transduced 
(TD) cells (therefore 8x106 cells assuming the 50% TD efficiency). An equal number (8x106) 
cells/animal were counted for the control untransduced (UT) animals. Due to cells numbers, 
only one mouse was injected with no Daudi + PBS, three with Daudi + PBS, five with Daudi 
+ UT PBMCs, three with Daudi + TD PBMCs, five with Daudi + UT CB, and seven with 
Daudi + TD CB.  
Mice were imaged by IVIS on Day 6, Day 9 and Day 14 by IP injection of luciferin at an 
optimal time-point and concentration. 
Marrow and spleen were harvested on Day 14. Marrow and spleen were lysed and processed 
for staining according to Dr.Brian’s phillip (UCL Cancer Institute, UK) protocol and full 
panel FACS staining was carried out.  Tumour cells and T cells were identified in both 
marrow and spleen in animals receiving UT effectors. Tumour cells were cleared in both 
cohorts of mice receiving TD PBMCs, or CB cells (Figure 68). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: In vivo activity of CD19CAR engineered CB and adult T cells on Daudi cellsexperiment illustrates slower tumor growth followed by rapid rejection of BCAR19 engineered CB-T cells and allogeneic PB T cells compared with mice receiving and control mice. B) Graph shows a drop in the percentages of Daudi cells post the injection of CAR19 engineered cells (CB and PBMCs); while for control cohort and UT group, the percentages of Daudi were still high even after receiving the modified CAR19 cells. 
A) 
-cell lymphoma in mice receiving allogeneic 
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7.5) Genome editing technology to knock out TCR expression: 
Mis-pairing endogenous and exogenous TCR chains has been clearly linked to sever toxicity 
in a pre-clinical model using mice (Aggen et al., 2012).Therefore, the absence of the 
endogenous TCR expression on TCR-edited cells is essential for the more robust and 
homogenous expression of the introduced antigen-specific receptor and for completely 
overcoming the safety issue raised by the risk of inducing autoimmune diseases. Although a 
large number of genetic modifications of exogenous antigen-specific receptors have been 
identified as a means of reducing the extent of this impairing effect, strategies that are able to 
completely abrogate this risk have not been previously reported. Several reports and studies 
have evaluated the potential use of a siRNA and ZFNs expression to specifically down 
regulate endogenous TCR expression. Despite their encouraging outcomes, both approaches 
reduced, but did not eliminate, the expression of endogenous TCR (Gaj et al., 2013). 
In this project, we tested the feasibility of genome-editing tools such as meganucleases 
TALENs and CRISPR/Cas9 to knock out the expression of endogenous TCR allowing for 
rapid generation of a large numbers of tumour-specific T lymphocytes expressing high 
functional levels of only the desired TCR, which eliminates the risk of TCR miss-pairing. 
Concluded results associated with the usage of meganucleases demonstrated that this tool is 
not effective to knock out TCR expression and it might have a toxic effect on the cells. So, an 
alternative platform was selected. 
TALENs have been designed and assembled to target sequences within the TCR α and β 
chains genes. A pair of TALENs targeting sequences within the constant region of the alpha 
chain was nucleofected as DNA or mRNA into various types of T cells: Jurkat, PBMCs and 
cord blood T cells. FACS analysis for the expression of endogenous TCR of the cells used in 
this study suggested that TALENs has the ability to recognise its target and reduce the 
expression of endogenous TCR in a remarkable manner. However, further investigation is 
required to ensure the safety of using this genetic-modified tool in clinics.  
Distinct from site-specific nucleases that have been described earlier, CRISPR/Cas9 system 
has widely emerged as an effective alternative approach to MGNs, ZFNs, and TALENs. 
Here, the forcefulness of CRISPR/Cas9 to knock out the expression of TCR was tested. 
Promising results were produced with a satisfying percentage of knock out; however, further 
experiments are required to elucidate the effect of CRISPR/Cas9 on TCR at the molecular 
level. To further investigate CRISPR/Cas9 system, some unnecessary elements, such as the 
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marker genes red cherry and its promoter sv40  should be removed. Another issue that should 
be taken in consideration is the way to deliver sgRNA and Cas9 in to T cells. A further 
experiment should test the feasibility of CRISPRs (gRNA) and Cas9 into third generation 
lentiviral vector backbones and produce a robust batch of lentiviral vectors that carry 
CRISPR/Cas9 system. 
Further investigation should be taken to decide either to shift to CRISPR/Cas9 or proceed 
with TRAC TALENs. 
The ethical use and safety of genome editing technology remains a fundamental issue that 
pulls this technology away. These problems were shoved into the spotlight in April, when 
news broke that scientists had used the CRISPR/Cas9 system to engineer the endogenous 
beta globin gene; the cause of beta thalassemia once it is mutated, in human zygots (Liang et 
al., 2015). The embryos whose genomes were edited were unable to result in a live birth; in 
addition, a surprisingly large number of off-targets were detected, and the paper has 
generated heated debate over whether the CRISPR/Cas9 system should be used to make 
heritable changes to the human genome.  
There are other concerns about genome editing technology, such as its potential risks to 
genome edits and the concern that edited organisms could disrupt entire ecosystems 
(Baltimore et al., 2015). Scientists are eager to conduct more studies to prove whether these 
concerns are warranted and to develop strategies for better targeted genome technology. 
Major safety concerns have been obviated in a recent clinical trial conducted by  Professor 
Waseem Qasim and his team (Great Ormond Street Hospital, UCL, UK) to treat an infant 
with refectory relapsed B-ALL. It is the first scientific team to use TALENs edited cells in a 
human with remarkable success (Qasim et al., 2015a). 
Additional improvements to generate universal, genetically engineered T cells may include 
denuding T cells of HLA molecules; consequently, these cells might evade immunological 
recognition and reduce the risk of rejection (Torikai et al., 2013). 
7.6) Conclusion: 
To sum up briefly, this project indicates that, in the field of T cell immunotherapy, 
engineered, antigen-specific cord blood T cells should be the first choice in terms of cells that 
should be used in “on-the-shelf” therapy. This holds the added benefit of eradicating the time 
and expense limitations of antigen-specific gene transfer therapy. Supporting this conclusion 
is the fact that CB-T cells have shown a significant expression level of WT1-TCR and CD19-
CAR genes following experiments with lentiviral gene delivery. Moreover, remarkably 
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positive results from functional trials support the previous hypothesis. It has been proposed 
that genome-editing technology can be used as a solution to the limitations of antigen-
specific gene transfer therapy. The feasibility of MGN and TALE nucleases’ ability to disrupt 
the sequence within the genome of TCR alpha or beta chains has been tested in vitro. The use 
of MGN was shown to be unsuccessful in causing genome disruption and this might be due 
to the toxic effect of MGN on the cells. TALENs studies demonstrated that the knocking-out 
expression of endogenous TCR might be feasible. Although this study appears to lead to the 
conclusion that CB-T cells are a valuable tool in T cell immunotherapy, and that genome-
editing technology might be the solution to most of the drawbacks involved in antigen-
specific gene transfer therapy, further research and monitoring is essential for the 
development of a more comprehensive understanding of this field. 
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